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Schizophrenia is a debilitating disease affecting approximately 70 million people worldwide. 
Response to treatment, much like the disorder itself, is highly heritable, heterogeneous, and 
poorly understood. Only 50% of patients respond well to medication, and extensive research 
has provided limited improvement on this figure. Advances in genetic technologies coupled 
with massive increases in study sample size have the potential to explain the “missing 
heritability” of both schizophrenia and treatment response. Genome-wide association studies 
(GWAS) are at the forefront of complex trait research, but have had minimal success in 
terms of explaining the biology of psychiatric drug response. Despite the majority of GWAS 
“hits” being located in noncoding regions, functional interpretation is usually restricted to the 
closest gene. The Encyclopedia of DNA Elements (ENCODE) project has recently shown 
that noncoding variation is not just a functional proxy of adjacent coding regions, but can 
have complex and pervasive regulatory effects.     
This study aimed to investigate the functionality of noncoding single nucleotide 
polymorphisms (SNPs) in schizophrenia treatment response. A novel bioinformatics pipeline 
incorporated coding and noncoding variants implicated in treatment response, regions of 
linkage disequilibrium (LD), regulatory data, and biological pathway predictions. Firstly, the 
literature was mined to identify all variants associated via GWAS with antipsychotic 
response, after which publically available data was employed to find markers in LD with 
these variants. This larger group of variants was analysed with bioinformatic tools such as 
RegulomeDB and rSNPBase to determine regulatory potential. Thereafter, affected gene 
targets and pathways were identified with DAVID and GeneMANIA. In order to investigate 
the findings further, the top predicted regulatory variants and their GWAS partners were 
genotyped with TaqMan® OpenArray® in a South African first episode schizophrenia (FES) 
cohort and analysed for associations with treatment outcomes.  
The bioinformatic portion of this study implicated a region on chromosome 4q24 associated 
with treatment-refractory schizophrenia through involvement of the nuclear factor of kappa 
light polypeptide gene enhancer in B-cells 1 (NFKB1) gene. This gene is a master regulator 
involved in immunity and has over 200 gene targets. NFKB1 and immune dysregulation 
have both previously been implicated in schizophrenia, pointing to a genetic overlap 
between schizophrenia risk and antipsychotic treatment response. The most significant 
variants in the association analyses occurred at the 4q24 locus, with rs230493 and 
rs3774959 significantly associated with poor response in the negative symptom domain (P < 
0.0001). These findings suggest a genetic link between persistent negative symptoms and 




treatment nonresponse. Additionally, a 14-variant haplotype containing these two 
polymorphisms was associated with 4.41% higher positive symptom severity.  
Not only do these results validate the importance of the 4q24 region in antipsychotic 
response, but they emphasise the overlap of schizophrenia risk and drug response, and the 
potential role of genomic dysregulation in undesirable treatment outcomes. NFKB1 and other 
associated genes should be studied in population-specific, replicative cohorts, in order to 
validate potential biomarkers of treatment response. This study illustrated the importance of 
thorough GWAS interpretation and inclusion of coding and noncoding variants to form 
biological hypotheses and better understand antipsychotic response. 
 
  





Skisofrenie is ŉ aftakelende siekte wat sowat 70 miljoen mense wêreldwyd raak. 
Behandelingsreaksie is, baie soos die siekte self, hoogs oorerflik en heterogeen, en word 
nog swak verstaan. Slegs 50% van pasiënte reageer goed op medikasie, en uitvoerige 
navorsing het slegs beperkte verbetering op hierdie syfer tot gevolg gehad. Vooruitgang in 
genetiese tegnologieë tesame met ŉ geweldige toename in studie-steekproefgrootte kan 
potensieel die “ontbrekende erflikheid” van sowel skisofrenie as behandelingsreaksie 
verklaar. Genoom-wye assosiasiestudies (GWAS) is aan die voorpunt van komplekse 
kenmerknavorsing, maar het tot dusver minimale sukses ten opsigte van die verklaring van 
die biologie van psigiatriese middelreaksie gehad. Ondanks die feit dat die meerderheid 
GWAS-trefpunte in niekoderende streke voorkom, is funksionele interpretasie gewoonlik tot 
die naaste geen beperk. Die Ensiklopedie van DNS-elemente- (ENCODE-)projek het 
onlangs bewys dat niekoderende variasie nie net ŉ funksionele sekundus van naasliggende 
koderende streke is nie, maar komplekse en deurdringende regulerende gevolge kan hê.  
Hierdie studie was daarop gemik om die funksionaliteit van niekoderende enkel-nukleotied-
polimorfismes (ENPs) in skisofreniebehandelingsreaksie te ondersoek. ŉ Nuwe 
bioïnformatika-pyplyn het koderende en niekoderende variante wat by behandelingsreaksie 
betrek word, streke van koppelingsdisekwilibrium (KD), reguleringsdata, en biologiese 
padvoorspellings geïnkorporeer. Eerstens is die literatuur ondersoek om alle variante te 
identifiseer wat via GWAS met antipsigotika-reaksie geassosieer word, waarna algemeen 
beskikbare data gebruik is om merkers in KD met hierdie variante te vind. Hierdie groter 
groep variante is met bioïnformatika-hulpmiddels soos RegulomeDB en rSNPBase ontleed 
om reguleringspotensiaal te bepaal. Daarna is geaffekteerde geenteikens en paaie met 
DAVID en GeneMANIA geïdentifiseer. Ten einde die bevindings verder te ondersoek, is die 
top- voorspelde reguleringsvariante en hul GWAS-vennote met TaqMan® OpenArray® in ŉ 
Suid-Afrikaanse eerste-episode-skisofrenie-kohort gegenotipeer en vir assosiasies met 
behandelingsuitkomste ontleed.  
Die bioïnformatika-gedeelte van hierdie studie het ŉ streek op chromosoom 4q24 
geïmpliseer wat deur betrokkenheid van die geen nukleêre-faktor-kappa ligte polipeptied 
geen bevorderaar in B-selle 1 (NFKB1) met behandelingsweerstandige skisofrenie 
geassosieer word. Hierdie geen, ŉ meester-reguleerder wat op immuniteit betrekking het, 
het meer as 200 geenteikens. NFKB1 en immuundisregulering is albei vantevore by 
skisofrenie geïmpliseer, wat op ŉ genetiese oorvleueling van skisofrenie-risiko en 
antipsigotika-behandelingsreaksie dui. Die mees beduidende variante in die assosiasie het 




by die 4q24-lokus voorgekom, met rs230493 en rs3774959 wat albei beduidend met swak 
ná-behandelingsreaksie in die negatiewe-simptoom-domein geassosieer was (P < 0.00001). 
Hierdie bevindings dui op ŉ genetiese verband tussen volhardende negatiewe simptome en 
niereaksie op behandeling. Daarbenewens is ŉ 14-variant-haplotipe wat hierdie twee 
polimorfismes bevat met ŉ 4.41% hoër graad positiewe simptome geassosieer.  
Hierdie resultate staaf nie net die belangrikheid van die 4q24-streek in antipsigotika-reaksies 
nie, maar beklemtoon ook die oorvleueling van skisofrenie-risiko en middelreaksie, en die 
potensiële rol van genoom-disregulering in ongewenste behandelingsuitkomste. NFKB1 en 
ander verwante gene moet in populasiespesifieke, repliseerbare kohorte bestudeer word ten 
einde potensiële biomerkers van behandelingsreaksie te staaf. Hierdie studie illustreer die 
waarde van deeglike GWAS-interpretasie en die insluiting van koderende en niekoderende 
variante om biologiese hipoteses te vorm en antipsigotika-reaksies beter te begryp. 
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CHAPTER 1                                                                                                   INTRODUCTION 
1 
 
CHAPTER 1: Introduction 
1.1. The global burden of mental illness 
Psychiatric disorders place an immense burden on individuals, families, and communities. 
Worldwide, the combination of high prevalence, high cost of treatment, and high disability 
has long called for mental health to be prioritised in public health care (Murray and Lopez, 
1996). Psychiatric illness constitutes approximately 13% of the global disease burden (World 
Health Organization, 2008). In 2010, mental and substance use disorders caused the fifth 
highest number of disability-adjusted life years (DALYs), according to the latest Global 
Burden of Disease study. In fact, these disorders were the leading cause of years lived with 
disability (YLDs), a subcategory of the DALY (Whiteford et al., 2013). Compounding the 
problem, psychiatric disorders often demonstrate comorbidity with other chronic medical 
conditions, and can significantly worsen a patient’s outcome (Patel et al., 2013).  
These findings have far-reaching consequences. Firstly, mental illness creates a global 
economic burden currently estimated at $2.5 trillion, which is predicted to increase almost 
three-fold by 2030 (Bloom et al., 2011). A major contributor to these costs is a lack of 
successful preventions and cures, resulting in relapse and hospitalisation (Ascher-Svanum 
et al., 2010; Collins et al., 2011). Secondly, stigmatisation of psychiatric disorders produces 
a large socioeconomic burden in both urban and rural settings. Affected individuals are often 
cut off from their community, thus restricted from health care, education, employment and 
social support, resulting in significantly shorter lifespans compared to the general population 
(Kadri and Sartorius, 2005). 
Despite the serious and diverse problems created by mental illness, most countries do not 
allocate sufficient resources to psychiatric treatment (Saxena and Skeen, 2012). Mental well-
being is not globally prioritised in comparison to other illness: according to the Mental Health 
Atlas, governments spend approximately $2 per person on mental health annually (World 
Health Organization, 2011a). Even when an effective treatment strategy exists, it may not be 
implemented within the healthcare system, due to a lack of qualified staff or budgetary 
constraints (Tomlinson et al., 2009). For the most part, individuals with mental disorders are 
treated in primary healthcare facilities, with only 20% of adults with common psychiatric 
problems in the United States of America (USA) consulting a mental health specialist (Wang 
et al., 2005). Lack of proper care increases complications, stigma, and the already high 
costs associated with mental well-being (World Health Organization, 2011b). 
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Not surprisingly, the burden of mental illness is amplified in low- to middle-income countries 
(LMIC) such as South Africa. There is extensive evidence that poverty is strongly associated 
with increased risk for mental disorders (Patel and Kleinman, 2003; Murali and Oyebode, 
2004). Despite LMIC taking on as much as 75% of the global burden of psychiatric illness, 
their general healthcare budgets are lower, each with an even smaller portion dedicated to 
mental health (World Health Organization, 2011b). Demyttenaere and colleagues (2004) 
estimate that fewer than 24% of affected people in LMIC receive treatment. Furthermore, 
70% of African countries allocate less than 1% of their healthcare budgets to mental health 
(Lund et al., 2010). 
The dire situation in LMIC is partly attributable to a lack of resources in the form of 
healthcare professionals. For example, there is an average of only one psychiatrist per two 
million individuals in low-income countries (Saxena and Skeen, 2012). To put this in 
perspective, the number of psychiatrists on the African continent is less than the number in 
the state of Massachusetts in the USA (Patel et al., 2013). Additionally, mental health is 
deprioritised in LMIC due to high rates of other diseases such as HIV/AIDS and tuberculosis 
(Lund et al., 2010). The immense health, socioeconomic, and financial burdens of 
psychiatric illness call for increased research, education, and healthcare resources, 
particularly in LMIC. Improving the understanding and treatment of these disorders is vital for 
ensuring sustainable mental well-being. 
1.2. Pharmacogenomics 
An important consideration for the treatment of any disease is pharmacogenomics, or the 
effect of genetic variation on drug response. Often, immense heterogeneity is seen in 
individuals treated with the same medication. This is largely influenced by variants in 
individuals’ DNA, particularly in drug metaboliser and transporter genes (Ozomaro et al., 
2013; Carr et al., 2014). In most cases, psychiatric drug treatment is standardised for all 
patients, proceeds by trial-and-error, and dose or medication type is adjusted only after a 
positive outcome is not reached (Cacabelos et al., 2011). This is a costly and potentially 
dangerous exercise for the treatment of any disease, as drug toxicity and side effects are a 
reality for many patients. For example, Nyakutira and colleagues (2008) discovered that 50% 
of African patients receiving efavirenz for HIV treatment had blood concentrations above the 
toxicity threshold, as a result of a gene-dose interaction. With reference to psychiatric 
treatment, the administration of common antipsychotics can cause tardive dyskinesia, a 
chronic and severe movement disorder, in up to 30% of patients (Chowdhury et al., 2011).  
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Psychiatric treatment is complex, chronic, and requires close monitoring of patients. 
Although expensive, standardised treatment is currently substantially cheaper than the 
resources required for personalised medicine. However, the implementation of 
pharmacogenomics in psychiatry is expected to reduce costs associated with long-term 
treatment outcomes. This field of research has the potential to minimise the development of 
side effects, treatment complications, and hospitalisations, ultimately lowering the amount of 
YLDs and DALYs associated with disease (León-Cachón et al., 2012). In fact, 
pharmacogenomics has already demonstrated its ability to save money on disease 
treatment. Recently, pharmacogenetic screening of patients prior to treatment with the anti-
cancer drug, trastuzumab, decreased the length of the clinical trial by approximately eight 
years, and saved millions of dollars (Cook et al., 2009). Further demonstrating the 
importance of pharmacogenomic considerations, many drugs approved by the Food and 
Drug Administration (FDA) contain labels with pharmacogenomic indications, including over 
30 psychiatric medications such as antipsychotics and antidepressants 
(http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.ht
m).   
Despite these findings, pharmacogenomic applications are limited, as the majority of large-
scale genetic studies have focused on disease susceptibility rather than treatment response.  
By investigating pharmacogenomic interactions in psychiatry, our understanding of treatment 
outcomes, and subsequently our ability to tailor treatment to the individual and improve drug 
design, will increase. The coupling of well-characterised clinical data with genetic and 
bioinformatic resources has great potential for alleviating the extensive burden placed on 
those with mental illness. This is particularly important in LMIC given the magnified burden of 
disease in these countries. Thus, pharmacogenomics is an essential starting point in the 
improved treatment of psychiatric diseases. 
1.3. Genetic diversity in South Africa 
Although pharmacogenomic research shows great promise, the overwhelming majority of 
studies is conducted in developed countries. Paradoxically, Hinds and colleagues (2005) 
estimate that LMIC contain up to 90% of human genetic variation, thus providing an 
unparalleled resource for genetic studies of complex disorders. In fact, Southern African 
populations have demonstrated the highest level of genetic diversity worldwide (Campbell 
and Tishkoff, 2008). The South African Coloured (SAC) population, for example, is highly 
admixed, with African, Asian, and European ancestry contributions (de Wit et al., 2010; Daya 
et al., 2013). South Africa therefore provides a rich genetic resource for uncovering the 
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architecture of complex traits (Ramsay, 2012), and should be viewed as an opportunity for 
genomic research rather than a disease burden to the world.  
 
Nevertheless, South African individuals remain understudied and underrepresented in 
pharmacogenomic research (Drögemöller et al., 2011). Indeed, the extreme gap between 
needs and available services in LMIC is mirrored by the so-called “10/90 gap” in research. 
This is the phenomenon that only 10% of global research funding is spent on the problems 
faced by the poorest 90% of the population (Global Forum for Health Research, 2000). 
Furthermore, only 5% of research published in high impact psychiatric journals originates 
from LMIC, with only 1% from South African authors (Patel and Sumathipala, 2001; de Jesus 
Mari et al., 2009). There is no doubt that South Africa is home to unique and heterogeneous 
genetic variation, and clinically actionable findings from high-income countries may not be 
applicable. Therefore, increased study of its populations is vital for identifying the genetic 
differences underlying complex phenotypes such as psychiatric illness and treatment 
response. By combining the latest technological advances in genetics with overburdened 
and understudied ethnic groups, novel insights into psychiatric pharmacogenomics and 
improved treatment become possible. 
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CHAPTER 2: Literature review 
2.1. Schizophrenia 
2.1.1. Symptoms and stages 
Schizophrenia is arguably the most debilitating psychiatric disorder, and consequently is 
highly stigmatised and costly to treat (van Os and Kapur, 2009). Indeed, of all the mental 
disorders investigated by the latest Global Burden of Disease study, schizophrenia 
accounted for the most disability (Whiteford et al., 2013). The disorder is complex and 
pervasive, permeating all aspects of an individual’s life and manifesting as a range of 
symptoms. Positive or psychotic symptoms are defined as exaggerated states of functioning, 
which are absent in the general population but present in schizophrenia, whilst negative 
symptoms constitute loss of a range of functions that are usually present in healthy 
individuals (Tandon et al., 2009). For example, individuals with schizophrenia may 
experience hallucinations and delusions on the one hand, but impairments in speech, 
motivation and social interest, on the other. General psychopathological symptoms also 
occur, which include mood, motor and cognitive deficits. These symptoms can be quantified 
by different scales, the most common of which is the Positive and Negative Syndrome Scale 
(PANSS; Kay et al., 1987). Seven items on this scale measure positive and negative 
symptoms, respectively, and 16 items measure general psychopathology, as shown in Table 
2.1. Each of the 30 items on the test is scored from 1-7, increasing in severity. Therefore the 
baseline PANSS score is 30, and the maximum possible score is 210. 
Table 2.1: Schizophrenia symptom items measured by the PANSS (Kay et al., 1987). 













Difficulty in abstract thinking 






Mannerisms and posturing 
Depression 
Motor retardation 




Lack of judgment and insight 
Poor impulse control 
Preoccupation 
Disturbance of volition 
Active social avoidance 
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The PANSS is widely used to determine symptom severity, response to treatment, relapse, 
and remission in schizophrenia (Levine et al., 2011). Other scales include the Scales for the 
Assessment of Negative (SANS) and Positive (SAPS) Symptoms (Andreasen, 1983; 1984) 
and the Brief Psychiatric Rating Scale (BPRS) (Overall and Gorham, 1962). 
Schizophrenia is a chronic disorder that typically displays a gradual deterioration in 
functioning. It can be divided into four stages or phases, indicated in Figure 2.1. Generally, 
negative and cognitive symptoms surface in childhood or adolescence, followed by the 
development of psychotic symptoms in young adulthood (Mueser and McGurk, 2004). The 
first psychotic episode marks the beginning of the psychotic phase and the official onset of 
schizophrenia, which is usually followed by subsequent episodes in between brief periods of 
remission (Lieberman et al., 2001). The disorder then reaches a stable plateau, which is 
characterised by residual negative and cognitive symptoms and a general decline in 
functioning (Tandon et al., 2009).  
 
Figure 2.1: Representation of the stages observed during the course of schizophrenia (Tandon et al., 
2009).  Reprinted with permission from Elsevier. 
Despite the classification of schizophrenia into different stages, diagnosis of the disorder is 
difficult. Tandon and colleagues (2009) discuss several limitations of the four-phase model of 
schizophrenia. Firstly, there is extensive heterogeneity in the type and severity of symptoms 
seen in individuals, making differentiation between phases difficult. Psychotic symptoms 
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often do not manifest in clear intervals, therefore the definition of the first episode of 
psychosis is somewhat arbitrary. Additionally, more than half of patients that experience mild 
positive symptoms in the prodromal stage do not go on to develop the disorder. Lastly, the 
time course of the illness and extent of deterioration vary between patients (Tandon et al., 
2009). Nevertheless, relapses and persistence of symptoms despite treatment create a 
chronic struggle with schizophrenia for the majority of individuals (Albus, 2012).    
2.1.2. Diagnosis 
The current diagnosis of schizophrenia is determined by clinical interview, based on criteria 
either in the fifth version of the Diagnostic and Statistical Manual of Mental Disorders (DSM-
5; American Psychiatric Association, 2013), or the International Classification of Diseases 
version 10 (ICD-10; World Health Organization, 2015), which are similar and display high 
diagnostic reliability (Peralta and Cuesta, 2003; Mueser and McGurk, 2004). The most 
commonly used system, the DSM-5, advises diagnosis when an individual exhibits two or 
more core symptoms, i.e. hallucinations, delusions, negative symptoms, or disorganised 
thinking. In addition, these symptoms must be present for at least a month before a patient 
can be diagnosed as experiencing their first psychotic episode (American Psychiatric 
Association, 2013). In contrast to previous versions, the DSM-5 does not divide 
schizophrenia into subtypes (paranoid, catatonic, disorganised, schizoaffective, 
undifferentiated, and residual), as this approach has shown limited reliability and validity, and 
poor clinical success (Tandon, 2014). Instead, the manual proposes a broad and thorough 
assessment of symptom severity to address the substantial variation that exists between 
patients.   
The heterogeneity of schizophrenia poses another problem to diagnosis: there is extensive 
overlap with other psychiatric disorders. On the whole, research does not support the 
compartmentalisation of these disorders, as most mental illnesses have been found to share 
risk factors, symptoms, and biological pathways (Adam, 2013; Doherty and Owen, 2014). 
This is displayed in Figure 2.2, in which psychiatric disorders lie upon a spectrum. There is a 
need for reconsideration of nosological boundaries, as many researchers agree that 
schizophrenia’s heterogeneity means it should not be defined as a single disease (Tandon, 
2012; Barch et al., 2013; Alvarez-Rodriguez et al., 2014; Arnedo et al., 2014). Although the 
DSM-5 does not address this developing paradigm shift, taking a dimensional approach to 
diagnosis is a promising first step towards an improved understanding of this complex 
disorder. To provide more precise diagnosing in psychiatry, the National Institute of Mental 
Health (NIMH) has developed the Research Domain Critera (RDoC), which shifts focus 
away from symptoms onto biologically distinct psychopathological mechanisms (Insel et al., 
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Figure 2.2: The spectrum of psychiatric disorders, illustrating overlap between symptoms (Adam, 
2013). Reprinted with permission from Nature Publishing Group. 
2010; Insel and Cuthbert, 2015). Classification of patient subgroups with RDoC considers 
specific biosignatures, identifiable through genetic research and neuroimaging (Insel et al., 
2010). Studies implementing this method are few and require validation, but this is a 
promising step in improving schizophrenia diagnosis and outcome.  
2.1.3. Risk factors 
Schizophrenia presents a lifetime risk of 0.7% (Tandon et al., 2008), with a prevalence of up 
to 1% in the general population (Curtis, 2013). Its aetiology and biological mechanisms are 
poorly understood, and much like the other features of schizophrenia, the risk factors for 
development of the disorder are heterogeneous. The establishment and severity of 
schizophrenia involve the interplay between several genetic and environmental influences 
(Tsuang et al., 2004; Singh et al., 2014).  
Pre- and perinatal risk factors for schizophrenia include maternal infection, stress, 
malnutrition and obstetric complications (Opler et al., 2013). Individuals that have 
experienced childhood trauma also show increased risk for the disorder (Schmitt et al., 
2014). Various sociodemographic stressors contribute towards schizophrenia, such as 
urbanicity (Krabbendam and van Os, 2005), migration (Cantor-Graae and Selten, 2005) and 
lower social class (Mueser and McGurk, 2004). The “social defeat hypothesis” suggests that 
occupying a lower social standing or belonging to a minority increases risk for the disorder 
(van Os et al., 2010). Finally, cannabis use has been linked to schizophrenia development 
(van Os and Kapur, 2009). Despite environmental elements, it is widely acknowledged that 
genetic predisposition is the top contributing risk factor for schizophrenia, with family history 
of the disorder being the most reliable predictor for development in an individual (Sullivan, 
2005; Clarke et al., 2012). 
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Family, adoption and twin studies have shown the heritability of schizophrenia to be 
approximately 81%, making it one of the most heritable psychiatric disorders (Sullivan et al., 
2003; Singh et al., 2014). The risk of developing the disorder increases with the degree of 
relatedness to an affected individual. For example, the concordance between monozygotic 
twins is three times greater than between dizygotic twins (Clarke et al., 2012, Girard et al., 
2012). Despite evidence of genetic aetiology, the complex, non-Mendelian nature of 
schizophrenia and other psychiatric disorders has made the exact biological underpinnings 
tricky to elucidate (Singh et al., 2014). 
Currently, there are two major hypotheses with regards to the genetic mechanisms of 
schizophrenia. The common disease – common variant (CDCV) hypothesis proposes that 
many commonly occurring genomic variants of small effect size bring about a cumulative 
increase in schizophrenia susceptibility. Conversely, the common disease – rare variant 
(CDRV) hypothesis states that a small number of rare, but highly penetrant variants of large 
effect size confer the majority of schizophrenia risk (Stefansson et al., 2009; van Dongen 
and Boomsma, 2013). Recent findings suggest that the truth lies somewhere between these 
two, with a combination of heterogeneous rare and common alleles culminating in the 
pathophysiology of the disease (Mowry and Gratten, 2013).  
Genetic research has unveiled extensive results across this spectrum of variants. Earlier 
studies relied on linkage analyses, which look at co-segregating variants in families, and can 
be a successful tool for understanding simple Mendelian diseases (Kerem et al., 1989; Muir 
et al., 1995; Mowry and Gratten, 2013). Poor replication and weak significance signals led to 
the abandonment of this approach, in favour of a more complex, polygenic view of 
schizophrenia (Rodriguez-Murillo et al., 2012). Candidate gene association studies were the 
next advancement in the study of schizophrenia. This method compares a particular gene in 
schizophrenia cases and controls and determines whether there are common variants that 
associate with the disease (Kim et al., 2011). The SzGene database is a record of all genetic 
association studies, and contains over a thousand genes studied with the candidate 
approach (Allen et al., 2008). However, many results are inconsistent and the majority of 
studies have not been replicated. Additionally, this hypothesis-bound method is restrictive, 
since selecting a candidate gene is based on the limited knowledge we have of 
schizophrenia (Collins et al., 2012). 
Almost a decade ago, fuelled by advances in genotyping technology, the first genome-wide 
association study (GWAS) on schizophrenia was performed (Mah et al., 2006). GWAS have 
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Figure 2.3: Bar graph demonstrating the exponential growth of sample size and discovery of 
schizophrenia risk loci in genetic studies (Flint and Munafò, 2014). Reprinted with permission from 
Nature Publishing Group.  
significant advantages over previous study designs. Firstly, they do not require selection of 
candidate genes; in other words they provide an unbiased and hypothesis-free approach, 
creating the potential for discovery of novel schizophrenia loci (Zhang and Malhotra, 2013a). 
Secondly, by scanning the entire genome, GWAS can simultaneously analyse millions of 
single nucleotide polymorphisms (SNPs) and determine association with schizophrenia in 
large case/ control groups (Kim et al., 2011).  
This approach gives enormous support to the CDCV hypothesis. Since GWAS have been 
applied to the field of schizophrenia, over 100 independent variants have been identified in 
more than 15 GWAS, in unprecedented sample sizes (Zhang and Malhotra, 2013a; 
McCarthy et al., 2014). This highlights the importance of large sample sizes, with increased 
sample size leading to more associations (Figure 2.3). The most notable findings that have 
been replicated in subsequent studies are variants in the zinc finger protein 804A (ZNF804A) 
gene, the major histocompatibility complex (MHC) genes, the neurogranin (NRGN) gene, the 
transcription factor 4 (TCF4) gene, and the dopamine receptor D2 (DRD2) gene (Rodriguez-
Murillo et al., 2012; Ripke et al., 2014). The MHC locus is currently the most replicated 
finding, suggesting a role for the immune system in schizophrenia development (Sullivan et 







The most noteworthy contributor to this field is the Psychiatric GWAS Consortium (PGC), 
which is spread across 19 countries and over 60 institutions, and currently has access to 
about 40 000 genomes for the study of schizophrenia (Sullivan, 2010; Wright, 2014). With 
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the aim of performing large-scale analyses of psychiatric disorders, the PGC has yielded a 
plethora of results relevant to schizophrenia. Their most recent study identified 108 
significant risk loci, 83 of which were novel. However, there were significant results for genes 
involved in neurotransmitter systems, such as DRD2, which are consistent with previous 
hypotheses of impaired neurodevelopmental functioning in schizophrenia (Ripke et al., 
2014).    
The growing number of novel loci for schizophrenia susceptibility suggests that the disorder 
is even more complex than previously assumed. Moreover, it is estimated that these 
common alleles only account for 1-2% of genetic risk for schizophrenia, making them neither 
vital nor sufficient for development of the disorder (Zhang and Malhotra, 2013a). One must 
also consider that GWAS have limitations. Firstly, the nature of multiple testing requires 
independent replication studies to ensure that variants are not simply statistical artefacts 
(Bertram, 2008), but the majority of GWAS “hits” have not been successfully replicated 
(Sham and Purcell, 2014). Secondly, there is a lack of post-GWAS functional analyses of 
significant loci, leading to a growing list of potentially important genomic regions, but minimal 
understanding of how they operate (Girard et al., 2012; refer to 2.3.2. for more about GWAS 
in relation to the current study).  
The case of missing heritability may in part be solved by analysing rare variants of large 
effect, as stipulated by the CDRV hypothesis. Copy number variants (CNVs) are rare 
mutations that are highly penetrant and demonstrate large effect sizes (Zhang and Malhotra, 
2013a). The most notable example is a de novo microdeletion on chromosome 22q11.2, with 
carriers exhibiting a three-fold increase in risk for schizophrenia (Sullivan et al., 2012). Rare 
point mutations have also been implicated in schizophrenia, although this type of study is in 
its infancy (Mowry and Gratten, 2013).  With advances in whole-genome and whole-exome 
sequencing, Xu et al. (2011) have shown that protein-altering de novo mutations are 
enriched in individuals with schizophrenia, which was confirmed in an independent study by 
Girard and colleagues (2011). More recently, a large study sequenced exomes of over 5000 
individuals, and found rare mutations across many genes that were significantly associated 
with schizophrenia (Purcell et al., 2014).  
These findings highlight the importance of rare variants in future studies of schizophrenia. A 
few years ago, the Grand Challenges in Global Mental Health initiative listed the 
identification of biomarkers as one of the top 25 challenges for progress in mental health 
(Collins, 2011). Ideally, genetic features of schizophrenia should be incorporated into its 
clinical conceptualisation and diagnosis, and there is a call for a more “biologically relevant” 
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nosology (Tandon, 2012; Kim and State, 2014). The current debate about the missing 
heritability of the disorder has generated progress in the form of many heterogeneous risk 
loci. It has been proposed that diverse, large-scale techniques in combination with functional 
analyses be used to identify the remaining predictors across the risk spectrum (Mowry and 
Gratten, 2013). This approach has the potential to improve our understanding of this 
complex disorder. 
2.2. Antipsychotic treatment of schizophrenia 
2.2.1. Background 
The treatment of schizophrenia was revolutionised with the chance discovery of 
chlorpromazine’s antipsychotic properties in the 1950s (Lopez-Munoz et al., 2005). Carlsson 
and Lindqvist (1963) subsequently determined that this drug’s success was brought about by 
dopamine receptor antagonism. This marked the establishment of the dopamine hypothesis 
in schizophrenia treatment (Kapur and Mamo, 2003). Today, over 60 years since the 
introduction of chlorpromazine, all antipsychotics include dopamine D2 receptor blockade in 
their mechanism of action (Brandl et al., 2014).   
Chlorpromazine was the first of over 60 antipsychotics designed to treat schizophrenia 
(Tandon et al., 2010). These drugs can be divided into two classes: the earlier, typical, or 
first generation antipsychotics (FGAs), and the more recent, atypical, or second generation 
antipsychotics (SGAs). Overall, studies have shown that FGAs effectively reduce psychotic 
symptoms and prevent relapses in schizophrenia, but other symptoms persist (Arranz and 
de Leon, 2007; Carpenter and Davis, 2012). These lingering negative and cognitive deficits 
contribute largely to general functional decline and long-term decreased quality of life 
(Kirkpatrick et al., 2006). The introduction of SGAs sought to improve upon treatment 
outcomes by incorporating a wider range of neurochemical targets than FGAs. Besides the 
D2 receptor, SGAs act on other components of the dopaminergic pathway, as well as the 
serotonergic, glutamatergic and adrenergic systems (Meltzer, 2013). 
Despite their multi-target profile, there is ongoing debate about whether SGAs offer 
treatment advantages over FGAs. Only a handful of large-scale studies comparing 
effectiveness of antipsychotics have been performed, including the Clinical Antipsychotic 
Trials of Intervention Effectiveness (CATIE; Lieberman et al., 2005) and the Cost Utility of 
the Latest Antipsychotic Drugs in Schizophrenia (CUtLASS; Jones et al., 2006). Both of 
these studies found no significant differences in the efficacy between the two generations of 
antipsychotics, but there were notable flaws in their study designs (Meltzer, 2013). The only 
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atypical antipsychotic that has clear, extensively replicated advantages over typical 
antipsychotics is clozapine, which is highly successful in treatment-refractory schizophrenia 
when other drugs fail (McEvoy et al., 2006; Bonham and Abbott, 2008; Chowdhury et al., 
2011). There is still much to learn about the mechanisms of these drugs, and advances in 
drug design have been relatively modest (Carpenter and Davis, 2012). Other treatment 
options for schizophrenia are illustrated in Figure 2.4. Despite antipsychotics being the most 
effective option, combining them with other forms of treatment is necessary for improved 
quality of life, given the complex and often lifelong nature of the disorder (Tandon et al., 
2010).  
 
Figure 2.4: Burdens and interventions as determinants of schizophrenia outcome (Tandon et al., 
2010). Reprinted with permission from Elsevier. 
2.2.2. Adverse drug reactions 
Perhaps the most apparent distinction between FGAs and SGAs is the different adverse 
drug reactions (ADRs) with which they are associated. Generally, ADRs caused by 
antipsychotics are diverse, severe, and can be long-lasting (Zandi and Judy, 2010). FGAs 
are associated with motor abnormalities, such as acute and reversible extrapyramidal side 
effects (EPS), namely dystonia, akathisia, and parkinsonism, or with chronic conditions, such 
as tardive dyskinesia (TD; Tandon et al., 2010). TD is the most extensively studied ADR and 
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occurs in 20-30% of individuals after three months of treatment with FGAs (Chowdhury et 
al., 2011).     
In contrast, SGAs present a significantly lower risk of EPS and are predominantly linked to 
weight gain and other metabolic side effects (Tandon et al., 2010). Antipsychotic-induced 
weight gain (AIWG) is observed in up to 30% of SGA-treated patients. Additionally, selected 
SGAs increase the risk of cardiac complications, such as the prolongation of the QT interval 
(Brennan, 2014). The uniqueness of clozapine applies to its side effect profile as well as its 
effect on treating nonresponse in schizophrenia. It has been associated with a small but life-
threatening risk of agranulocytosis, a condition characterised by a decrease in neutrophil 
count (Alvir et al., 1993). Clozapine is thus not recommended as a course of treatment 
unless previous administration of two other antipsychotics has failed (Zhang and Malhotra, 
2013b).  
The potentially detrimental side effects of antipsychotics significantly worsen compliance, 
lead to treatment discontinuation, and inhibit positive outcomes, necessitating the 
improvement of treatment strategies (Brandl et al., 2014). To achieve mental well-being and 
ensure sustained quality of life for schizophrenia patients, these adverse reactions must be 
better understood and minimalised. 
2.2.3. Treatment response 
The goal of antipsychotic treatment is complete and sustained remission without relapse. 
However, much like other aspects of schizophrenia, treatment response is complex and 
heterogeneous, and this is rarely a reality (Robinson et al., 2004). Although methods have 
not been standardised, the quantitative measurement of treatment outcome is commonly 
achieved with scales that measure symptom severity (Leucht et al., 2008). For instance, 
general improvement is determined by comparing baseline and post-treatment BPRS 
scores,  and changes in individual symptom domains are investigated with pre- and post-
treatment PANSS, SANS, and SAPS scores (Remington et al., 2010). In 2005, the 
Remission in Schizophrenia Working Group agreed upon criteria to define remission in the 
disorder (Andreasen et al., 2005). Schizophrenia remission is achieved when particular core 
symptoms, such as hallucinations and blunted affect, are absent or mild (that is, they do not 
affect functioning) for at least six months. These criteria are unambiguous absolutes, as 
opposed to scale-specific degrees of symptom improvement, making them amenable to 
cross-study comparison (Emsley et al., 2011).  
Stellenbosch University  https://scholar.sun.ac.za
CHAPTER 2                                                                                         LITERATURE REVIEW 
15 
 
There are several predictors of treatment outcome in schizophrenia. The most significant of 
these is the duration of untreated psychosis (DUP), which has an inverse relationship with 
positive outcome (Jeppesen et al., 2008). Indeed, individuals experiencing their first episode 
of psychosis show 57-67% better response than those in more advanced stages of the 
disorder, highlighting the importance of early intervention (Emsley et al., 2013). Another 
major influence on treatment efficacy is adherence to medication, with non-adherers five 
times more likely to relapse than adherent patients (Robinson et al., 2004). This problem has 
largely been combatted by the replacement of oral administration with long-acting injectables 
(LAI; Nasrallah, 2007). Lastly, early response and nonresponse have been shown as reliable 
clinical markers for longer term outcome, with response at two weeks predictive of positive 
outcomes, and nonresponse indicative of treatment-refractoriness (Kinon et al., 2010; Case 
et al., 2011).    
Unfortunately, remission is not achieved by the vast majority of patients, and approximately 
50% of individuals show minimal to no response to antipsychotics (Lohoff and Ferraro, 
2010). This is represented in Figure 2.5, which summarises the balance of good and poor 
outcomes in 18 independent studies on antipsychotics. All patients were experiencing their 
first episode of psychosis when recruited, and were monitored for more than one year post-
treatment (van Os and Kapur, 2009). Nonresponse or treatment-refractoriness can be 
defined as a lack of improvement in symptoms after treatment with two different 
antipsychotics for at least six weeks each (Suzuki et al., 2012). In these cases, clozapine is 
the go-to antipsychotic and has shown effective improvement in nonresponsive patients 
(Chowdhury et al., 2011). 
Considering the diverse scope of treatment outcomes, there is much to be discovered with 
regards to the workings of schizophrenia and antipsychotics. The heterogeneous clinical 
presentation of the disorder, high percentage of nonresponders, and severe ADR profiles of 
antipsychotics preclude the option of a standardised, one-for-all treatment design. Currently, 
genetic research into schizophrenia and antipsychotics is the starting point for developing 
individualised treatment and improved outcomes.  
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Figure 2.5: 18 studies demonstrating balanced outcomes of good vs. poor response to antipsychotic 
treatment (van Os and Kapur, 2009). Reprinted with permission from Elsevier. 
2.3. Antipsychotic pharmacogenomics 
2.3.1. Background 
The term pharmacogenetics was created by Vogel in 1959 to explain the interaction between 
genetic differences on the range of treatment outcomes observed between individuals. 
Pharmacogenomics takes this a level further, by encapsulating differences across the entire 
genome that affect drug response. As for schizophrenia, antipsychotic response is 
considered to be a complex, multifactorial trait with a strong genetic basis (de Leon, 2009). 
Twin and family studies have demonstrated the high heritability of treatment response, 
including ADRs, and it is hypothesised that the genetic component of this heterogeneous 
phenotype is brought about by multiple variants of small effect across the genome (Arranz 
and de Leon, 2007; Sun et al., 2012).  
Researchers first investigated genetic predictors of schizophrenia treatment efficacy in the 
early 1990s, and many candidate pharmacogene studies have been performed since then 
(Zhang and Malhotra, 2013b). The roles of these genes in treatment response can be 
divided into two classes, namely pharmacodynamics and pharmacokinetics. The former 
refers to the interaction between a drug, transporters, and its target molecule(s), whilst the 
latter involves the absorption, distribution, and excretion of a drug (Zandi and Judy, 2010). 
Stellenbosch University  https://scholar.sun.ac.za
CHAPTER 2                                                                                         LITERATURE REVIEW 
17 
 
With regards to pharmacodynamics, considerable research has been performed on variation 
within dopamine receptor genes following the establishment of chlorpromazine’s 
antidopaminergic action. Several polymorphisms in dopamine receptor genes, namely 
DRD2, DRD3, and DRD4, have shown associations with the extent of treatment efficacy and 
occurrence of ADRs in independent studies, the results of which are summarised by Arranz 
and Munro (2011). Furthermore, serotonin has been the secondary focus of 
pharmacodynamic studies. Alterations in the serotonergic system have been shown to play a 
role in both cognitive and negative symptoms of schizophrenia (Blanc et al., 2010). As 
previously stated, this system is targeted by SGAs, and polymorphisms in both serotonin 
receptors and transporters have been implicated in treatment outcome and the extent of 
metabolic side effects (Blanc et al., 2010).   
In addition to neurotransmitter systems, numerous studies have been performed on the 
pharmacokinetics of antipsychotics, with a focus on drug-metabolising enzymes (DMEs) 
such as the Cytochrome P450 (CYP) family. CYP2D6 codes for an enzyme essential for the 
majority of FGA metabolism (Lohoff and Ferraro, 2010), and is also highly polymorphic, with 
over 80 alleles having been identified (Rieder, 2014). This variation results in extreme 
individual differences, ranging from poor to ultra-rapid metabolism of drugs. Poor 
metabolisers of antipsychotics are at risk for developing drug toxicity and ADRs, whilst ultra-
rapid metabolisers receive insufficient doses (Lohoff and Ferraro, 2010). In addition, 
CYP1A2 is important for antipsychotic metabolism, and variation in this gene results in 
decreased enzyme activity (Murayama et al., 2004). Other CYP polymorphisms have also 
been associated with variable treatment outcomes, such as those in CYP3A4 and CYP3A5 
(Zandi and Judy, 2010). These studies have provided insight into the potential mechanisms 
of antipsychotics, but given the limited treatment success of drugs for the disorder, the 
candidate gene method has made way for more advanced, hypothesis-free approaches.   
2.3.2. Genome-wide association studies 
Unfortunately, the progress seen in schizophrenia susceptibility GWAS (2.1.4) is not 
matched by antipsychotic response GWAS. Only a handful of genome-wide studies have 
been conducted on the treatment response of schizophrenia, with the majority conducted in 
less than a thousand individuals per study (Alkelai et al., 2009; Lavedan et al., 2009). These 
GWAS are included in the National Human Genome Research Institute (NHGRI) GWAS 
Catalog, a database of all SNPs that have reached genome-wide significance (P ≤ 5x10-8) 
for associations with one of 17 complex traits, including general drug response (Welter et al., 
2013). A diagrammatical layout of the Catalog is shown in Figure 2.6.  





Figure 2.6: The NHGRI GWAS Catalog: 17 traits, including drug response, with significantly associated SNPs (P ≤ 5x10-8) across the genome, as 
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Collecting samples of suitable size with sufficient statistical power for a GWAS is difficult for 
a complex phenotype such as antipsychotic response. This is likely because a large-scale 
study of schizophrenia treatment outcome ideally involves strict and replicable response 
criteria, as well as a clinically well-defined cohort (Meltzer, 2013). The gap between current 
pharmacogenomics research and clinical utility is vast. Zhang and Malhotra (2013b) state 
that “to date, there is no randomised clinical trial that provides solid support for using genetic 
testing to guide drug treatment in psychiatry”. However, antipsychotic pharmacogenomic 
GWAS do provide us with potential leads for new hypotheses on the mechanisms of both the 
drugs and the disorder, and the findings of these GWAS will be analysed in the current 
study.  
2.4. Functional effects of genetic variation 
2.4.1. Background 
Focus in genetic research has shifted from identifying genes to determining their functions 
and revealing the biology that links genotype to phenotype (Auerbach et al., 2013). With so-
called “next-generation” approaches such as whole-genome sequencing and GWAS, there 
is a wealth of data available on genetic variation, which can provide us with clues to gene 
function, disease aetiology, and the manifestation of complex traits. The current challenge is 
to interpret the plethora of significant results in order to gain understanding of their 
mechanisms (Girard et al., 2012).   
Nonsynonymous variants in protein-coding regions have been widely studied. Predictive 
tools such as Polymorphism Phenotyping (PolyPhen-2; Adzhubei et al., 2010) and Sorting 
Intolerant from Tolerant (SIFT; Kumar et al., 2009) are commonly used to assess the 
functional impact of a SNP based on resulting amino acid changes. There are several 
databases of coding variants that have been linked to disease, including Online Mendelian 
Inheritance in Man (OMIM; McKusick, 1998) and The Human Gene Mutation Database 
(HGMD; Stenson et al., 2009). With regards to pharmacogenomics, all variants that have 
been linked to drug response traits are curated in the PharmGKB database (Thorn et al., 
2010). This resource currently contains over 2000 genes, with information on associated 
drugs and clinical associations (http://www.pharmgkb.org/). Searching for the drug class 
“antipsychotics” returns 114 publications, the majority of which are candidate gene studies. 
These examples illustrate that coding variants have been studied extensively. This is due to 
their being amenable to functional analyses; that is they demonstrate a clear phenotypic 
alteration (Cooper and Shendure, 2011). However, noncoding variants have recently come 
into focus and have important implications for complex traits such as antipsychotic response. 
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2.4.2. Noncoding variation 
Even though studies on coding variation have revealed harmful disease-associated changes 
at the protein level, approximately 98% of the genome contains untranslated DNA and thus 
the majority of genomic variation. Some noncoding regions are transcribed into regulatory 
noncoding RNAs, whilst others act as sequence-specific binding sites for regulatory 
machinery that subsequently affect gene expression (Cooper and Shendure, 2011).  
Gene regulation is a multilevel process involving cis-elements, namely promoters, silencers, 
and enhancers, and trans-elements such as transcription factors that bind to cis-elements 
(Georgitsi et al., 2011). Illustrating the complexity of regulation, transcription factors are 
known to bind to thousands of different downstream target sites (Cooper and Shendure, 
2011). Furthermore, epigenetic mechanisms and environmental factors also influence gene 
expression (Pastinen, 2010).    
Polymorphisms in noncoding regions of the genome may contribute substantially to complex 
trait phenotypes. It is hypothesised that perturbations in regulatory pathways may have 
widespread effects and be significant in schizophrenia development, severity, and 
antipsychotic response (Arranz and de Leon, 2007). Substantiating this, the majority of 
common SNPs associated with disease lie in noncoding regions (Freedman et al., 2011). 
Regulatory SNPs (rSNPs) affect the phenotype by modifying gene expression, and may 
produce larger effects than coding mutations. Georgitsi and colleagues (2011) propose that 
rSNPs likely create greater alterations in the level of protein product, since coding SNPs do 
not necessarily affect efficient transcription and translation.  
Despite the hypothesised functional consequences of rSNPs, there is a shortage of studies 
demonstrating their effect. This is due, in part, to the difficulty of studying these regions. For 
example, tools such as PolyPhen-2 are based on evolutionary constraint analysis, an 
approach that is feasible for protein-coding regions because they are highly conserved. 
However, regulatory regions undergo many more changes over time and are not amenable 
to this type of analysis (Schmidt et al., 2010). Furthermore, the complexity of gene regulation 
and lack of information on the mechanisms of this multifactorial system have made 
characterising rSNPs difficult (Drögemöller et al., 2014a; Ritchie et al., 2014).     
Employing candidate gene approaches, pharmacogenetics has investigated a handful of 
regulatory regions flanking genes coding for DMEs, drug transporters and targets. Selected 
examples of rSNPs for treatment outcomes are listed in Table 2.2. Although these studies 
are hypothesis-bound, they suggest the importance of rSNPs in altering the response 
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phenotype via expression changes in well-studied genes. Indeed, patients are commonly 
genotyped for the VKORC1 promoter variant prior to warfarin administration, and dosage is 
tailored accordingly to avoid warfarin-resistance (International Warfarin Pharmacogenetics 
Consortium, 2009). There are many more pharmacogenes than those listed in the table, but 
a scarcity of studies on related regulatory variants (Georgitsi et al., 2011).   
Table 2.2: Selected rSNPs associated with changes in expression of pharmacogenes. 
Gene Variation Disease and/ or effect References 
UGT1A1 c.-3279T>G Gilbert’s syndrome 
Decreased bilirubinemia in G allele carriers 




Poorer treatment outcomes in T 
homozygotes 
Sim et al., 2006 
Li-Wan-Po et al., 2010 
CYP2D6 c.-1584C>G Psychiatric disorders 
Ultrarapid thioridazine metabolism in G 
allele carriers 
Zanger et al., 2001 
Dorado et al., 2009 
CYP3A4 c.522-191C>T Cardiovascular disease 
T allele carriers require lower statin doses 
Wang et al., 2010 
SLCO1B1 g.-11187G>A 
in linkage with 
c.521T>C(*5) 
Hypercholesterolemia 
Reduced pravastatin transport activity and 
reduced cholesterol concentration reduction  
Niemi et al., 2004 
Kameyama et al., 
2005 
VKORC1 c.-1639G>A Warfarin-resistance 
G allele carriers require higher dose 
Yuan et al., 2005 
Flockhart et al., 2008 
c. = mutation in coding DNA; g. = mutation in genomic DNA. 
The development of hypothesis-free, genome-wide approaches allows for the exploration of 
noncoding variation within the genome. In fact, the majority of observed GWAS “hits” are 
located in noncoding regions (Hindorff et al., 2009; Adkins et al., 2011). Unfortunately, 
characterisation of these regions in previous GWAS is rare, because most studies tend to 
focus solely on the functionality of adjacent genes, without investigating the potential role of 
the polymorphism in regulatory networks (Schaub et al., 2012; Ritchie et al., 2014). 
Restricting focus to the closest gene creates problems, since a significant polymorphism 
may only be a proxy for the causal SNP due to linkage disequilibrium (LD). Research has 
shown that significant variants can be in perfect LD with SNPs that are hundreds of 
kilobases away, sometimes outside of the range accounted for by the GWAS tag SNP 
(Schaub et al., 2012). Alternatively, a nearby SNP in perfect LD with the associated variant 
may be ignored in the interpretation phase of GWAS, because it falls within a noncoding 
region. 
Recently, characterisation of noncoding variation has focused on expression quantitative 
trait loci (eQTLs). eQTLs have been identified by combining whole-genome approaches 
such as sequencing and GWAS with quantification of genome-wide expression levels. This 
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allows for a link between variant identification and functional classification (Cookson et al., 
2009). These noncoding loci are associated with the expression of a particular gene that can 
be either proximally or distally located (Pastinen, 2010).  Recently, Qiu et al. (2014) used 
over 300 expression microarrays to assess gene expression levels in treated and untreated 
childhood asthma. The results constituted over 2000 drug-response eQTLs associated with 
several hundred genes; many compelling new targets for asthma treatment research. 
Another study conducted by Mamdani and colleagues (2013) investigated peripheral gene 
expression in antipsychotic treatment response, and identified 22 differentially expressed 
genes between responders and nonresponders. Importantly, many of these genes contain 
eQTLs that could be used as biomarkers for treatment response in future work. These 
studies serve as examples of the benefit of eQTL studies in pharmacogenomics. 
2.4.3. Recent bioinformatic developments 
In the wake of newer genomic techniques generating an abundance of genotype data, result 
interpretation and functional analyses have fallen behind. The mass of results generated has 
little clinical utility and our improvement in understanding complex traits is minimal. However, 
the development of bioinformatic tools to examine the functional implications of genomic 
variation is rapidly breaking through this research bottleneck.  
The first of its kind, the Encyclopedia of DNA Elements (ENCODE) sought to characterise 
and make publicly available all the functional elements of the genome. A functional element 
is defined by its creation of a reproducible biochemical signal (The ENCODE Project 
Consortium, 2007). This definition includes coding and noncoding DNA, noncoding RNAs, 
and cis-regulatory elements. The concept of functional elements is illustrated in Figure 2.7. 
In order to characterise genomic regions, several experimental approaches were used, 
including chromatin immunoprecipitation and sequencing (ChIP-seq), to identify transcription 
factor biding sites (TFBS) across the genome. Additionally, the binding of regulatory factors 
to cis-elements produces changes in chromatin states, which were identified by 
deoxyribonuclease I (DNase I) hypersensitive site (DHS) mapping (Maurano et al., 2013). 
The results generated by ENCODE were overwhelming: 1640 data sets performed on 147 
different cell types, with the controversial conclusion that 80% of the genome is functional, 
much of it previously believed to be “junk” DNA (The ENCODE Project Consortium, 2011). 
Interestingly, ENCODE has revealed that rSNPs are significantly enriched for GWAS 
associations (Schaub et al., 2012). Conversely, noncoding variants associated with GWAS 
were found to be concentrated in regions implicated in regulation (Maurano et al., 2013).   
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The functional annotation of the genome has mapped out regulatory regions and provided 
links between regulatory elements and gene expression. This plethora of findings enables 
researchers to analyse functional implications of noncoding variation, to predict whether they 
significantly alter a regulatory element. For example, in a recent schizophrenia susceptibility 
GWAS by the PGC, the authors used ENCODE to analyse the overlap of significant variants 
with DHSs, in order to assess their regulatory potential (Ripke et al., 2013). The ENCODE 
findings are encouraging for future antipsychotic treatment response studies. With the vast 
amounts of new information at our fingertips, progress in the development of new drugs, as 
well as improvement in the use of existing ones, becomes a possibility.       
 
Figure 2.7: Illustration of the various types of functional elements within the genome defined by 
ENCODE (Ecker et al., 2012). Reprinted with permission from Nature Publishing Group.  
Subsequent to the ENCODE project, several bioinformatic tools were created to pinpoint the 
biological implications of rSNPs; a task that was previously impossible on a large scale 
(Cooper and Shendure, 2011). Several examples are listed here. Firstly, RegulomeDB is a 
database that incorporates ENCODE datasets, computational predictions, a large amount of 
eQTLs, and other published literature to predict the effect that a single base pair change can 
have on the binding of regulatory elements across the genome (Boyle et al., 2012). This tool 
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has been widely used to analyse the impact of noncoding SNPs on gene regulation (Chung 
et al., 2013; Juraeva et al., 2014).  
Another bioinformatic tool, Transcription factor Affinity Prediction (TRAP), is utilised to 
assess the impact of SNPs on known transcription factor motifs (Manke et al., 2010). An 
application specifically designed to predict the impact of single nucleotide changes, sTRAP, 
compares “wild-type” and “mutant” sequences, i.e. potential rSNPs, and evaluates 
subsequent changes in affinity for transcription factors (TFs) to known TFBS motifs. 
rSNPBase is a resource of curated rSNPs identified by experimental analysis including 
ENCODE. Additionally, rSNPs uncovered by eQTL studies and computational predictions 
are included (Guo et al., 2014). The data is used to assess the functionality of noncoding 
variants, as well as predict which downstream genes are affected in which tissue types. This 
tool would be useful for discovering regulators of pharmacogenes, novel candidate 
pharmacogenes, and their corresponding expression levels in relevant tissues such as the 
brain and liver. 
Also analysing genome-wide expression levels, the functional annotation of the mammalian 
genome 5 (FANTOM5; The FANTOM Consortium et al., 2014) is a database of mammalian 
gene expression patterns across different tissues. This catalogue provides functional 
annotation of rSNPs and cell-specific transcriptome profiles, and has information available 
for at least one promoter for 95% of protein-coding genes.  
These resources allow scientists to broaden their focus to whole-genome functionality. 
Inclusion of all possible candidate SNPs via a hypothesis-free approach, coupled with in-
depth functional analyses, increases the likelihood of uncovering true causal variants. If a 
noncoding causal variant is elucidated, downstream gene targets can be predicted, and their 
expression levels in relevant tissues can be determined. This could improve our 
understanding of the complex biological mechanisms behind antipsychotic response. 
Additionally, such biological insights could lead us to biomarkers that improve diagnosis and 
treatment of schizophrenia. 
2.5. The South African context 
As discussed in chapter one, South Africa is home to unique and genetically diverse 
population groups. Pharmacogenetic studies on South African individuals have studied this 
variation with regards to drug response, contributing to the narrowing of the “10/90” research 
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gap between high- and low-to-middle income countries. For example, the population-specific 
diversity of the CYP alleles was illustrated by Gaedigk and Coetsee (2008) in a study of 99 
SAC individuals. The authors uncovered two novel CYP2D6 alleles, and observed 
frequencies vastly different to previously characterised variation in individuals of European 
descent. Both of these findings point to diminished CYP enzyme activity, and thus the need 
for ethnicity-specific treatment regimens. CYP2D6 is an important metaboliser of 
antipsychotics, suggesting that these results have implications for schizophrenia treatment 
as well as other drug responses (Zanger et al., 2004). Mitchell and associates (2011) also 
identified 26 novel alleles in the CYP2C9 gene in a black South African cohort. Additionally, 
this study investigated variation in the well-studied VKORC1 gene, associated with warfarin 
dosage. Variation in these two genes – as well as minor environmental covariates accounted 
for in the study – were found to contribute to approximately 45% of the heterogeneity in 
warfarin dosage. In a larger-scale study, Ikediobi and colleagues (2011) genotyped over 200 
SNPs across 12 genes that have been previously associated with antiretroviral treatment 
response in two genetically unique South African population groups. Significant differences 
in CYP allele frequencies were seen between the two groups, illustrating the diversity of 
South African ancestry and the heterogeneity of treatment response (Ikediobi et al., 2011; 
Warnich et al., 2011).    
With specific reference to antipsychotic pharmacogenomics, a novel approach applied 
exome sequencing to 11 South African first episode schizophrenia (FES) patients, followed 
by variant prioritisation and genotyping in a larger FES and Xhosa cohort (Drögemöller et al., 
2014b). Several loss-of-function variants were identified, the majority previously unidentified 
or at very low frequencies in Asian and European population groups. Once again, this study 
highlights the uniqueness of South African genomes and the need for increased research in 
this field.  
Unfortunately, the pharmacogenomic studies in South Africa have mostly spanned a handful 
of candidate genes in relatively small sample sizes (Warnich et al., 2011). Due to high 
incidence of diseases such as HIV and tuberculosis, the few GWAS that have been 
performed on Southern Africans have focused on these illnesses (Petrovski et al., 2011; 
Chimusa et al., 2014). Globally, GWAS are performed at a ratio of approximately 10:1 
European ancestry vs. all other ancestry groups combined (Need et al., 2009). To date, only 
seven GWAS have been performed exclusively on African individuals, with four others 
including some Africans, none of these focusing on schizophrenia treatment response 
(http://www.genome.gov/gwastudies/).  This is problematic, since the allele frequency of a 
GWAS variant can vary up to 40-fold between population groups (Adeyemo and Rotimi, 
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2010), and patterns of linkage disequilibrium are vastly different between Caucasian and 
African genomes (Dalal et al., 2010). Therefore, the progress made in developed countries 
in schizophrenia risk and treatment GWAS may not be applicable to South Africans.  
These factors call for increased study of the genetic diversity of South African individuals, as 
well as psychiatric pharmacogenomic research applications, in the hope of improving and 
understanding treatment response in schizophrenia in a population-specific manner. 
Optimising treatment with the use of pharmacogenomics is particularly important in LMIC, 
since countries such as South Africa experience a greater health burden. Even though there 
is much research to be done, South Africa is considered the leader amongst developing 
countries in pharmacogenomics and biomarker research (Gupta et al., 2014). 
2.6. Overview of the current study 
2.6.1. Aim and objectives 
This study aims to explore the functional consequences of noncoding genetic variants that 
contribute to complex and heterogeneous antipsychotic treatment outcomes in 
schizophrenia, and subsequently investigate these findings in South African individuals. 
The specific objectives of this study are as follows: 
PART 1: Bioinformatic identification of potential regulatory variants associated with 
antipsychotic treatment response 
 Survey the literature to identify GWAS SNPs that are significantly associated with 
antipsychotic treatment response, including ADRs, in schizophrenia. 
 Make use of publicly available genetic variation data to determine the variants in LD 
with the associated SNPs. 
 Employ recent publicly available data and bioinformatic tools to identify noncoding 
SNPs that potentially affect regulation. 
 Identify affected genes and pathways and assess likelihood of their involvement in 
treatment response. 
PART 2: Associations between predicted regulatory variants and antipsychotic treatment 
outcomes in a South African schizophrenia cohort 
 Prioritise SNPs and genotype in a South African first episode schizophrenia cohort. 
 Perform association analyses to determine which variants are associated with 
treatment outcomes within the cohort. 
 Compare associations with regards to original GWAS SNPs.  
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Bioinformatic identification of potential regulatory variants 
associated with antipsychotic treatment response 
3.1. Summary 
Advances in genetic data generation have increased exponentially in recent years. For 
example, results of the ENCODE project provide masses of novel information on noncoding 
DNA and gene regulation. To interpret the multitude of results, bioinformatic resources are 
constantly being developed and improved upon. These tools allow in-depth interpretation, 
including uncovering the functional implications of noncoding variants associated with 
complex traits. One such trait is antipsychotic treatment response. Antipsychotics are the 
most effective treatment for schizophrenia, a debilitating psychiatric disorder, but up to half 
of patients respond poorly to these drugs and can develop adverse drug reactions.  
To improve our limited understanding of the biological mechanisms underpinning 
schizophrenia treatment outcomes, a novel bioinformatics pipeline was applied in this study. 
Previously significant GWAS variants (P ≤ 5x10-7) were mined, and publically available 
population data was used to find SNPs in LD (r2 ≥ 0.8) with these variants. This approach 
allowed for hypothesis-free evaluation of genome-wide variants. Subsequently, tools making 
use of ENCODE data, namely RegulomeDB and rSNPBase, predicted the regulatory impact 
of the variants and their affected gene targets, including eQTLs. Pathway and network 
analyses were performed with DAVID and GeneMANIA respectively, and tissue-specific 
expression of the affected genes was assessed by FANTOM5.  
Despite few GWAS and poorly-characterised cohorts, several regulatory effects were 
identified. The most important results of this study were that i) treatment-refractory 
schizophrenia was the most common trait significant for regulation, with 16 rSNPs on 4q24 
affecting NFKB1 expression, and ii) there was extensive overlap with regions and functions 
that had been previously implicated in schizophrenia risk, particularly with regards to 
immune dysregulation. NFKB1, which also plays an important role in immune functioning 
and has been previously implicated in schizophrenia, was affected by almost half of the 
identified rSNPs. The significance of NFKB1 was confirmed with pathway and network 
analyses, which illustrated interactions with other genes for three of four predicted pathways. 
Lastly, gene expression analyses showed that four of the top 10 affected genes were most 
upregulated in brain tissues. This study provides evidence for the overlap between 
schizophrenia risk and treatment response. Additionally, the importance of well-
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characterised cohorts for clinical and genetic analyses is clear. NFKB1 and other associated 
genes should be further studied in different, population-specific, and replicative cohorts in 
order to validate potential regulatory biomarkers of treatment response.        
3.2. Introduction 
In the last decade there have been major advancements in elucidating the genetics of 
complex traits and diseases. GWAS enable the simultaneous analyses of hundreds of 
thousands to millions of variants across the genome. This approach is popular, shown by the 
thousands of GWAS recorded in the NHGRI GWAS Catalog (Welter et al., 2013). Despite 
the abundance of data, the biological interpretation of genetic signals associated with 
particular traits is mostly insufficient, and subsequently misguided. The majority of significant 
GWAS variants lie in noncoding regions. Even so, biological interpretations tend to assess 
SNPs in terms of the function of the closest gene, even if the SNP is intergenic and 
hundreds of kilobases away (Ritchie et al., 2014). This approach restricts interpretation, 
particularly since the closest gene may not incorporate all variants within the tag SNP’s 
haplotype, and LD can vary extensively between population groups (Christoforou et al., 
2012).  
Traditionally, coding SNPs have proved far more amenable to functional analyses, which 
means that they are often prioritised post-GWAS for further study, whilst noncoding variants 
are ignored (Cooper and Shendure, 2011). Recently, we have learnt a great deal more about 
noncoding regions with the results of the ENCODE project, which sought to characterise all 
the functional elements of the genome, including regulatory factors (The ENCODE Project 
Consortium, 2011). With this knowledge, it has been revealed that noncoding SNPs 
implicated in regulation, or rSNPs, are enriched for GWAS associations, highlighting the 
importance of analysing these regions for implications in disease (Schaub et al., 2012; 
Maurano et al., 2013). Indeed, rSNPs are potentially more damaging than coding SNPs, 
considering the wider range of expression dysregulation associated with transcription and 
translation candidates (Georgitsi et al., 2011). 
Many bioinformatic tools that make use of the abundance of ENCODE data have recently 
been developed. For example, RegulomeDB (Boyle et al., 2012) and rSNPBase (Guo et al., 
2014) both assess the regulatory potential of a SNP, the former looking at eQTL evidence 
and proximal regulation, and the latter assessing proximal, distal and post-transcriptional 
functioning and predicting downstream gene targets.  
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Schizophrenia, an example of a widely studied heterogeneous disease, is a chronic and 
debilitating psychiatric disorder. Antipsychotics are the main treatment for this disease, 
although treatment proves ineffective for roughly a third of patients (Liou et al., 2012). 
Despite the fact that genetic variation has shown to substantially contribute to antipsychotic 
treatment response, the mechanisms involved are not well understood. Consequently, in the 
last five years, GWAS have been applied to schizophrenia treatment response in an attempt 
to shed light on the genetics of poor treatment response and adverse drug reactions. 
The purpose of this study was to analyse previous antipsychotic response GWAS and 
investigate functionality with the use of these recent bioinformatic advancements. By 
incorporating LD variants from HapMap (The International HapMap Consortium, 2003) and 
1000 Genomes (The 1000 Genomes Project Consortium, 2010) populations, all the potential 
“causal” SNPs to date were accounted for. These variants were then investigated with the 
use of experimentally validated data as well as predictive tools to isolate rSNPs and their 
gene targets. Subsequently, pathways, networks, and tissue-specific expression of these 
genes were assessed. To our knowledge, this is the first study of its kind to investigate 
antipsychotic response GWAS with regards to genomic regulation, and the use of this 
bioinformatics pipeline has the potential to improve our understanding of the biology of 
treatment response in schizophrenia. 
3.3. Materials and methods 
Refer to Electronic Sources (p. 107) for dates of access to online tools. 
3.3.1. Data-mining 
The literature was mined in order to identify all variants from GWAS that have been 
significantly associated with antipsychotic response in schizophrenia, including ADRs. This 
was accomplished with the use of a database of complex disease GWAS, the human 
genome epidemiology (HuGE) Navigator GWAS Integrator version 2.0 (Yu et al., 2008), 
available at http://hugenavigator.net/HuGENavigator/home.do. The search terms 
“antipsychotic”, “schizophrenia”, and “adverse drug reaction” were used successively to 
identify all relevant GWAS. The corresponding articles were accessed in PubMed via HuGE 
Navigator and further investigated. HuGE Navigator is updated regularly, but a survey of the 
NHGRI GWAS Catalog (http://www.genome.gov/gwastudies/) and a manual literature search 
of PubMed (http://www.ncbi.nlm.nih.gov/pubmed) were performed with the same search 
terms to account for any studies that may not have been included on HuGE Navigator.  
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Due to multiple testing, it is generally accepted that the genome-wide significance threshold 
should be P ≤ 5x10-8 (Sham and Purcell, 2014). Using this cut-off point, less than 10 SNPs 
from four GWAS qualified for further analysis (highlighted in Table 3.3), over half of which 
related to antipsychotic-induced metabolic side effects (Adkins et al., 2011; Malhotra et al., 
2012). Due to the restrictive nature of these results, the threshold for inclusion of SNPs was 
raised to P ≤ 5x10-7 in order to increase the amount of variants, independent studies, and 
response phenotypes. Kingsmore and colleagues (2008) refer to this value as a “respected 
threshold” in a review of GWAS study designs. 
Additionally, the SNPs were investigated with SeattleSeq Annotation 137 version 8.07 
(http://snp.gs.washington.edu/SeattleSeqAnnotation137/) to confirm their position with 
respect to the genes listed in the nine GWAS, since there is a tendency to relate the function 
of the closest gene to the effect of the SNP, without considering the variant’s potential role in 
other pathways. SeattleSeq acquires gene information from the Human Genome 
Organisation (HUGO) Gene Nomenclature Committee (HGNC; http://www.genenames.org/).  
3.3.2. Variants in linkage disequilibrium 
To find SNPs in high LD (r2 ≥ 0.8; Carlson et al., 2004) with the significant GWAS variants, 
SNP Annotation and Proxy search (SNAP) version 2.2 was employed 
(http://www.broadinstitute.org/mpg/snap/). This tool conveniently combines two large-scale 
and widely used repositories of human genetic variation, namely HapMap (The International 
HapMap Consortium, 2003) and 1000 Genomes (The 1000 Genomes Project Consortium, 
2010). SNAP allows one to choose between four data sets: 1) 1000 Genomes Pilot 1, 2) 
HapMap phase II release 21, 3) HapMap phase II release 22, and 4) HapMap phase 3 
release 2. For each set, one can specify which population group to analyse. 1000 Genomes 
and HapMap population groups available on SNAP are indicated in Table 3.1. 
Different population groups were analysed depending on the ancestral make-up of the 
patient samples in the GWAS. For example, many of the identified GWAS studied SNPs 
within the CATIE cohort (discussed in 2.2.1), which consisted of 57% Caucasian, 29% 
African American and 14% “other” individuals (McEvoy et al., 2005). Therefore, for CATIE, 
all population groups on SNAP were analysed to account for LD structures within these 
diverse ancestry groups. In another GWAS (Liou et al., 2012), all individuals under study 
were of Han Chinese descent, therefore only the CHBJPT and JPT+CHB+CHD population 
options were used for analysis of these SNPs.   
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Table 3.1: Population groups on SNAP (http://www.broadinstitute.org/mpg/snap/). 
Population code Description Dataset 
CEU Utah residents with Northern and Western European ancestry from 
the Centre d'Etude du Polymorphisme Humain (CEPH) collection 
1, 2, 3, 4 
YRI Yoruba in Ibadan, Nigeria 1, 2, 3, 4 
CHBJPT Han Chinese in Beijing, China, and Japanese in Tokyo, Japan 1, 2, 3, 4 
ASW African ancestry in south west America 4 
CHD Chinese in metropolitan Denver, Colorado 4 
GIH Gujarati Indians in Houston, Texas 4 
LWK Luhya in Webuye, Kenya 4 
MEX Mexican ancestry in California, Los Angeles 4 
MKK Maasai in Kinyawa, Kenya 4 
TSI Toscans in Italy 4 
CEU+TSI Combined panel of CEU and TSI 4 
JPT+CHB+CHD Combined panel of JPT, CHB and CHD 4 
1 = 1000 Genomes Pilot 1; 2 = HapMap phase II release 21; 3 = HapMap phase II release 22; 4 = 
HapMap phase 3 release 2. 
Separate analyses for each dataset for each relevant population were performed. 
Subsequently, the results were manually combined into the appropriate population 
supergroups as defined in this study (Caucasian: CEU, CEU+TSI; African: YRI, ASW, LWK, 
MKK; and other: CHBJPT, CHD, GIH, MEX, JPT+CHB+CHD). For each GWAS, only SNPs 
in common between the supergroups were included for further analyses. Additionally, SNPs 
were excluded if they occurred in either a HapMap or 1000 Genomes dataset, but not the 
other. The SNPs were, therefore, filtered to include only those that were i) in LD with a 
GWAS SNP with an r2 equal to or greater than 0.8, and ii) present in all relevant population 
supergroups in both 1000 Genomes and HapMap datasets (1 and 2 or 3 or 4).   
3.3.3. RegulomeDB analysis 
Original GWAS variants and SNPs in LD were analysed with several bioinformatic 
resources. RegulomeDB (http://regulome.stanford.edu/) is a database that incorporates 
ENCODE datasets, computational predictions, a large amount of eQTLs, and other 
published literature to predict the effect that a single base pair change can have on the 
binding of regulatory elements to DNA (Boyle et al., 2012). This tool has been widely used to 
analyse the impact of noncoding SNPs on gene regulation (Chung et al., 2013; Juraeva et 
al., 2014).  
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RegulomeDB annotates intergenic SNPs within regulatory elements, and predicts the degree 
to which a SNP will interfere with binding and downstream regulatory processes. Regulatory 
elements include promoters, enhancers, and TFBS. Predictions are made using a heuristic 
scoring system based on the amount of evidence available for a particular SNP, as 
illustrated in Table 3.2.   
Table 3.2: RegulomeDB scoring system, with category 1 being most significant and category 6 least 
significant (Boyle et al., 2012).  
Category Description 
 Likely to affect binding and linked to expression of a gene target 
1a eQTL + TF binding + matched TF motif + matched DNase footprint + DNase peak 
1b eQTL + TF binding + any motif + DNase footprint + DNase peak 
1c eQTL + TF binding + matched TF motif + DNase peak 
1d eQTL + TF binding + any motif + DNase peak 
1e eQTL + TF binding + matched TF motif 
1f eQTL + TF binding/DNase peak 
  
 Likely to affect binding 
2a TF binding + matched TF motif + matched DNase footprint + DNase peak 
2b TF binding + any motif + DNase footprint + DNase peak 
2c TF binding + matched TF motif + DNase peak 
  
 Less likely to affect binding 
3a TF binding + any motif + DNase peak 
3b TF binding + matched TF motif 
  
 Minimal binding evidence 
4 TF binding + DNase peak 
5 TF binding or DNase peak 
6 Motif hit 
 
According to Boyle et al. (2012), eQTLs classify a SNP as being highly significant, since 
eQTLs display direct experimental evidence for altering expression levels of a particular 
gene. Therefore, SNPs in category 1 are more significant than any other evidence for 
regulation. Category 1 decreases in significance from subcategories “a” to “f”, with “a” having 
more annotations available than “b”, and so on. These annotations include experimental 
evidence for transcription factor (TF) binding, and computational predictions such as DNase 
footprinting. Category 2 is identical to category 1, with the exception of eQTL evidence. 
Category 3 consists of SNPs with less evidence of regulatory impact and categories 4-6 
exhibit minimal evidence thereof (Boyle et al., 2012).    
The list of combined GWAS and LD SNPs was entered into RegulomeDB and SNPs were 
ranked according to the scoring system. Seven SNPs returned a server error. These rs 
numbers were entered into the Ensembl Genome Browser 
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(http://www.ensembl.org/index.html) to identify synonyms, and the new rs numbers were 
successfully analysed by RegulomeDB. SNPs in categories 1-3 are considered important for 
further investigation, and were prioritised for further study (Chung et al., 2013).    
3.3.4. rSNPBase analysis 
The rSNPBase (http://rsnp.psych.ac.cn/) allows for the assessment of different types of 
regulation, including proximal, distal and post-transcriptional processes (Guo et al., 2014). 
For further insight into the regulatory potential of antipsychotic response variants, the GWAS 
and LD SNPs were analysed with rSNPBase to identify potential rSNPs. Additionally, genes 
predicted to be affected by these rSNPs were retrieved.  
3.3.5. Variants affecting binding motifs 
Concurrent to the rSNPBase and RegulomeDB analyses, Transcription factor Affinity 
Prediction (TRAP) was utilised to assess the impact of the SNPs on known transcription 
factor motifs (Manke et al., 2010). A tool specifically designed to predict the impact of single 
nucleotide changes, sTRAP (http://trap.molgen.mpg.de/cgi-bin/trap_two_seq_form.cgi),  
compares “wild-type” and “mutant” sequences, and evaluates subsequent changes in affinity 
for TFs to known TFBS motifs, attained from the Jaspar database 
(http://jaspar.genereg.net/). In this computational model, changes in affinity are calculated 
based on the log ratio of binding probability between “wild-type” and “mutant” sequences 
(Manke et al., 2010).  
The R package (R Development Core Team, 2010) of sTRAP, tRap, is freely available and 
was utilised to evaluate all SNPs simultaneously (http://trap.molgen.mpg.de/cgi-
bin/download.cgi). A custom Unix script incorporating tRap was designed by Dr N. Ishaque 
of the German Cancer Research Center (Heidelberg, Germany; Script S1). These 
commands were performed in the Unix shell and the output was exported to a .txt file. Firstly, 
a list of all the SNPs were converted to a Browser Extensible Data (BED) file, for which a 
FASTA file was generated. Similarly, BED and FASTA files for the regions 15 base pairs up- 
and downstream of each variant were created. A Perl script was written by Dr Ishaque to 
combine the FASTA files (Script S2), in order to analyse the sequences with tRap.     
The results were ranked by log ratio, r, with the largest positive or negative value indicating 
the most significant increase or decrease in binding affinity respectively, with reference to 
the “wild-type” sequence (Manke et al., 2010). Significant motifs present in humans were 
obtained from Jaspar (http://jaspar.genereg.net/) from the TRAP motif identifiers. 
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To assess the uniqueness of results obtained for schizophrenia treatment response, the 
same workflow was applied to three other complex traits. HuGE Navigator was surveyed for 
drug response GWAS, and two traits with sufficient results were analysed further, namely 
response to antidepressants, and response to hepatitis C treatment. Response to 
antidepressants was selected because, as previously discussed, psychiatric disorders have 
shown biological overlap in susceptibility and treatment response. On the other hand, 
hepatitis C treatment response has not been shown to be related to antipsychotic response. 
Additionally, GWAS on variants associated with eye colour, a complex trait, were analysed. 
The purpose of this was to establish a “baseline” level of regulation within the genome and to 
determine if any motifs were enriched for drug response, and more specifically, response to 
antipsychotics. These “control” traits were evaluated using the methods outlined in 3.3.2 and 
then assessed with the customised tRap script (Script S1).     
3.3.6. Nonsynonymous coding variants 
As an additional analysis, SNPs in coding regions were assessed for effects on protein 
function. To achieve this, PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/) was used. 
This resource uses computational prediction to characterise nonsynonymous SNPs based 
on their predicted impact on protein-coding regions of the genome (Adzhubei et al., 2010). 
PolyPhen-2 classifies SNPs as either “benign”, “possibly damaging”, or “probably 
damaging”. Additionally, a score is assigned that translates as the probability of the variant 
being damaging, i.e. a score closer to one indicates a more damaging SNP (Adzhubei et al., 
2010).  
3.3.7. Affected genes and pathways 
To assess the affected genes, functional clustering was performed with the use of pathway 
and network analyses. A list of genes was compiled containing i) eQTL targets from 
RegulomeDB and rSNPBase,  ii) affected genes according to rSNPBase, and iii) genes 
containing any nonsynonymous variants classified by PolyPhen-2.  
The Database for Annotation, Visualization and Integrated Discovery (DAVID) version 6.7 is 
a commonly used online pathway analysis tool available at 
http://david.abcc.ncifcrf.gov/home.jsp (Huang et al., 2009). By entering the gene list into 
DAVID, the aim was to investigate whether the genes were common to any pathways, and 
what the biological significance of these pathways is. The Functional Annotation Clustering 
tool was used to identify pathways via several databases: the Biological Biochemical Image 
Database (BBID), the Kyoto Encyclopedia of Genes and Genomes (KEGG), BioCarta, 
Protein Analysis Through Evolutionary Relationships (PANTHER) and Reactome.  
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Clustered genes from DAVID were further explored with GeneMANIA 
(http://www.genemania.org/). This graphical interface forms connections between genes 
based on co-expression, cell or tissue co-localisation, genetic and physical interactions, and 
predicted functional relationships (Warde-Farley et al., 2010). Relevant genes were grouped 
and visualised together based on functional and pathway classifications from DAVID. 
Subsequently, these annotations were assessed for their likelihood to be of relevance to 
antipsychotic treatment response. 
3.3.8. Tissue-specific gene expression 
Affected genes were assessed with regards to tissue-specific activation. Firstly, genes were 
ranked according to the number of rSNPs predicted to affect them. Subsequently, to 
determine the gene’s potential involvement in antipsychotic response mechanisms, 
expression levels were identified in healthy brain and liver cell lines via the Semantic 
catalogue of Samples, Transcription initiation And Regulators (SSTAR) on the FANTOM5 
database (http://fantom.gsc.riken.jp/5/sstar). This resource uses Cap Analysis of Gene 
Expression (CAGE) sequencing to identify cDNA and subsequently map it to a particular 
transcription start site. The number of sequenced fragments, or “tags”, correlates with the 
level of gene expression in that particular tissue (Kodzius et al., 2006). Expression is 
measured in tags per million (TPM), where a gene is considered to be “switched on” if it 
shows at least 10 TPM (The FANTOM Consortium et al., 2014). Cell lines relating to brain 
and liver tissue on FANTOM5 are listed in Box S1. Each brain and liver cell line was 
analysed for each gene, and the cell line with the highest expression levels was also 
recorded for comparison.   
3.4. Results 
3.4.1. Antipsychotic response GWAS 
The HuGE Navigator GWAS Integrator and the NHGRI Catalog were mined to identify 
previous GWAS on antipsychotic pharmacogenomics. Nine studies with SNPs reaching 
genome-wide significance (P ≤ 5x10-7) were identified. All but one GWAS was found by both 
databases. The most recent study, by Clark et al. (2013), was only listed in the NHGRI 
Catalog, most likely because it is more regularly updated than HuGE Navigator. A literature 
search with PubMed did not reveal any additional studies. The GWAS covered a range of 
responses, namely: adverse motor side effects (EPS), metabolic changes [including 
increases in cholesterol, triglycerides and body mass index (BMI)], changes in 
neurocognitive functioning, changes in symptom severity rated both by the patient and 
clinician, adverse cardiac symptoms, and treatment-refractoriness. The identified GWAS 
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found a combined total of 62 SNPs significantly associated with antipsychotic treatment 
response, as shown in Table 3.3. These variants are ranked by earliest to most recent study 
and, within this ranking, by most significant P-value. Considering the location of the 62 
variants identified, the most commonly occurring region is 4q24, with five SNPs at this locus 
having reached significance in four different GWAS. One of these variants, rs230529, was 
significant for treatment-refractoriness (Liou et al., 2012), whilst the other four – rs7669317, 
rs1405687, rs2636697 and rs2636719 – were associated with EPS, metabolic side effects, 
and clinician-rated symptom severity respectively (Åberg et al., 2010; Adkins et al., 2011; 
Clark et al., 2013). Most of the GWAS indicated the SNP position in terms of the closest 
gene, without specifying whether it is located in an intron or whether it is intergenic. Once 
annotated with SeattleSeq Annotation 137, it was shown that only one SNP, rs17727261, 
occurs in a protein-coding region, namely in an exon of the contactin associated protein-like 
5 (CNTNAP5) gene. Of the other SNPs, 27 are intronic, one occurs in the 3’-UTR of the zinc 
finger protein 202 (ZNF202) gene, and the remaining 33 are intergenic. As shown in bold in 
Table 3.3, there were four instances in which SeattleSeq classified SNPs as intergenic whilst 
the GWAS listed them as occurring within a gene (Clark et al., 2013). 
3.4.2. GWAS cohort ancestry and LD analyses 
The 62 significant SNPs were analysed for variants in linkage disequilibrium according to the 
1000 Genomes and HapMap population groups. Populations were selected according to the 
ancestral make-up of each GWAS, as indicated in Table 3.4. All GWAS were corrected for 
ancestry, in cases where the cohort was comprised of more than one ethnic group. 
Additionally, many of the studies performed subsample testing in order to ascertain whether 
a particular population group was driving a significant association. Except for a few instances 
in which a SNP was invariant in a particular subgroup, the majority of SNPs were significant 
– albeit to varying degrees – across population subgroups. Therefore, to be as inclusive as 
possible, no population groups were excluded for further LD analysis.  
There were several instances in which a variant found on SNAP was in LD (r2 ≥ 0.8) with 
more than one GWAS SNP. No SNPs from independent GWAS studies shared LD for any 
population groups, although there were significant SNPs in LD within specific GWAS. For 
example, rs2636697, and rs2636719 from the Clark et al. study (2013) are in perfect LD (r2 = 
1 for 1000 Genomes CEU), as well as rs7105881, rs7119817, and rs7108821 (r2 = 1 for 
each pair for 1000 Genomes CEU) from the Adkins et al. GWAS (2011). Once all variants for 
all relevant populations were combined, as described in 3.3.2, there was a total of 535 
unique SNPs, including the original 62 GWAS SNPs.  







VARIANT                          LOCUS
GENEa   
RESPONSE MEASUREMENT P-VALUE                      EFFECTb Initial,  
Replication 
Designated Mapped 
Åberg et al., 
2010 
738c 
rs17022444 2p12 None Intergenic EPS (SAS) 1 x 10-10 + 
rs7669317 4q24 None Intergenic EPS (AIMS) 8 x 10-8 + 
rs2126709 11q24.1 ZNF202 ZNF202 (3'-UTR) EPS (SAS)  4 x 10-7 + 
Adkins et al., 
2011 
738c 
rs1568679 15q14 MEIS2 MEIS2 (intron) Hip circumference  1 x 10-8 + 
rs1967256 5q14.3 GPR98 GPR98 (intron) Haemoglobin A1c 3 x 10-8 + 
rs11954387 5q14.3 GPR98 GPR98 (intron) Haemoglobin A1c 3 x 10-8 + 
rs1405687 4q24 None Intergenic Hip circumference  5 x 10-8 - 
rs1568679 15q14 MEIS2 MEIS2 (intron) Waist circumference  6 x 10-8 + 
rs13224682 7p22.3 PRKAR2B  PRKAR2B (intron) Triglycerides 6 x 10-8 + 
rs1464500 12p12.1 SOX5 SOX5 (intron) HDL cholesterol 1 x 10-7 + 
rs17651157 18q12.2 FHOD3 FHOD3 (intron) Triglycerides 1 x 10-7 + 
rs6735179 2p25.3 None Intergenic Triglycerides 1 x 10-7 + 
rs518590 13q12.11 None Intergenic HDL cholesterol 2 x 10-7 + 
rs10502661 18q12.2 FHOD3 FHOD3 (intron) Triglycerides 2 x 10-7 + 
rs1187614 14q32.13 CLMN CLMN (intron) Total cholesterol 2 x 10-7 - 
rs6741819 2p25.1 RNF144A RNF144A (intron) Triglycerides 2 x 10-7 + 
rs4838255 9q33.1 ASTN2 ASTN2 (intron) Triglycerides 3 x 10-7 + 
rs2994684 10p11.22 None Intergenic Triglycerides 3 x 10-7 + 
rs977396 8q22.3 None Intergenic Total cholesterol 3 x 10-7 + 
rs7105881 11q23.1 None Intergenic Hip circumference  3 x 10-7 + 
rs1117324 2p24.1 None Intergenic Hip circumference  3 x 10-7 + 
rs4783227 16q23.3 None Intergenic Total cholesterol 4 x 10-7 - 
rs320209 9q31.1 None Intergenic Glucose  4 x 10-7 + 
rs7108821 11q23.1 None Intergenic Hip circumference  4 x 10-7 + 
rs10499504 7p21.1 None Intergenic Total cholesterol 4 x 10-7 - 
rs7119817 11q23.1 None Intergenic Hip circumference  5 x 10-7 + 
rs9658108 6p21.31 PPARD PPARD (intron) Glucose  5 x 10-7 + 































Table 3.3: Significant SNPs from antipsychotic pharmacogenomic GWAS identified by HuGE Navigator and the NHGRI GWAS Catalog. 
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VARIANT                          LOCUS
GENEa                      
RESPONSE MEASUREMENT P-VALUE                      EFFECTb Initial,  
Replication 
Designated Mapped 
Adkins et al., 
2011 
738c rs399885 2p12 None Intergenic Heart rate 5 x 10-7 + 
McClay et al., 
2011a 
738c 
rs286913 11p13 EHF  EHF (intron)  Neurocognition: vigilance 7 x 10-8 - 
rs11240594 1q32.1 SLC26A9 SLC26A9 (intron) Neurocognition: processing speed 1 x 10-7 - 
rs11110077 12q23.1 ANKS1B ANKS1B (intron) Neurocognition: working memory 4 x 10-7 + 
rs7520258 1q42.3 GPR137B GPR137B (intron) Neurocognition: working memory 5 x 10-7 + 
rs12726652 1p13.3 None Intergenic Neurocognition: working memory 5 x 10-7 + 
rs11214606 11q23.2 DRD2 DRD2 (intron) Neurocognition: working memory 5 x 10-7 + 
rs2833556 21q22.11 HUNK HUNK (intron) Neurocognition: reasoning 5 x 10-7 - 
McClay et al., 
2011b 
738c 
rs17390445 4p15.1 None Intergenic Positive symptoms (PANSS) 1 x 10-7 + 
rs888219 9q33.3 None Intergenic Negative symptoms (PANSS) 2 x 10-7 - 
rs7968608 12q23.1 ANKS1B ANKS1B (intron) Negative symptoms (PANSS) 3 x 10-7 - 
rs17727261 2q14.3 CNTNAP5 CNTNAP5 (exon) Negative symptoms (PANSS) 5 x 10-7 - 
rs11722719 4p15.1 None Intergenic Positive symptoms (PANSS) 5 x 10-7 + 
Åberg et al., 
2012 
738c 
rs4959235 6p25.2 SLC22A23 SLC22A23 (intron) 
QTc interval prolongation 
2 x 10-7 + 
rs10458561 1p31.1 None Intergenic 4 x 10-7 + 
Athanasiu et al., 
2012 
594 
rs7838490 8q21.3 None Intergenic BMI  6 x 10-8 + 
rs11615274 12q21.1 None Intergenic HDL cholesterol 9 x 10-8 - 
Liou et al.,  
2012 
522 cases and 
806 controls, 
273 cases 
rs230529  4q24 NFKB1 NFKB1 (intron) 
Treatment-refractory 
schizophrenia 
2 x 10-7 d + 
rs11265461 1q23.3 None Intergenic 2 x 10-7 d + 
rs10218843 1q23.3 None Intergenic 3 x 10-7 d + 
Malhotra et al., 
2012 
139  
73, 40, 92 
rs489693 18q21.32 None Intergenic 
Severe weight gain, several other 
metabolic indices 
6 x 10-12 d + 
Clark et al., 
2013 
738c 
rs8050896 16q22.1 None Intergenic 
Clinical global impression severity 
scale (CGI-S) 
4 x 10-8 - 
rs17382202 5q12.1 PDE4D PDE4D (intron) 
Patient global impression (PGI) 
scale 
4 x 10-8 - 
rs10170310 2q22.1 SPOPL SPOPL (intron) PGI 1 x 10-7 + 
rs6688363 1q23.2 ATP1A2 Intergenic CGI-S 2 x 10-7 + 
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VARIANT                          LOCUS
GENEa                      
RESPONSE MEASUREMENT P-VALUE                      EFFECTb Initial,  
Replication 
Designated Mapped 
Clark et al., 
2013 
738c 
rs17742120 5q12.1 PDE4D PDE4D (intron) PGI 2 x 10-7 - 
rs2164660 5q12.1 PDE4D PDE4D (intron) PGI 2 x 10-7 - 
rs711355 15q13.1 TJP1 Intergenic PGI 2 x 10-7 - 
rs2980976 18q21.3 TNFRSF11A Intergenic CGI-S 3 x 10-7 + 
rs2636697 4q24 PPA2 PPA2 (intron) CGI-S 4 x 10-7 + 
rs2636719 4q24 PPA2 PPA2 (intron) CGI-S 5 x 10-7 + 
rs785423 15q13.1 TJP1 Intergenic PGI 5 x 10-7 - 
rs813676 15q13.1 TJP1 Intergenic PGI 5 x 10-7 - 















a Gene designated to the SNP by GWAS authors vs. gene mapped by SeattleSeq Annotation 137 (differences in bold).  
b Direction of effect of minor allele, where “+” denotes minor allele frequency (MAF) associated with poorer response or presence of ADR. 
c Identical cohort from the CATIE study (Lieberman et al., 2005). 
d Joint probability from meta-analysis of initial and replication cohorts. 
Shaded values indicate SNPs with P ≤ 5x10-8. 
SAS = Simpson-Angus Scale; AIMS = Abnormal Involuntary Movement Scale; UTR = untranslated region; Haemoglobin A1c = glycohaemoglobin 
(used to measure plasma glucose levels); HDL = high-density lipoprotein; QTc = interval between ventricular depolarisation (Q wave) and 
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Table 3.4: Ancestry breakdown of the four cohorts studied by relevant GWAS and corresponding 
SNAP populations included for LD analysis (http://www.broadinstitute.org/mpg/snap/). 
Study 
Sample ancestry proportions Included SNAP 
populations Initial Replication 
Åberg et al., 2010 
57%  EA,  
29% AA,  
14% other 
None All 
Adkins et al., 2011 
McClay et al., 2011a 
McClay et al., 2011b 
Åberg et al., 2012 
Clark et al., 2013 
Athanasiu et al., 2012 100% Caucasian None CEU, TSI, CEU+TSI 
Liou et al., 2012 100% Han Chinese 100% Han Chinese 
CHBJPT, CHD, 
JPT+CHB+CHD 
Malhotra et al., 2012 
55% Caucasian,  
23% AA,  
22% other 
70% Caucasian, 
30% AA; and  
100% Caucasian 
All 
EA = European American; AA = African American; CEU = Utah residents with Northern and Western 
European ancestry from the Centre d'Etude du Polymorphisme Humain (CEPH) collection; TSI = 
Toscans in Italy; CHBJPT = Han Chinese in Beijing, China, and Japanese in Tokyo, Japan; CHD = 
Chinese in metropolitan Denver, Colorado; JPT = Japanese in Tokyo, Japan; CHB = Han Chinese in 
Beijing, China. 
3.4.3. RegulomeDB analysis 
The total of 535 variants was analysed with RegulomeDB and each SNP was assigned a 
score based on its regulatory potential. Twenty SNPs scored significantly (≤ 3), and are 
listed in Table 3.5 together with their predicted regulatory effect. The results include two 
original GWAS SNPs, namely rs6741819 (Adkins et al., 2011) and rs10458561 (Åberg et al., 
2012). The remaining 18 SNPs were identified from LD analyses. The top 10 results 
obtained a score of one, meaning that they have shown to act as eQTLs, altering the 
expression of the following genes: mannosidase, beta A, lysosomal (MANBA), collagen, type 
IX, alpha 2 (COL9A2), and DEAD/H box helicase 11 (DDX11). Nine of these SNPs were in 
LD with rs230529 from the Liou et al. (2012) study, and rs10492354 was in LD with a 
significant SNP identified by McClay et al. (2011b). Proteins, such as TFs, that bind in the 
region of the SNP are indicated in Table 3.5. Additionally, their corresponding motifs and 
predicted position weight matrices (PWMs) are shown. All 20 SNPs show evidence for 
changes in chromatin state and histone modifications at their particular locus. A full list of 
these can be obtained for each SNP by entering the rs number into the database 
(http://regulome.stanford.edu/).   
Since 14 of the 20 SNPs occur in the 4q24 region, this locus was further investigated with 
the use of the University of California, Santa Cruz (UCSC) ENCODE browser 
(http://genome.ucsc.edu/ENCODE/). As shown in Figure 3.1, there are several lines of 
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evidence across different cell types that point to regulatory function in this region, including 
TFBS, histone marks and open chromatin, DNase I hypersensitive sites, and the start of 
transcription of the nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 
(NFKB1) gene. 
 
3.4.4. rSNPBase analysis 
Variants were also analysed with rSNPBase. This tool predicted that 222 of the 535 SNPs 
affected regulation, either proximally, distally, or post-transcriptionally. Additionally, it 
identified the predicted affected genes. Table 3.6 shows the 16 SNPs that were deemed 
significant by both rSNPBase and RegulomeDB. Motifs, genes, proteins, affected genes, 
and eQTLs common to both sets of results are highlighted in the table. 
3.4.5. Variants affecting binding motifs 
Changes in motif binding affinity were assessed with tRap and the most significant results 
are shown in Table 3.7. A total of 111 of the 535 variants were predicted by tRap to alter 
binding affinity, with many SNPs affecting more than one motif. This table includes the ten 
SNPs that are predicted to cause the largest decreases and increases in affinity 
respectively, measured by the log ratio. Overlaps with rSNPBase or RegulomeDB results are 
highlighted. The variant rs10492354 was predicted to be an eQTL for DDX11 expression by 
RegulomeDB, and caused the second highest decrease in binding affinity, at the breast 
cancer type I susceptibility protein (BRCA1) motif. Secondly, rs230493 was predicted by 
tRap to increase binding significantly at the GATA binding protein 2 (GATA2) motif, as well 
as show eQTL evidence and distal and post-transcriptional regulatory effects by 
RegulomeDB and rSNPBase. The GATA2 motif is the only motif that overlaps with 
significant bound proteins or motifs predicted by RegulomeDB or rSNPBase. 
The variants implicated in the control traits (response to antidepressants, response to 
hepatitis C treatment, and eye colour) were also analysed with tRap. Extensive overlap of 
motifs between antipsychotic response SNPs and the control SNPs was found. Table S1 
shows that only 12 motifs were unique to antipsychotic response, with a maximum of two 
SNPs significantly predicted to affect binding of each motif. 
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Scorea eQTL target(s) Bound protein(s) 
Sequence motif(s) Other evidence 





rs3774959 4:103511113 1b MANBA, COL9A2 RFX3 Lmo2complex 
 
Yes Yes 
rs230505 4:103481350 1d MANBA, COL9A2 BATF 




rs230532 4:103450166 1f MANBA, COL9A2 None Nanog 
 
Yes Yes 
rs230520 4:103465611 1f MANBA, COL9A2 None None  Yes Yes 
rs1599961 4:103443568 1f MANBA, COL9A2 None None 
 
Yes Yes 
rs230504 4:103481560 1f MANBA, COL9A2 None None 
 
Yes Yes 
rs230493 4:103486215 1f MANBA, COL9A2 RFX3 Six-1 
 
Yes Yes 
rs747559 4:103414174 1f MANBA, COL9A2 None Pitx2, Cdc5 
 
Yes Yes 
rs4648055 4:103515312 1f MANBA, COL9A2 FOS None 
 
Yes Yes 
rs10492354 12:31357101 1f DDX11 None FOXP1, Foxk1 
 
Yes Yes 
rs3774933 4:103426338 2a None FOXA1, CEBPB C/EBP 
 
Yes Yes 




































Table 3.5: Top predicted rSNPs from RegulomeDB with associated regulatory targets and effects (http://regulome.stanford.edu/).  
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Scorea eQTL target(s) Bound protein(s) 
Sequence motif(s) Other evidence 















rs17032850 4:103507702 2b None SPI1, EBF1, BATF TCF-4, HNF1 
 
Yes Yes 
rs2272676 4:103423325 2b None 
POLR2A, TCF4, 
ZNF263, CDX2, 






rs1352318 8:89566902 2c None CTCF, RAD21 CTCF 
 
Yes Yes 
rs10458561c 1:70921172 3a None EP300 C/EBPalpha 
 
Yes Yes 
rs230495 4:103487299 3a None MAFK AP-1, Nanog 
 
Yes Yes 












a Score definitions are listed in Figure 3.1. 
b PWM corresponds to motif in bold. Red box indicates SNP position. 
c SNP from original GWAS study. 
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Figure 3.1: Magnified view of the 4q24 genomic region on the UCSC Genome Browser with ENCODE data tracks (http://genome.ucsc.edu/ENCODE/). This 
region contains 14 of 20 predicted rSNPs according to RegulomeDB. ENCODE tracks show A) transcription start of NFKB1 gene, B) common SNPs (MAF > 
1%) identified in this region, C) peaks for histone mark H3K27Ac, associated with open chromatin, D) TFBS determined by ChIP-Seq and E) DNaseI 
hypersensitive sites determined by various experiments. Different colours indicate evidence in different cell lines.     
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 Table 3.6: rSNPBase annotations for significant RegulomeDB SNPs, arranged by genomic position (http://rsnp.psych.ac.cn/). 
SNP eQTL target(s) 
Type of regulation 
Affected gene(s) 
Proximal: TF  
Post-transcriptional: 
RNA-binding protein  
Distal  












Max, Rad21, BCLAF1, ELF1, 
FOXM1, Pol2-4H8, Pol2, 
NFKB, ZNF263, CTCF, EBF1,  
several others* 
PABPC1 Yes 






CHD1, MafK, ARID3A, CEBPB PABPC1 
 
NFKB1 
rs1599961 COL9A2, MANBA, MAPKSP1 
 
PABPC1 Yes NFKB1 
rs230532 
CCNG2, COL9A2, MANBA, ADH7, 
BANK1, CISD2  
PABPC1 Yes NFKB1 






PLEKHA4, COL9A2, MANBA, ADH7, 
BANK1, CISD2  
PABPC1 Yes NFKB1 










rs230493 CACNB1, COL9A2, MANBA 
 
PABPC1 Yes NFKB1 
rs230495 
 
MafF, MafK PABPC1 Yes NFKB1 
rs17032850 
  
PABPC1 Yes NKFB1 














Shaded genes, proteins and motifs indicate commonalities between rSNPBase and RegulomeDB SNPs.  
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Table 3.7: Top 10 SNPs predicted by TRAP to increase or decrease motif binding affinity significantly. 
Decreases in binding affinity 
SNP log ratio Jaspar motif ID Motif Total SNPsa 
rs2367184 -3.78665 MA0133.1 BRCA1 9 
rs10492354 -3.60905 MA0133.1 BRCA1 9 
rs1585215 -3.27794 MA0084.1 SRY 8 
rs60371688 -2.70746 MA0133.1 BRCA1 9 
rs11613776 -2.48881 MA0036.1 GATA2 4 
rs246430 -2.47982 MA0042.1 FOXI1 1 
rs67609022 -2.09686 MA0098.1 ETS1 9 
rs11214606 -2.09355 MA0098.1 ETS1 9 
rs3113628 -2.0879 MA0098.1 ETS1 9 
rs56293675 -2.08772 MA0098.1 ETS1 9 
Increases in binding affinity 
SNP log ratio Jaspar motif ID Motif Total SNPsa 
rs1020760 3.872955 MA0069.1 Pax6 6 
rs4648052 2.659042 MA0084.1 SRY 8 
rs71526953 2.337937 MA0133.1 BRCA1 9 
rs17742544 2.240923 MA0043.1 HLF 6 
rs230493 1.968377 MA0036.1 GATA2 4 
rs58133638 1.777604 MA0095.1 YY1 2 
rs62328542 1.725868 MA0099.2 JUN::FOSb 2 
rs55999909 1.715268 MA0259.1 HIF1A::ARNTb 1 
rs111577254 1.700943 MA0098.1 ETS1 9 
rs821102 1.656439 MA0258.1 ESR2 1 
a Total number of SNPs predicted to increase or decrease binding affinity significantly for each motif in 
the study. 
b Heterodimer  
Shaded SNPs and motifs were also deemed significant by RegulomeDB and/or rSNPBase. 
 
3.4.6. Nonsynonymous coding SNPs 
PolyPhen-2 was utilised to assess functional implications of the 535 SNPs with regards to 
protein-coding regions. One SNP located in an exon of the CNTNAP5 gene, rs17727261, 
was classified as nonsynonymous. This missense variant, identified as significant in the 
McClay et al. (2011b) GWAS, results in a serine to leucine substitution at codon 452 
(S452L). Polyphen-2 predicted this variant to be benign, with a score of 0.011. Therefore, 
none of the SNPs are expected to have damaging effects on protein products. This is 
expected given that the majority are in noncoding regions. 
3.4.7. Affected genes and pathways 
A list of affected genes was compiled by combining eQTL targets from rSNPBase and 
RegulomeDB, and affected genes predicted by rSNPBase. CNTNAP5 was also included, for 
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a total of 126 genes. After excluding pseudogenes and unprocessed transcripts, the list 
consisted of 118 unique genes, listed in Table S2. This gene set was uploaded to DAVID for 
functional annotation.   Four pathways were identified by DAVID and are ranked by P-value 
in Table 3.8. Terms with larger fold change values (> 1.5) and smaller uncorrected P-values 
(< 0.1) should be considered significant for further investigation (Huang et al., 2009). 
Therefore, all four pathways identified are of interest. NFKB1, affected by a total of 104 
rSNPs, plays a role in three of these pathways, namely HIV-I negative factor (Nef) 
functioning, chronic myeloid leukaemia, and human cytomegalovirus (CMV) and mitogen-
activated protein kinase (MAPK) pathways. The retinoblastoma 1 (RB1) gene also occurs in 
all three of these pathways. The fourth pathway, platelet-derived growth factor (PDGF) 
signalling, contains four genes affected by a total of six rSNPs. 
Table 3.8: Pathways identified by DAVID for affected genes (http://david.abcc.ncifcrf.gov/home.jsp). 
Tool Pathway Fold change P-value Genes Total SNPs* 



















* Total SNPs predicted by RegulomeDB and/ or rSNPBase to affect particular gene. 
Nef = negative factor; PDGF = platelet-derived growth factor; CMV = cytomegalovirus; MAPK = 
mitogen-activated protein kinase.   
 
The genes for each pathway were uploaded to GeneMANIA for further analysis. Networks, 
as well as corrected probability scores for common functions between genes, were 
assessed. Figure 3.2 shows the network for genes involved in the HIV-I Nef pathway. Two of 
the three genes in this pathway, NFKB1 and the actin, gamma 1 (ACTG1) gene, were 
identified by GeneMANIA to play a role in immune response-activating cell surface receptor 
signalling and Fc receptor signalling, with false discovery rate (FDR) values of 0.07 and 0.08 
respectively.  
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Figure 3.2: GeneMANIA network for affected genes in the HIV-I Nef pathway according to DAVID 
(ACTG1, NFKB1 and RB1), with related genes in grey. Red genes are involved in immune response-
activating cell surface receptor signalling and Fc receptor signalling pathways. Red connections 
indicate physical interactions (http://www.genemania.org/). 
Additionally, Figure 3.3 illustrates the affected genes involved in the chronic myeloid 
leukaemia pathway. No functions common to all three genes in this pathway were found, 
however there were several functional overlaps between NFKB1 and the Src homology 2 
domain containing (SHC) transforming protein 1 (SHC1) gene. These include Fc receptor 
signalling (FDR = 0.001) and neurotrophin signalling (FDR = 0.002), as well as the 
previously mentioned functions that are common to NFKB1 and ACTG1. Connections 
between genes involved in the Human CMV and MAPK pathways (NFKB1 and RB1) can 
also be viewed in Figure 3.3 (B). These genes both take part in regulatory region DNA 
binding (FDR = 0.015) as well as the regulation of lipid metabolism (FDR = 0.030). The 
network for PDGF signalling did not show functions common to any of the four genes and 
thus is not shown.  




Figure 3.3: GeneMANIA networks indicating genes in the chronic myeloid leukaemia pathway, and human CMV and MAPK pathways according to 
DAVID, with related genes in grey. Red genes in A) are involved in Fc receptor signalling and neurotrophin signalling pathways, and red genes in B) play a 
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3.4.8. Tissue-specific gene expression 
Expression patterns of the ten genes affected by the most number of SNPs were analysed 
with FANTOM5. The highest brain- and liver-related expression values, as well as highest 
overall expression value, were measured as shown in Table 3.9. For four of the affected 
genes, indicated in bold, the highest overall expression was in a cell line related to the brain, 
i.e. the pineal gland, globus pallidus, and astrocytes in the cerebellum. A few genes showed 
negligible expression (TPM < 10) in either brain or liver cells, with the alcohol 
dehydrogenase class 4 mu/sigma chain (ADH7) gene showing no expression in either. Of 
the ten genes, the highest liver-related expression was demonstrated by calmin (calponin-
like, transmembrane) (CLMN) in hepatocytes (TPM = 81.6).  











Tissue TPMa Tissue TPMa Tissue TPMa 
















35.2 Neutrophils 290.5 


























21.0 Foetal liver 10.6 Neutrophils 65.8 
ADH7 6 None 0.0 None 0.0 Oesophagus 130.6 
a TPM = tags per million; TPM ≥ 10 represents active gene expression.  
Cases in which relevant tissue expression is also highest overall expression are indicated in bold. 
3.5. Discussion 
This study aimed to assess the functional impact of SNPs implicated in previous 
antipsychotic response GWAS, in order to improve our understanding of the mechanisms 
behind antipsychotics and the genetics of treatment response. The novel and 
comprehensive bioinformatics pipeline provides an approach that includes the analysis of 
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predicted and experimentally validated regulatory regions overlapping the SNPs, and 
assesses the regulatory potential of each variant. Furthermore, functional interpretations can 
be made by exploring the predicted regulated genes, implicated pathways, and expression in 
relevant tissue types. These factors allow for hypothesis-free evaluation of significant 
genomic variants, and thus could uncover novel genes and pathways associated with 
treatment response.   
3.5.1. Antipsychotic response GWAS 
3.5.1.1. GWAS study design 
Firstly, the shortage of studies on antipsychotic treatment response is apparent. For 
example, when the interactive version of the NHGRI GWAS Catalog is consulted 
(http://www.ebi.ac.uk/fgpt/gwas/), one can see the plethora of significant SNPs for other 
traits or disorders, such as those of the immune or digestive systems. Using the Catalog’s 
genome-wide significance cut-off of P ≤ 5x10-8, only seven SNPs in Table 3.3 qualify as 
significant. Even with a more lenient threshold of P ≤ 5x10-7, only 62 SNPs from a total of 
nine studies are deemed important. However, this is not surprising since, to date, only twelve 
GWAS on antipsychotic response have been performed, and they do not match the large-
scale studies like those conducted by the PGC (Ripke et al., 2013; 2014). Additionally, the 
generally weak association signals contrast with those found in schizophrenia susceptibility 
GWAS, for which the strongest association signal has a P-value of 1.47x10-16 (Strange et al., 
2012). The reason for relatively weak associations can be explained by the limited sample 
size of previous treatment response GWAS, as well as the difficulty in obtaining a well-
characterised and clinically homogeneous cohort. 
The CATIE cohort, consisting of 738 genotyped individuals, was tested for associations with 
different response traits for six of the nine studies, as shown in Table 3.3. This cohort is both 
the largest and most thoroughly assessed antipsychotic response trial that has patient DNA 
available (Adkins et al., 2011). Individuals in CATIE began treatment on either one of four 
SGAs (ziprasidone, risperidone, quetiapine or olanzapine), or the FGA perphenazine. If 
treatment was deemed ineffective, patients could either go on to clozapine or a different 
SGA. The main aim of this multiphase, randomised trial was to compare effectiveness of 
different SGAs, and measure the efficacy of SGAs against perphenazine (Stroup et al., 
2003). The comprehensive clinical data obtained in the CATIE trial is useful for assessing 
different aspects of treatment response. The range of outcomes assessed include adverse 
metabolic and cardiovascular measures, EPS, rated with three different scales, general 
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cognitive and psychosocial functioning, and treatment response measured with the PANSS, 
PGI and CGI-S (Lieberman et al., 2005). 
Although differences in treatment efficacy are still under debate (Lewis and Lieberman, 
2008; Meltzer, 2013), these agents have demonstrated significantly different side effect 
profiles, particularly in the case of clozapine (Brandl et al., 2014). Our understanding of the 
mechanisms of antipsychotics is limited, but it is likely that different adverse reactions 
indicate different biological pathways, and thus antipsychotic heterogeneity limits statistical 
power in GWAS (Ni et al., 2013). In order to improve this, five of the CATIE GWAS 
increased clinical homogeneity at the price of decreasing sample size; in other words, the 
authors performed drug-specific GWAS on patient subgroups. For example, the two 
significant SNPs identified by Åberg et al. (2012) mediated the effects of quetiapine and 
risperidone on adverse cardiac events respectively. Additionally, Adkins and colleagues 
(2011) showed that, grouping by medication, risperidone was the antipsychotic with the most 
number of corresponding significant associations. Clozapine and perphenazine were also 
significantly associated with a number of different outcomes in this study. The Clark et al. 
GWAS (2013) and the two McClay et al. studies (2011a; 2011b) only found significant 
associations for the four SGAs ziprasidone, risperidone, quetiapine, and olanzapine. Åberg 
et al. (2010) did not indicate drug-specific results.  
Despite grouping patients by antipsychotic, the multiphase nature of CATIE meant that the 
majority of patients were on more than one type of antipsychotic (including clozapine) for the 
duration of the trial, and patients had not been required to be drug-naïve at the 
commencement of the study. Although there is an abundance of data available, this trial was 
not designed with pharmacogenomic application in mind. Nevertheless, CATIE provides a 
valuable resource of genetic and clinical data, without which the study of antipsychotic 
pharmacogenomics would be extremely limited. Furthermore, even with smaller, drug-
specific GWAS, many SNPs reached genome-wide significance for various treatment 
outcomes (Table 3.3).  
Of the remaining three GWAS cohorts, two stand out as being well-characterised in nature. 
The first study, by Liou et al. (2012), investigated schizophrenia treatment-refractoriness in 
Han Chinese individuals. Working under the hypothesis that refractoriness may be a “distinct 
and homogenous subgroup of schizophrenia”, the authors compared refractory individuals to 
healthy controls. Refractoriness was defined as nonresponse to two antipsychotic trials 
(chlorpromazine or one of six SGAs) or clozapine. This is in line with recommended 
treatment-refractoriness criteria (Suzuki et al., 2012). The homogeneity of the cohort, 
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comparison to controls, and lack of population stratification allowed for greater power to 
detect associations. Furthermore, replication of three associations in an independent cohort 
of 273 individuals provided robustness to the results. To evaluate the hypothesis that 
treatment-refractoriness is a unique endophenotype of schizophrenia, the top SNPs were 
then genotyped in a larger cohort of schizophrenia cases and healthy controls. Interestingly, 
none of the SNPs reached significance, providing credence for this concept. 
The second well-characterised study was conducted by Malhotra and colleagues (2012). 
Impressively, three independent cohorts were genotyped to validate the findings of the initial 
GWAS. This provided a joint P-value of 6 x 10-12 for rs489693, which was consistently 
associated with poor metabolic outcomes. This is the most significant SNP across all nine 
GWAS. The significance of this finding is emphasised by the fact that the discovery cohort 
and one replication cohort were drug-naïve prior to the study. Additionally, the large majority 
of patients received SGAs, with less than a third of one replication cohort (9% of all 
individuals) having been administered with haloperidol. Clinical uniformity was further 
maintained by the use of an exclusively clozapine-administered replication cohort, and 
exclusion of clozapine-treated patients from the discovery cohort (Malhotra et al., 2012). This 
GWAS demonstrates that good clinical characterisation is vital, and allows for robust results 
that provide valuable insight into the genetics of treatment response.   
Lastly, in contrast to the Malhotra et al. (2012) GWAS, the study designed by Athanasiu and 
colleagues (2012) has many flaws. The clinical data was obtained in a naturalistic setting, 
i.e. a hospital. Therefore, antipsychotic type and dose were adjusted when necessary, and 
patients were on different and multiple types of medication. Although this is how treatment 
operates in clinical practice, it is not ideal for a pharmacogenomic study attempting to draw 
statistically sound conclusions about the biology of adverse drug reactions. Patients 
receiving different classes of psychopharmacological agents (FGAs, SGAs, antidepressants 
and/ or mood stabilisers) were analysed together, and medications were grouped based on 
their likelihood of resulting in adverse reactions. This means that different drug types were 
included in the same subgroup. Bearing in mind that these medication types have different 
targets, pathways and side effects, finding true genetic associations would be difficult, if not 
impossible. The authors acknowledge that grouping in such a manner increases 
heterogeneity and subsequently the risk of type II errors (Athanasiu et al., 2012). A more 
suitable design would have been to group patients by medication type. Incidentally, 84% of 
the second group of patients received antipsychotics, and this was the only group for which 
significant associations were found. Therefore, the results were included in this study, but 
analyses were interpreted with caution.              
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3.5.1.2. Significant GWAS findings 
As expected, the majority of significant variants were not in protein-coding regions (Table 
3.3). For the most part, the authors’ annotation and the classification according to 
SeattleSeq were concordant, however differences were noted for the Clark et al. (2013) 
study. The authors clearly state that rs711355, rs785423, and rs813676 are located in the 
tight junction protein 1 (TJP1) gene, and that rs2980976 occurs in the tumour necrosis factor 
receptor superfamily, member 11a, NFKB activator (TNFRFS11A) gene. However, all four of 
these SNPs are in fact intergenic and may not affect the function of the latter genes, even 
though they were interpreted to do so. With regards to regulation, the majority of the GWAS 
acknowledge that the intergenic findings may affect regulatory processes, but this was not 
investigated further. For example, Åberg et al. (2010) state that the intergenic SNPs 
rs17022444 and rs7669317 may impact long-range regulatory effects. Considering the SNPs 
occurring in introns, the GWAS either did not acknowledge that the variant was intronic, or 
did not discuss the implications thereof, such as potential effects on post-transcriptional 
processing. For the most part, the nine GWAS follow the trend of interpreting function in 
terms of the closest gene, and deprioritise genes that have not previously been implicated in 
antipsychotic response, neurological functioning, or schizophrenia. All of the studies 
investigated LD to a limited extent, with some performing haplotype analyses, but once 
again these variants or haplotypes were related back to the closest gene. A more thorough 
and all-inclusive approach to GWAS interpretation could lead to novel pathway associations 
and improve biological hypotheses. 
3.5.2. Predicted rSNPs and their genomic effects 
3.5.2.1. Regions implicated in immunity 
Of all the variants accounted for by GWAS and LD analyses, 20 SNPs were classified by 
RegulomeDB to have regulatory potential (Table 3.5). Interestingly, two of these originate 
from the Adkins et al. (2011) GWAS on metabolic side effects, and the Åberg et al. (2012) 
GWAS on QT interval prolongation, respectively. This reaffirms the importance of accounting 
for LD structures when interpreting associations, as the most significant rSNPs were not 
tagged or assessed by previous GWAS. None of the remaining 18 rSNPs have been 
previously associated with schizophrenia, pharmacogenomics or antipsychotic treatment 
response. The first GWAS SNP, rs6741819 on chromosome two, was predicted to affect the 
binding of the transcription factors EBF1, GATA1 and CTCF, and the motif CNOT3. The 
corresponding PWM for CNOT3 indicates that the position of this SNP is the most conserved 
relative to other bases, suggesting that substitutions at this locus are undesirable. EBF1 is a 
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transcription factor that has been shown to play an important role in B cell differentiation 
within the adaptive immune system (Nechanitzky et al., 2013).  
Interestingly, the results include several other regulatory factors involved in immunity. For 
example, RFX3 is a protein that binds to MHC class II promoters to influence MHC 
expression (Reith et al., 1995). According to rSNPBase, RFX3 is affected by rs3774959 – 
the most significant RegulomeDB SNP – and rs230493, both associated via LD with 
treatment-refractory schizophrenia (Liou et al., 2012). Secondly, CEBPB was predicted to be 
affected by rs3774933 by both RegulomeDB and rSNPBase analyses. This SNP is similarly 
in LD with a significant SNP from Liou et al. (2012). Lending evidence to this finding, a 
matched DNase peak for the corresponding C/EBP motif was identified at this locus by 
RegulomeDB. The CEBPB transcription factor has been shown to play an important role in 
immune suppression (Marigo et al., 2010). There is a long-standing hypothesis that 
schizophrenia development is associated with abnormal immune functioning. In fact, the 
MHC locus is the most replicated genomic region with regards to associations with 
schizophrenia risk (Sullivan et al., 2012). These results suggest that regulation of different 
aspects of the immune system could contribute to variation in schizophrenia treatment 
response, particularly nonresponse. Supporting this idea, a recent meta-analysis of 23 
studies revealed that antipsychotics produce anti-inflammatory effects in schizophrenia 
(Tourjman et al., 2013). Although the exact mechanisms remain unclear, the interplay 
between antipsychotic response and the immune system should be explored further.  
3.5.2.2. Ubiquitous regulatory factors 
In addition to the immune system, there are several implicated regulatory factors that are 
involved in many widespread developmental and regulatory processes. For example, EP300 
is a histone acetyltransferase that plays a role in chromatin remodelling and thus regulates 
gene expression, functioning ubiquitously in processes such as cell growth and proliferation 
(Ogryzko et al., 1996). Furthermore, TCF4 is a widely expressed transcription factor affected 
by the rSNPs rs2272676 (associated via LD with treatment-refractoriness) and rs17440909 
(associated via LD with patient-rated symptom severity; Clark et al., 2013). Interestingly, 
TCF4 has been consistently associated with schizophrenia development in independent 
studies (Stefansson et al., 2009; Wirgenes et al., 2012; Ripke et al., 2013). Other 
widespread regulatory effects are illustrated by the RNA-binding proteins associated with 
post-transcriptional processing (Table 3.6). PABPC1 binds the poly(A)-tail of transcribed 
mRNA, and has demonstrated involvement in nonsense-mediated decay (Behm-Ansmant et 
al., 2007). ELAVL1, on the other hand, binds to the 3’-UTR of mRNA and promotes 
transcript stability (Lebedeva, 2012). SNPs in the regions that bind the latter proteins may 
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affect general functioning in many cell types, suggesting that pathways nonspecific to drug 
response may influence antipsychotic treatment outcomes. This notion is supported by the 
results of the tRap analysis (Tables 3.7 and S1). Considering the three traits used as 
controls, there are only twelve motifs that are unique to antipsychotic response, and none of 
these are the top ten most significantly affected motifs.  
3.5.2.3. The 4q24 locus and NFKB1 
The most notable characteristic of the rSNPs predicted by RegulomeDB and rSNPBase is 
that results are enriched for the q24 region of chromosome four. Of the 20 SNPs predicted to 
be significant by RegulomeDB, 14 occur at this locus. Additionally, nine of these scored 1b-f, 
therefore this region has the most experimental evidence that supports its involvement in 
regulation, in comparison to other SNPs associated with treatment response. All of the 4q24 
rSNPs are in LD with rs230529; one of three SNPs implicated in treatment refractoriness by 
Liou et al. (2012). Interestingly, the original GWAS variant was not predicted by 
RegulomeDB to affect regulatory regions significantly, even though all the SNPs in this 
region were in strong linkage disequilibrium for CHBJPT, CHD and JPT+CHB+CHD 
population groups. This emphasises the importance of analysing each variant within a region 
instead of interpreting the impact of the tag SNP alone. 
As shown in Figure 3.1, the 4q24 region includes the start of transcription of the NFKB1 
gene. The ENCODE tracks in this region show extensive evidence of regulation in different 
cell lines, including ChIP-Seq and DNase peaks, as well as the histone mark H3K27Ac, 
which is associated with open chromatin and active transcription. rSNPBase predicted the 
majority of input SNPs in this region to affect the expression of NFKB1. In fact, this gene was 
predicted to be affected by 104 SNPs – almost half of the rSNPs characterised by 
rSNPBase. NFKB1 encodes a highly conserved transcription factor that regulates over 200 
genes, and plays important roles in cancer and the immune system (Shishodia and 
Aggarwal, 2004; Liou et al., 2012). Once again, this implicates immune dysregulation in 
antipsychotic response. Polymorphisms in NFKB1 have previously been associated with the 
pharmacogenetics of anti-tumor necrosis factor (TNF) treatment response (Bank et al., 
2014) and with schizophrenia susceptibility (Narayan et al., 2008). Interestingly, a 2015 
review identified the most replicated finding in first episode schizophrenia studies to be 
increased TNF-α levels (Fond et al., 2015). This pro-inflammatory cytokine is regulated by 
NFKB1 (Hall et al., 2005), suggesting alterations in this regulatory pathway may be 
responsible for the identified associations with the disorder. 
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The enrichment for SNPs that affect expression of NFKB1 is significant, however one must 
keep in mind that NFKB1 may be overrepresented in the results of this study. All significant 
RegulomeDB SNPs at this locus are proxies for one single SNP. It is possible that the 
results revealing regulatory potential are indicative of a single signal. Furthermore, variation 
within or affecting NFKB1 may not have effects specific to antipsychotic treatment response, 
since this gene has control over hundreds of downstream loci. Having said that, it is 
interesting to note that the 4q24 region came up in three of the other original GWAS, which 
investigated associations with different treatment outcomes (Åberg et al., 2010; Adkins et al., 
2011; Clark et al., 2013). This region could be important for treatment response and should 
be investigated further.  
3.5.3. Genes and pathways relevant to antipsychotic response 
Apart from NFKB1, a number of other affected genes and eQTLs were determined by 
RegulomeDB and rSNPBase. Notably, the most significant of these have all shown 
associations with schizophrenia susceptibility or symptom severity in the past. 
Experimentally, the most significant SNPs are those predicted to act as eQTLs. Overlap 
between RegulomeDB and rSNPBase was seen for the 4q24 rSNPs and eQTL targets 
MANBA and COL9A2. MANBA was the third most affected gene in the study and has been 
linked to schizophrenia (Jungerius et al., 2007). This gene codes for the lysosomal β-
mannosidase protein, and mutations can lead to β-mannosidosis (Huynh et al., 2011). The 
second most affected gene, with a total of 25 rSNPs implicated in its expression (Table 3.9), 
is the cAMP-specific phosphodiesterase 4D (PDE4D) gene, which, like the other two top 
genes, has also shown links to schizophrenia (Tomppo et al., 2009). The PDE4D gene was 
implicated in the Clark et al. (2013) GWAS, and a SNP in one of its introns was significantly 
associated with patient-rated symptom severity. Interestingly, PDE4D inhibition increases 
dopamine receptor signalling, suggesting that this gene could be a potential antipsychotic 
target (Halene and Siegel, 2008; Kuroiwa et al., 2011).  
Upon first inspection, the pathways and networks predicted by DAVID and GeneMANIA do 
not indicate any mechanisms that have been traditionally associated with neuropsychiatric 
disorders or drug response. Relatively few genes were included in each pathway, but mostly 
high fold change values suggest that these findings are significant. Interestingly, NFKB1 is a 
node in three of the four pathways identified by DAVID, demonstrating its diverse and 
widespread function. Analysis of function with GeneMANIA substantiated the potential role of 
immunity in treatment response: NFKB1 and ACTG1 both function in cell receptor signalling 
during an immune response (Figure 3.2). Additionally, pointing to effects on neurological 
functioning, NFKB1 and SHC1 are both involved in neurotrophin signalling (Figure 3.3). 
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Therefore, although these clustered pathways seem unlikely candidates for drug response 
biology, they should be investigated further to search for clues regarding the mechanisms of 
antipsychotic treatment outcomes.  
3.5.4. Study limitations 
The limitations associated with this study concern both the antipsychotic response GWAS 
and the tools used to analyse them. As discussed, there are relatively few GWAS that have 
investigated schizophrenia treatment response, and even fewer that have been well-
designed and are statistically robust. The majority of results are based on information from 
one cohort of less than 1000 individuals, therefore the methods applied in this study must be 
investigated in other samples and population groups. Furthermore, drug-speicific cohorts are 
essential, as mechanisms may differ between FGAs and SGAs, and unique SGAs such as 
clozapine. There is great need for improvement in clinical characterisation of patients, 
clinical and genetic homogeneity, and increased GWAS sample sizes. The difficulties in 
assessing and defining treatment response, as well as obtaining drug-naïve individuals, 
have thus far restricted these developments. 
The range of tools one can use to assess the functional impact of genetic variation is 
growing rapidly. The analysis of genomic regulation is still in its infancy, and there are many 
improvements to be made. Inconsistencies between tools and insufficient data may have 
prevented the discovery of a gene or pathway involved in treatment response. The limited 
consensus between the tools demonstrates the need for improved bioinformatic design and 
database curation, as well as the complexity of genetic regulation. Lastly, ENCODE has 
received criticism for its claim that 80% of the genome is functional (Graur et al., 2013). 
Although it is the only resource of its kind, one must keep in mind that the data may 
overestimate functionality within the genome. For example, almost half of the variants 
analysed were assigned at least one regulatory function by rSNPbase. Although regulation is 
complex and extensive, such results must be interpreted with caution. With time and 
additional studies, the regulatory networks behind complex traits and disorders such as 
antipsychotic response will likely become clearer.   
3.6. Conclusion 
This study has provided a novel approach to the functional analysis of genomic variation. 
With a bioinformatics pipeline that can be applied to other complex traits, regulatory changes 
and downstream effects can elucidate the mechanisms involved in the workings of 
antipsychotics and the development of adverse drug reactions. Given that previous studies 
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have revealed little about the biology of antipsychotics, a hypothesis-free approach such as 
this one provides the best means of understanding the heterogeneity of treatment response.       
Importantly, this study reaffirmed the functionality of noncoding regions of the genome, and 
the widespread impact that rSNPs can have; affecting proximal, long-range and post-
transcriptional processes. The most significant finding of this study was the predicted role of 
NFKB1 in treatment-refractory schizophrenia, which provided further evidence that 
refractoriness is a distinct endophenotype of the disorder. The 4q24 locus may be important 
for immune-mediated response to antipsychotics, and it is essential that this is investigated 
in future. Additionally, this study lends evidence to the hypothesis that there is extensive 
overlap between schizophrenia risk and treatment response pathways, perhaps particularly 
with regards to immune functioning. Much like each symptom domain of schizophrenia, it is 
likely that different treatment outcomes reflect different pathways, and that cumulative 
variants in both coding and noncoding regions contribute to their inception and severity.  
Future research on antipsychotic response should involve large-scale GWAS coupled with 
bioinformatic and functional analyses. Ideally, results should be validated in multiple cohorts, 
and include previously underrepresented populations, since these groups experience the 
majority of the mental health burden. This process begins with better study design and 
clinical assessments and, with the use of bioinformatics, has the potential to conclude with 
improvements in our understanding of complex disorders. This paves the way for better 
treatment response and medication tailored for each individual.   
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CHAPTER 4:  
Associations between predicted regulatory variants and 
antipsychotic treatment outcomes in a South African schizophrenia 
cohort 
4.1. Summary 
Although antipsychotics are effective at reducing the positive symptoms associated with 
schizophrenia, remission is currently not a realistic goal for the majority of patients, and 
relapse is often a reality. Pharmacogenomics has the potential to elucidate the genetic 
factors contributing to this heritable trait, and ultimately guide future drug design and 
treatment improvement. This study attempted to validate the findings of a novel bioinformatic 
pipeline that assessed previous antipsychotic pharmacogenomic GWAS hits for regulatory 
impact on treatment response. TaqMan® OpenArray® was utilised to genotype 31 SNPs in 
a South African cohort, which were subsequently assessed for associations with treatment 
outcomes and ADRs with the use of mixed-effects repeated measures analyses. Significant 
associations were observed for several outcomes, including changes in PANSS scores, 
refractoriness, remission, and metabolic side effects.  
The associations that survived Bonferroni correction were located on chromosome 4q24, 
which was the most significant regulatory locus identified in the bioinformatic portion of the 
study. Furthermore, this region has been previously implicated in schizophrenia. The SNPs 
rs230493 and rs3774959 were both significantly associated with greater post-treatment 
PANSS Negative scores (P < 0.00001). Additionally, a 14-SNP haplotype containing these 
two variants was predicted to elicit a 4.41% higher post-treatment positive symptom score. 
These results validate the importance of the 4q24 region in antipsychotic response, the 
biological overlap of schizophrenia susceptibility and drug response, and the hypothesised 
role of genomic dysregulation in adverse treatment outcomes. Interestingly, nonconcordance 
was observed with regards to dichotomous outcomes of refractoriness and remission, and 
significant variants. This suggests that clinical characterisation of these states should be re-
evaluated with respect to genetic variables. Lastly, the study of a well-characterised South 
African cohort not only contributes to our knowledge of pharmacogenomics, but also 
improves our understanding of this genetically rich and distinct population group. These 
findings have the potential to aid in improving treatment outcome in schizophrenia.       
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Schizophrenia is a severe, lifelong psychiatric disorder for which treatment is often complex 
and ongoing. Treatment response can be measured by several different scales that assess 
changes in symptom severity. This includes the PANSS, which accounts for different 
symptom domains, including positive and negative symptoms (Kay et al., 1987). Additionally, 
there are a few terms that are important to define when assessing treatment response. 
Firstly, remission has been classified by the Remission in Schizophrenia Working Group as 
a period of at least six months in which symptoms are absent or mild, and do not affect an 
individual’s functioning (Andreasen et al., 2005). In contrast, treatment-refractoriness or 
nonresponse is generally established when a patient’s symptoms do not adequately improve 
after at least two trials of different antipsychotics (Suzuki et al., 2012). It is important to note 
that these states are not absolutes and are difficult to define and predict, due to differences 
between individuals and different response criteria. One reliable predictor of long-term 
outcome is early treatment response. Studies have shown that an individual responding well 
as early as two weeks into treatment is an indicator of later remission, whilst refractoriness 
can be predicted by early nonresponse (Kinon et al., 2008; Chiliza et al., 2015a).   
The complexity and heterogeneity of treatment response is largely brought about by the 
genetic differences between individuals in drug metabolism, neurotransmitter, and other 
pathways (Blanc et al., 2010; Klein and Zanger, 2013; Ni et al., 2013). However, studies to 
date have mostly provided inconsistent results. Much like other complex traits, there are 
likely to be hundreds to thousands of common variants across the genome that cumulatively 
contribute to individual treatment response phenotypes (Arranz and de Leon, 2007). With 
large and well-characterised sample groups, pharmacogenomics enables the discovery of 
these variants. Specifically, GWAS have recently been employed to study antipsychotic 
response. While this approach trumps a priori candidate gene studies by analysing variants 
across the genome, the majority of GWAS lack sufficient biological interpretation. Often, 
variants are considered in isolation and exclusively with regards to the function of their 
neighbouring gene (Åberg et al., 2012; Clark et al., 2013). This restricts the creation of new 
hypotheses and further understanding of treatment response mechanisms.   
Overall, GWAS have neglected individuals of non-European descent. This potentially 
precludes the development of effective treatment for all individuals, since populations vary 
extensively with regards to genetics. Indeed, the allele frequency of a GWAS variant has 
been shown to vary 40-fold between different ethnicities (Adeyemo and Rotimi, 2010). 
Africans have been shown to be the most genetically diverse population group, yet they are 
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underrepresented in genetic studies (Drögemöller et al., 2011). This group’s unique genetic 
make-up could provide invaluable information about variation contributing to complex 
phenotypes such as treatment response. Further motivation to study African populations is 
the fact that they suffer a greater mental health burden due to poor resources and public 
health care (refer to chapter one).  
The current study combines the need to better interpret GWAS results, while also 
considering previously understudied population groups. To improve functional interpretation 
of GWAS, a previous study employed a bioinformatic pipeline to assess all variants 
associated with treatment response by GWAS (chapter two). This included making use of 
several tools and large-scale datasets to assess the noncoding variants’ regulatory potential, 
as well as the impact of significant coding variants. The study found merit in approaching 
GWAS interpretation more comprehensively, as results suggested the novel hypothesis that 
NFKB1 and the immune system may contribute to antipsychotic response. However, the 
complexity of treatment response and the purely bioinformatic nature of this study require 
these results to be validated. Therefore, the current study aimed to perform association 
analyses in a well-characterised South African cohort of FES patients. As a second phase to 
the bioinformatic pipeline, this could provide validation for new treatment response 
hypotheses, as well as decrease the research gap between different population groups. The 
coupling of bioinformatics with specific studies in different ethnicities provides a 
comprehensive method to elucidate common genetic factors contributing to antipsychotic 
treatment outcomes. In the long term, understanding the biological mechanisms of 
antipsychotics provides a platform for better drug design and effective treatment of 
schizophrenia.  
4.3. Materials and methods 
Refer to Electronic Sources (p. 107) for dates of access to online tools. 
4.3.1. Patient samples 
A South African FES cohort of 103 patients (median age 23 ± 7 years; 74% male) was used 
to investigate associations with SNPs previously implicated in treatment response. The 
cohort consisted of 82 SAC, 13 Xhosa and 8 Caucasian individuals. Patients were recruited 
over four years at Stikland Hospital in the Western Cape and assessed with the Structured 
Clinical Interview for the DSM-IV (American Psychiatric Association, 1994). Demographic 
and medical data were obtained at the time of recruitment. Signed written and informed 
consent was provided by all patients or their caregivers prior to the study. Ethical approval 
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was obtained from the Human Research and Ethics Committee (HREC), Faculty of Health 
Sciences, Stellenbosch University (ethics numbers for clinical and genetic aspects: 
N06/08/148 and 1907/005 respectively). 
All patients received treatment with flupenthixol decanoate, an FGA, by injection. Dose was 
gradually increased until remission was achieved – defined according to the Remission in 
Schizophrenia Working Group (Andreasen et al., 2005) – or until the maximum 
recommended dose was reached. Response to treatment was measured by the PANSS 
over a period of 12 months, with measurements taken every two weeks for the first six 
weeks, and every three months thereafter. A decrease of 25% or greater in PANSS scores 
at six weeks was considered indicative of early response to treatment in this study. 
Furthermore, treatment-refractory patients were defined as those who 1) discontinued 
treatment because of poor response, 2) showed a < 25% reduction in total PANSS scores at 
12 months, or 3) had a PANSS score > 70 at 12 months (Chiliza et al., 2015a). The latter 
two categories of patients must have completed treatment for at least three months without 
relapse in order to qualify as treatment-refractory. Lastly, data on metabolic outcomes was 
recorded:  BMI, lipid profiles, and changes in cholesterol were measured for each patient at 
three, six, nine and twelve months (Chiliza et al., 2015b). 
Prior to the current study, genomic DNA (gDNA) was extracted from whole blood samples 
from each patient, using the Miller et al. (1988) protocol.   
4.3.2. SNP prioritisation 
Variants previously predicted to affect regulation were prioritised for genotyping in the cohort 
(refer to chapter three). Regulatory predictions include those from RegulomeDB 
(http://regulome.stanford.edu/), rSNPBase (http://rsnp.psych.ac.cn/) and sTRAP 
(http://trap.molgen.mpg.de/cgi-bin/trap_two_seq_form.cgi).  SNPs were prioritised according 
to the RegulomeDB results. Even though this includes SNPs with a score > 3, these findings 
are the most robust compared to other tools, since they are based on experimentally 
validated data such as ENCODE (Boyle et al., 2012). In contrast, TRAP works only with 
computational predictions (Manke et al., 2010), and, although it deemed 222 SNPs to be 
involved in regulation, rSNPBase does not use a scoring system to rank variants. There is, 
however, extensive overlap between the top RegulomeDB variants and rSNPs predicted by 
rSNPBase. RegulomeDB variants were coupled with their proxy SNPs from antipsychotic 
response GWAS (provided the GWAS SNP was not already classified as an rSNP) for a set 
of 30 variants. Additionally, one exonic SNP (rs17727261) was predicted to be 
nonsynonymous by PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/). This variant was 
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also included for genotyping, creating a total of 31 SNPs for further analysis. The final set of 
genotyped SNPs, along with their associated response traits, is indicated in Table 4.1. In 
cases where a SNP failed assay design (4.3.3 below), the variant and its GWAS partner 
were replaced by the next most significant pair according to RegulomeDB.   
4.3.3. SNP genotyping 
The 31 SNPs in Table 4.1 were genotyped in the South African FES cohort with the use of 
TaqMan® OpenArray® Real-Time Polymerase Chain Reaction (PCR) (Life Technologies™, 
New York, USA). TaqMan® assays were obtained from the SNP Genotyping Assay Search 
Tool (http://www.lifetechnologies.com/za/en/home/life-science/pcr/real-time-pcr/real-time-
pcr-assays/snp-genotyping-taqman-assays.html). In cases where no predesigned assay was 
available, a custom assay was designed by Life Technologies™ in New York. SNPs that 
failed custom assay design or functional testing were excluded and replaced. The 
customised 31-SNP assay was manufactured by Life Technologies™ and shipped directly to 
the University of Utah DNA Sequencing and Genomics Core Facility for genotyping, along 
with genotyping master mix, OpenArray® 384-Well Sample Plates and necessary 
consumables. The SNPs and their corresponding assays are indicated in Table S3.   
Concentrations of previously extracted DNA samples for all 103 patients were measured 
using the NanoDrop spectrophotometer (NanoDrop® ND-100, NanoDrop Technologies Inc., 
Wilmington, Delaware, USA) and diluted to 25 µl at 80 ng/µl per sample. Thereafter, 20 µl of 
each sample was added to two MicroAmp® 96-well plates (Applied Biosystems™, 
California, USA). Duplicate samples were included as positive genotyping controls, and two 
empty wells per plate served as negative controls. The plates were sealed with optical 
adhesive film, frozen, and shipped on dry ice to the University of Utah.  Subsequently, 
genotyping was performed according to the manufacturer’s instructions and analysed with 
the OpenArray® SNP Genotyping Analysis Software version 1.3.1. 








Associated response measurement RegulomeDB 
Score 
rSNPBase TRAP GWAS PP-2 
Chr 1 




QTc interval prolongation Åberg et al., 2012 




Clinical impression of severity (CGI-S) Clark et al., 2013 




Treatment-refractory schizophrenia Liou et al., 2012 




Treatment-refractory schizophrenia Liou et al., 2012 
160634587 rs6427540 4 x 
   
Treatment-refractory schizophrenia Liou et al., 2012 




Neurocognition: working memory McClay et al., 2011a 
Chr 2 




Triglycerides Adkins et al., 2011 
125281909 rs17727261 N/A x 
 
x x Negative symptoms (PANSS) McClay et al., 2011b 
139259221 rs62161711 4 x 
   
Patient global impression (PGI) scale Clark et al., 2013 
139278921 rs10170310 N/A x x x 
 
Patient global impression (PGI) scale Clark et al., 2013 
Chr 4 
103414174 rs747559 1f x 
   
Treatment-refractory schizophrenia Liou et al., 2012 
103426338 rs3774933 1b x 
   
Treatment-refractory schizophrenia Liou et al., 2012 
103443568 rs1599961 1f x 
   
Treatment-refractory schizophrenia Liou et al., 2012 
103449040 rs230534 4 x 
   
Treatment-refractory schizophrenia Liou et al., 2012 
103450166 rs230532 1f x 
   
Treatment-refractory schizophrenia Liou et al., 2012 




Treatment-refractory schizophrenia Liou et al., 2012 
103458824 rs230526 2b x 
   
Treatment-refractory schizophrenia Liou et al., 2012 
103463006 rs118882 4 x 
   
Treatment-refractory schizophrenia Liou et al., 2012 
103465611 rs230520 1f x 
   
Treatment-refractory schizophrenia Liou et al., 2012 
103481350 rs230505 1d x 
   
Treatment-refractory schizophrenia Liou et al., 2012 
103481560 rs230504 1f x 
   
Treatment-refractory schizophrenia Liou et al., 2012 
103485779 rs230492 4 x 
   
Treatment-refractory schizophrenia Liou et al., 2012 
103486215 rs230493 1f x x 
  
Treatment-refractory schizophrenia Liou et al., 2012 
103487299 rs230495 3a x 
   
Treatment-refractory schizophrenia Liou et al., 2012 
103495531 rs230539 4 x 
   
Treatment-refractory schizophrenia Liou et al., 2012 
103511113 rs3774959 1b x 
   
Treatment-refractory schizophrenia Liou et al., 2012 
103515312 rs4648055 1f x 
   
Treatment-refractory schizophrenia Liou et al., 2012 
Chr 5 
58957830 rs17440909 3a x 
   
Patient impression of severity (PGI) Clark et al., 2013 
58999041 rs17742120 N/A x x x 
 
Patient impression of severity (PGI) Clark et al., 2013 
Chr 8 89566902 rs1352318 2c 
    
BMI Athanasiu et al., 2012 




Negative symptoms (PANSS) McClay et al., 2011b 
a Relevance of SNP with regards to regulatory evidence (RegulomeDB, rSNPBase, TRAP) or protein impact (PolyPhen-2), as well as proxy GWAS SNPs. 































Table 4.1: SNPs genotyped in the South African FES cohort, including predicted rSNPs and corresponding GWAS SNPs. 
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4.3.4. Statistical analyses 
Allele and genotype frequencies for successfully genotyped SNPs were determined, and 
deviations from Hardy-Weinberg equilibrium (HWE) were calculated by means of a 
Pearson’s Chi-square (χ²) test or analogue to Fisher’s Exact Test with SNPStats (Solé et al., 
2006; http://bioinfo.iconcologia.net/snpstats/start.htm). SNPs with P < 0.01 were considered 
to deviate from HWE. SNP frequencies within the cohort were compared to those in HapMap 
(The International HapMap Consortium, 2003) and 1000 Genomes (The 1000 Genomes 
Project Consortium, 2010) population groups. Subsequently, LD between SNPs was 
assessed with Haploview version 4.2 (Barrett et al., 2005). Haploview designated haplotype 
blocks by assessing pairwise LD. SNPs with r2 ≥ 0.8 were considered to be in LD, but D’ 
confidence intervals (D’ > 0.7 - > 0.98) were also assessed for comparison (Gabriel et al., 
2002). The haplotypes were subsequently assessed for associations with treatment 
outcomes, along with all individual SNPs.  
Allelic, genotypic and haplotypic association analyses were performed in the R Linear and 
Nonlinear Mixed Effects Models package (Pinheiro et al., 2014). To determine the presence 
of associations with treatment outcomes (measured by changes in PANSS scores as well as 
several metabolic variables), mixed-effects model repeated measures analyses were 
conducted. Additionally, any associations with dichotomous outcomes, i.e. treatment-
refractoriness, remission, or early response, were determined with logistic regression 
models.  
Since the SAC population is highly admixed, any spurious associations due to population 
stratification were accounted for by correcting for ancestry contributions. This was 
accomplished by utilising ancestry informative markers (AIMs) as covariates to estimate 
ancestry proportions in ADMIXTURE (Alexander et al., 2010; Daya et al., 2013). The 
ancestry proportions of the SAC individuals are indicated in Figure 4.1. In addition to 
proportion ancestry, all analyses were adjusted for age, gender, and ethnic group, and the 
mixed-effects model repeated measures analysis was adjusted for baseline PANSS scores 
when assessing change in PANSS over time.  
Bonferroni was used to correct for multiple testing after association analyses. Modes of 
effect and inheritance were tested for the most significant associations, and estimates of 
effect size with 95% confidence were determined for all models. 
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4.4.1. Clinical outcomes 
The FES cohort was assessed for various treatment response outcomes. Firstly, considering 
the PANSS scores and criteria defined by the Remission in Schizophrenia Working Group, 
77 patients (74.8%) achieved early response at six weeks, and 10 individuals (9.7%) were 
classified as being treatment refractory. 58 patients (56.3%) achieved full remission by the 
end of the twelve month treatment period (Chiliza et al., 2015a). With the use of linear mixed 
effect models for continuous repeated measures, Chiliza and colleagues (2015b) observed 
significant weight gain within the cohort (P < 0.0001), with 58.2% of individuals gaining more 
than 7% weight. Additionally, increases in BMI (P < 0.0001) and triglycerides (P = 0.03), and 
a significant decrease in HDL cholesterol (P = 0.005) were observed.  
4.4.2. SNP genotyping 
All 31 SNPs were successfully genotyped, with an average call rate of 97.7%. Sample 
duplicates (FS027, FS095, and FS122) displayed concordant genotypes across all assays, 
except in a few cases where one or both failed to amplify, where the genotype was classed 
as “undetermined”. The allelic discrimination plot for rs6427540 is shown in Figure 4.2. For 
this SNP, all genotypes were determined, and the assay achieved a call rate of 100%. 
All genotyped SNPs demonstrated a MAF ≥ 0.05 in the cohort of 103 patients, and are thus 
considered common variants within this cohort (Iyegbe et al., 2014). Additionally, all SNPs 
were in HWE (P ≥ 0.01). The SNP with the lowest frequency, rs17727261 (MAF = 0.05) has 
similar frequencies in both HapMap and 1000 Genomes CEU samples, but does not occur in 
the other population groups, as shown in Figure 4.3. On the other hand, the SNP with the 
highest MAF (0.49), rs230505, is the major allele in all other HapMap and 1000 Genomes 
populations. Population comparisons for two other SNPs of intermediate frequency in the 
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FES cohort HapMap CEU 1000 Genomes CEU
HapMap CHB HapMap JPT 1000 Genomes CHB+JPT
HapMap YRI 1000 Genomes YRI
Figure 4.2: Allelic discrimination plot for rs6427540. VIC® and FAM® relative dye intensities indicate 
genotype: VIC/VIC (CC); VIC/FAM (CT); FAM/FAM (TT). NTC = no template control. 
Figure 4.3: Frequency comparisons between the FES cohort and HapMap and 1000 Genomes 
populations.  Allele depicted refers to the minor allele within the FES cohort. 
South African cohort are also shown in Figure 4.3. Overall, the majority of SNPs displayed 
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Figure 4.4: Two haplotype blocks on chromosome four, designated by Haploview version 4.2 (r2 ≥ 
0.8; LOD ≥ 3) (Barrett et al., 2005). Dark red squares indicate significant LD between SNPs; r2 values 
are shown as a percentage in each square. 
4.4.3. Haplotype analyses 
Analysis with Haploview showed that SNPs on chromosome four are in strong LD within the 
FES cohort, similar to the LD observed in previous analysis of a Han Chinese cohort (Liou et 
al., 2012). This region, with LD measured by r2, is indicated in Figure 4.4. The same 
haplotype blocks were designated according to D’ confidence intervals, shown in Figure S1. 
The two designated haplotype blocks for chromosome four were analysed further for 
associations with treatment outcomes. Similarly, haplotypes were identified for variants on 
chromosomes one, two, and five. All haplotypes and their inferred frequencies within the 
FES cohort are indicated in Tables S4a-e. Only those with frequencies greater than 0.01 are 
shown, and haplotypes with lower frequencies were removed from further analyses. 
4.4.4. Association analyses 
In total, there were 23 SNPs and 10 haplotypes that were significantly associated with 
treatment outcomes (P < 0.05), and 97 unique associations, as shown in Table S5. Three 
associations survived Bonferroni correction and are highlighted in the table. Table 4.2 shows 




Table 4.2: Top significant SNP and haplotype associations with treatment outcomes in the FES cohort, with effect models and sizes indicated. 
Chr Variant/ haplotype 
Associated response 
measurement  
Effect model Comparison P-value Effecta 95% CI 
4 
rs230504 PANSS Negative Dominant TT + CT vs. CC 0.0001 1.47 0.71 2.24 
rs230493 PANSS Negative Genotype TA vs. TT < 0.0001 1.98 1.20 2.76 
rs230493 PANSS Negative Genotype AA vs. TT < 0.0001 0.38 -0.84 1.62 
rs230493 PANSS Total Dominant TA + AA vs. TT 0.0004 1.28 0.58 1.98 
rs230495 PANSS Negative Dominant AA + AG vs. GG 0.0006 1.59 0.68 2.50 
rs3774959 PANSS Negative Genotype  GA vs. GG < 0.0001 1.82 1.01 2.63 
rs3774959 PANSS Negative Genotype  AA vs. GG < 0.0001 0.31 -0.85 1.48 
rs3774959 PANSS General Genotype GA vs. GG 0.0004 1.58 0.78 2.39 
rs3774959 PANSS General Genotype AA vs. GG 0.0004 0.57 -0.59 1.75 
rs3774959 PANSS Total Genotype GA vs. GG 0.0001 1.67 0.91 2.44 
rs3774959 PANSS Total Genotype AA vs. GG 0.0001 0.72 -0.39 1.84 
C.A.T.A.C.A.G.T.G.A.A.A.A.G* PANSS Positive Each additional haplotype   0.0002 4.41 2.10 6.78 
a Effect measured in percentage change in PANSS score per month. Shaded variants/ haplotypes maintained significance after correcting for multiple testing.  
CI = confidence interval. 
* SNPs: rs230534, rs230532, rs230529, rs230526, rs118882, rs230520, rs230505, rs230504, rs230492, rs230493, rs230495, rs230539, rs3774959, 































Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
CHAPTER 4                                                                                  ASSOCIATION ANALYSES 
74 
  
the top five significant SNPs and haplotypes, including those that survived correction for 
multiple testing, together with their associated outcomes, inheritance models, and predicted 
effect sizes with confidence intervals. As shown in the table, change in PANSS scores – 
particularly PANSS Negative scores – was the most significant treatment outcome within the 
cohort. Surviving associations are limited to regions on chromosome four, with the significant 
haplotype containing the minor alleles of the two individually significant SNPs (rs230493 and 
rs3774959; Table 4.2).  
4.5. Discussion 
This study made use of the results of a novel bioinformatics pipeline designed for more 
comprehensive and biologically relevant interpretations of significant GWAS variants. These 
variants have been previously implicated (either by GWAS or LD and predicted regulatory 
effects) in antipsychotic treatment outcome. The SNPs and relevant haplotypes were tested 
for associations with various schizophrenia treatment outcomes, including improvement or 
decline in symptoms, changes in BMI and other metabolic outcomes, as well as indicators of 
early response or nonresponse to treatment.  
4.5.1. Clinical outcomes 
General treatment outcomes were assessed based on changes in PANSS scores over a 12 
month period. Firstly, 56% of the FES cohort achieved remission, i.e. their symptoms were 
deemed absent to mild for at least six consecutive months (Andreasen et al., 2005; Chiliza et 
al., 2015a). A majority of individuals achieving remission is expected, as first-episode 
patients generally respond well to treatment in comparison to second- or multi-episode 
patients (Kahn and Sommer, 2015). It is well-known that a shorter DUP is linked to an 
improved response (Perkins et al., 2004; Jeppesen et al., 2008).  Secondly, only 10% of 
patients were classified as treatment-refractory, according to the criteria outlined in 4.3.1. 
Again, refractoriness is more common in multi-episode patients, and it has been suggested 
that nonresponsiveness often emerges in individuals that have previously responded to 
medication and subsequently relapsed (Caspi et al., 2004).  Lastly, a high percentage of 
patients achieved early response, i.e. their total PANSS scores decreased by at least 25% 
after six weeks of treatment. Antipsychotics bring about the greatest symptom changes 
within the first few weeks of use (Agid et al., 2003). Since the majority of patients achieved 
remission, and early symptom improvement is an accurate predictor of remission, this high 
percentage is expected (Kinon et al., 2010).  
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Although the majority of the cohort achieved remission, severe adverse metabolic outcomes 
were observed. Over half of the cohort gained > 7% weight, which was accompanied by a 
significant increase in BMI and triglycerides, and a significant decrease in HDL cholesterol – 
all risk factors for metabolic syndrome (Chiliza et al., 2015b). Such metabolic reactions are 
common to SGA-administered patients (Newcomer, 2005; Tandon et al., 2010). The 
distinguishing characteristic of SGAs is that their improved design does not lead to adverse 
motor effects as seen with FGA usage, but can cause undesirable metabolic reactions 
(Brennan, 2014). Nevertheless, FGAs, particularly those of low potency such as flupenthixol, 
have also been associated with metabolic ADRs to a lesser extent (Leucht et al., 2009). The 
severity of metabolic outcomes in the FES cohort can be further explained by the 
observation that treatment-naïve first-episode patients are particularly sensitive to 
antipsychotics (McEvoy et al., 1991; Oosthuizen et al., 2004). In fact, many previous studies 
have shown considerable adipogenic side effects in FES treatment cohorts (Strassnig et al., 
2007; Tarricone et al., 2010; Correll et al., 2011). The clinical data suggests that improving – 
or ideally, preventing – metabolic side effects should be a priority for FES patients, whether 
they are receiving FGAs or SGAs. 
4.5.2. SNP genotyping and frequency comparisons 
All 31 SNPs were informative and could be analysed further for associations with treatment 
outcomes. When compared to HapMap and 1000 Genomes population frequencies, the 
majority of variants displayed frequencies in the cohort that were intermediate between other 
populations groups, for example, rs1352318 and rs10170310, shown in Figure 4.3. This is 
expected, since 80% of the cohort comprises SAC individuals, a population group that is 
highly admixed and contains ancestry contributions from several different populations 
documented on HapMap and 1000 Genomes (Daya et al., 2013). 
4.5.3. Associations with treatment outcomes 
Upon first inspection of the findings from the association analyses, it is clear that there are 
many SNPs significantly correlated with changes in PANSS scores. In fact, all but nine of the 
31 variants are nominally associated (P < 0.05) with at least one treatment outcome (Table 
S5). This is not unexpected, since these SNPs were chosen for genotyping on the basis of 
previous associations with treatment outcomes. The majority of these SNPs occur on 
chromosome four and have previously been associated with treatment-refractoriness (Liou 
et al., 2012), and several SNPs are associated with more than one outcome. For example, 
rs3774959 reached significance for changes in all PANSS symptom domains, and a large 
haplotype containing this SNP was also significantly associated with early treatment 
response and increases in triglyceride levels. These associations suggest that this locus 
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plays an important role in antipsychotic response. Furthermore, the rs3774959 variant was 
the top result in previous regulatory analyses, classified as an eQTL by RegulomeDB and 
rSNPBase (Tables 3.5 and 3.6). Therefore, this variant could contribute to dysregulation of 
one or more gene targets that are involved in drug response. In particular, this variant was 
predicted to affect expression of MANBA – previously implicated in schizophrenia – as well 
as the binding of RFX3, a protein involved in immunity. The region containing rs3774959 and 
other significantly associated variants – particularly those SNPs and haplotypes that 
survived Bonferroni correction – will be discussed further.  
4.5.3.1 The 4q24 region 
The large haplotype on chromosome four that contains the minor alleles for rs230504, 
rs230493, rs230495, and rs3774959 was associated with PANSS Positive, Negative, and 
Total scores, and maintained significance with positive scores after correction for multiple 
testing (Tables 4.2 and S5). Many of the 14 SNPs within this haplotype were also nominally 
associated with at least one PANSS domain, although only the associations of rs230493 and 
rs3774959 with negative symptoms survived Bonferroni correction. These results suggest 
that the four minor alleles of the haplotype produce an additive effect when combined, in 
relation to positive symptom changes over the course of treatment. Although this haplotype 
occurred at a low frequency in the cohort (0.03), its presence is associated with a substantial 
difference in change in PANSS positive scores (4.41% per month higher; Table 4.2). The 
effect size here is notable, given that the two individually significant SNPs demonstrated 
much smaller effects, with the lower and upper confidence intervals for their homozygous 
(AA) genotypes on either side of zero. Therefore, this haplotype should be further studied in 
larger as well as replicative cohorts to validate these findings. 
The 4q24 rSNPs originate from the Liou et al. (2012) study or are in LD with the SNPs 
identified in this GWAS. The authors found that rs230529, the tag SNP of this region, was 
associated with treatment-refractory schizophrenia. Direct comparison between the Han 
Chinese cohort studied by Liou et al. (2012) and the South African cohort is difficult for a 
number of reasons. Firstly, only 10 patients in the FES cohort were classified to be 
treatment-refractory, since the majority of patients achieved remission (Chiliza et al., 2015a). 
This limits the statistical power of the analyses and the ability to identify significant 
associations. In fact, none of the 4q24 SNPs were associated with treatment-refractoriness 
as defined in the cohort. Secondly, the clinical environment was vastly different and 
refractoriness was defined in different ways. Liou et al. (2012) characterised treatment-
refractoriness as two failed antipsychotic trials (chlorpromazine or an SGA) or nonresponse 
to clozapine. The Severity (CGI-S) and Improvement (CGI-I) subscales of the Clinical Global 
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Impression scale were used to determine the extent of treatment response (Conley and 
Kelly, 2001). On the other hand, the FES cohort was only treated with an FGA, and the 
PANSS scale was used to determine response or nonresponse. These differences in 
assessment make direct comparison problematic. Nevertheless, the top associations within 
the FES cohort were all predicted to worsen PANSS score outcomes, with effect sizes 
ranging from 0.31 to 1.98% per month for individual SNPs. This relative lack of improvement 
points to nonresponse for these symptom domains, which is consistent with the association 
observed by Liou et al. (2012), and may contribute to treatment-refractoriness. 
The symptom domain most commonly associated with this region in the FES cohort is the 
PANSS Negative subscale. Two SNPs in the haplotype were highly significant for post-
treatment increases in PANSS Negative scores (P < 0.00001). Interestingly, the region 
significantly associated with worsened negative symptoms within the FES cohort was 
associated with refractoriness by Liou and colleagues (2012). The negative symptoms of 
schizophrenia, i.e. avolition and blunted emotion, are especially complex and difficult to treat 
(Millan et al., 2014). These symptoms tend to linger even when positive symptoms have 
improved, and have been shown to influence the extent of residual cognitive deficits and 
functional outcomes in schizophrenia patients (Lin et al., 2013; Malaspina et al., 2014; 
Woodward et al., 2014). The associations with PANSS Negative scores unveiled in this 
study suggest that i) there is a genetic link between severe, persistent negative symptoms 
and treatment-refractoriness, ii) there are regulatory mechanisms involved in the 
pathophysiology and manifestation of negative symptoms and perhaps cognitive deficits in 
the disorder, and iii) these novel loci could be used as new drug targets to improve negative 
symptoms and prevent treatment-refractoriness in schizophrenia. Lastly, one must keep in 
mind the hypothesis that treatment-refractoriness is a biologically distinct endophenotype of 
schizophrenia (Liou et al., 2012), which is supported by the findings of the bioinformatic 
analyses. The involvement of the 4q24 region may point to a unique mechanism that 
influences the progression of treatment nonresponse.  
This region of variation is found within NFKB1 and was previously predicted to affect its 
regulation (see chapter three). NFKB1, in turn, regulates hundreds of genes, and has been 
linked to immune functioning (Shishodia and Aggarwal, 2004), schizophrenia susceptibility 
(Narayan et al., 2008), and anti-TNF treatment response (Bank et al., 2014). Additionally, the 
highly significant 4q24 SNPs, rs230493 and rs3774959, are eQTLs for several genes, 
including CACNB1 and MANBA (Table 3.5). CACNB1 encodes a neuronal calcium channel 
subunit, and decreased expression of this gene has been implicated in schizophrenia 
(Smolin et al., 2012). As discussed in chapter three, variation in the MANBA gene has also 
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been associated with schizophrenia risk (Jungerius et al., 2007). The significant associations 
within the FES cohort validate the findings of the bioinformatic pipeline, and add weight to 
hypotheses regarding a connection between treatment response and immunity, as well as a 
biological overlap between schizophrenia risk and treatment outcomes.   
4.5.3.2 Refractoriness, remission, and early response 
This study revealed four associations for the dichotomous outcomes, i.e. treatment-
refractoriness, remission, and early treatment response, however none survived correction 
for multiple testing. Firstly, two variants, rs7520258 and rs1352318, were associated with 
treatment-refractoriness in the cohort. Interestingly, neither of these variants were 
associated with any other treatment outcomes, such as changes in PANSS scores. Again, 
this could point to a unique mechanism involved in refractoriness. The rs7520258 variant 
was previously associated with neurocognition outcomes (McClay et al., 2011a), and 
rs1352318 was associated with changes in BMI (Athanasiu et al., 2012). Both variants were 
predicted by bioinformatic analyses to play a regulatory role (Table 4.1), although the 
biological consequences of these rSNPs remain unclear.    
There are no variants in Table 4.2 that were associated with increased or decreased PANSS 
scores, as well as refractoriness or remission, respectively. Since these states of response 
are classified according to PANSS score changes, one would expect commonalities 
between variants for the continuous and dichotomous outcomes. On the contrary, instances 
of nonconcordance were observed. As discussed, rs1352318 was nominally associated with 
refractoriness (P = 0.0338), but unexpectedly showed an association with remission (P = 
0.0083). Furthermore, a chromosome four haplotype containing minor alleles for rs230495 
and rs3774959 was significantly associated with early response at six weeks and worsened 
endpoint response. As discussed, these two SNPs – individually and in combination – 
correlate with poorer PANSS outcomes, which is incongruent with their involvement in early 
response. Since there are no variants that were associated with both early treatment 
response and improved outcome or remission, these loci do not serve as predictive 
biomarkers of treatment outcomes for this cohort, and further study of the genetics of early 
response is warranted.  
Nonconcordance between genetic and clinical data suggests that definitions of refractoriness 
and remission should be more carefully and specifically defined, and take genetic correlates 
into consideration. Having said that, the statistical analyses were somewhat restricted, since 
only 10 patients qualified as treatment-refractory (Chiliza et al., 2015a). Additionally, states 
of remission and refractoriness are notably difficult to define in clinical settings, since there is 
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extensive inter-individual heterogeneity in both schizophrenia symptom severity and 
antipsychotic response. For example, patients with high baseline PANSS scores can 
achieve a greater than 25% reduction with treatment, but still meet other criteria for 
nonresponse, since their endpoint PANSS scores will be high in relation to other individuals 
(Chiliza et al., 2015a). Therefore, these loci should be investigated in a larger group of FES 
patients to i) provide insight into biological definitions of response states, and ii) investigate 
the potentially unique genetic mechanisms of treatment-refractoriness.  
4.5.3.3 Metabolic outcomes 
In comparison to PANSS outcomes, there were few associations with metabolic responses, 
i.e. changes in weight, BMI, HDL, LDL, total cholesterol, and triglycerides. Although none 
survived correction for multiple testing, the most significant association was between 
rs230539 and changes in total cholesterol (P = 0.0096). Furthermore, a 4q24 haplotype 
containing the major allele of this variant was significantly associated with changes in 
triglyceride levels (P = 0.0237; Table S5). Several other SNPs in this haplotype were 
nominally associated with metabolic changes. These results suggest a role for this haplotype 
in metabolic dysregulation, although this has not been previously observed. Another 
haplotype, A.T.C, containing the major alleles of rs10218843, rs11265461, and rs6427540, 
was also nominally associated with change in triglyceride levels (P = 0.0492). Similar to the 
4q24 haplotype, this trio of SNPs also originates from the Liou et al. GWAS (2012), the first 
two minor alleles having been implicated in treatment-refractoriness and the third in LD with 
the pair. One possible link between refractoriness and increased metabolic ADRs is that 
patients who showed no response were consequently administered higher doses of 
flupenthixol; these increased doses may contribute more to adipogenic side effects than 
lower doses of the antipsychotic (Emsley, personal communication). Although the 
mechanisms are as yet undetermined, these regions should be further investigated for 
involvement in regulation of antipsychotic response and metabolic side effects.   
The FES patients demonstrated considerable adverse metabolic changes after treatment. 
Indeed, AIWG and other metabolic side effects are common in antipsychotic-treated 
patients, and can have serious consequences such as metabolic syndrome and 
cardiovascular disease (Brennan, 2014; Chiliza et al., 2015b). The lack of strong 
associations found within this study may be due to several factors. Firstly, only two rSNPs 
investigated were implicated in metabolic outcomes, namely rs6741819 (increase in 
triglycerides; Adkins et al., 2011) and rs1352318 (increase in BMI; Athanasiu et al., 2012). 
These two studies were not particularly well-characterised (refer to 3.5.1.1), making 
replication difficult. Secondly, while the PANSS is a standardised scale with high reliability 
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and validity (Levine et al., 2011), several metabolic indices were measured, and techniques 
may have been inconsistent between measurements and/ or independent studies. Finally, 
this study focused on SNPs implicated in regulation. It may be the case that abnormal 
regulatory processes do not influence metabolic side effects to as great an extent as 
changes in coding regions do. Whatever the case, genome-wide studies accounting for 
coding and noncoding variation should be undertaken in order to identify genetic correlates 
and adequately manage metabolic-related ADRs.  
4.5.4. GWAS comparisons 
The variants originally associated with treatment outcomes in previous GWAS were included 
in the association analyses for two reasons: firstly, to directly compare outcomes in the 
GWAS cohorts with the FES cohort, and secondly, to assess the accuracy of a GWAS 
variant as a proxy for a region, by determining differences in association patterns between 
GWAS SNPs and corresponding LD SNPs. Several GWAS SNPs were significant for 
treatment response. For example, the haplotype on chromosome five contains two variants, 
rs17440909 and rs17742120, which were both previously associated with symptom severity 
as perceived by the patient (Clark et al., 2013). Both SNPs, as well as the C.A and T.G 
haplotypes, were nominally associated with changes in PANSS Negative scores (Table S5). 
Opposite combinations of haplotypes reaching significance is unexpected. This finding 
suggests that the SNPs in the Clark et al. (2013) study served together as a tag for the 
causal region in their cohort. However, European ancestry individuals display much larger 
blocks of LD than Africans (Dalal et al., 2010; Chimusa et al., 2015), therefore this tag may 
be ineffective for the FES cohort, considering the ancestry make-up of the patients. This 
demonstrates the importance of population-specific studies in identifying causal variants. 
Additionally, the SNP previously associated with treatment-refractoriness (rs230529; Liou et 
al., 2012) in the large haplotype block on chromosome four (Figure 4.4), was not significant 
for any treatment outcomes in the FES cohort, despite having a relatively high frequency of 
0.46. This haplotype and several of its individual variants were significantly associated with 
various response traits. Therefore, it is expected that the rs230529 SNP should reach 
significance in the FES cohort too, in order to function as an accurate proxy for the region. 
The r2 values for this haplotype range from 0.22 to 0.96 (Figure 4.4), however when 
assessing D’ confidence intervals, strong pairwise LD (D’ > 0.7) is shown between all the 
SNPs within the haplotype (Figure S1). Differences between D’ and r2 values can be 
explained by their differing properties. D’ is more sensitive to both allele frequency and 
sample size, and is usually inflated with a smaller cohort such as this one (Carlson et al., 
2004; Meadows et al., 2008). There is debate over which measure should be used to define 
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LD between markers, but r2 is generally preferred and accepted to be more applicable for 
association studies (Mueller, 2004; Zhao et al., 2005).  
The lack of associations for rs230529 within the South African cohort illustrates the 
importance of analysing each variant at a locus, since patterns of LD vary extensively 
between different population groups. This has implications for the way in which GWAS are 
currently designed and interpreted. 
4.5.5. Study limitations 
The greatest limitation of this study is the comparison of significant variants between 
different treatment cohorts. There are several factors that restrict direct comparison, and 
thus the results should be interpreted with caution and validated in other cohorts. Firstly, the 
differences in the types of antipsychotics the patients received has an impact on comparison 
of clinical outcomes. Although their equivalence in efficacy is still under debate, FGAs and 
SGAs produce vastly different side effect profiles, and ideally only drugs of the same class 
should be analysed together (Meltzer, 2013). Drug heterogeneity within previous GWAS, for 
example the studies assessing the CATIE cohort (Lieberman et al., 2005), may also distort 
the clinical phenotype and prevent the identification of true associations. Furthermore, 
clinical assessments differ between studies, and clinical scores and classifications – even 
PANSS scores – are dependent on the evaluating psychiatrist to a certain extent. This has 
been illustrated by the lack of standard definitions for treatment refractoriness or remission 
(Chiliza et al., 2015a).   
Another limitation of this study is the small size of the FES cohort compared to the tens of 
thousands of individuals analysed by the PGC (Ripke et al., 2014). However, it is important 
to note that the cohort is extremely well-characterised and homogenised. The patients were 
treatment-naïve at the commencement of the study, and all received the same antipsychotic 
via injection, ensuring adherence. It has been demonstrated that smaller clinical cohorts of 
well-characterised individuals have equivalent power to larger cohorts of less well-
characterised patients (Samuels et al., 2009).  Furthermore, first episode cohorts provide 
increased power in pharmacogenetic studies (Zhang and Malhotra, 2013b). Considering 
these factors, this study minimised confounders and provided increased statistical power to 
detect associations (Reynolds, 2007), demonstrated by the emergence of significant findings 
that survived multiple testing, and the large effect size of 4.41%. The benefits of this cohort 
are particularly apparent when compared to the scarcity of similar cohorts available for the 
study of antipsychotic pharmacogenomics. The only exception is the study by Malhotra and 
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colleagues (2012), which demonstrated the ability to detect and replicate a genome-wide 
signal in a patient group of comparable size (n = 139) to the FES cohort.  
4.6. Conclusion 
This study successfully validated some of the bioinformatic results and demonstrated that 
rSNPs are important in antipsychotic response. There are several novel findings with 
regards to the potential mechanisms of treatment response in schizophrenia. Firstly, 
variation in the 4q24 region and NFKB1 should be considered as novel targets when 
investigating antipsychotic mechanisms and heterogeneous treatment outcomes. Their 
connection to regulation, negative symptom severity, immunity, as well as the treatment-
refractoriness endophenotype suggest that this locus has important and widespread 
implications in schizophrenia.   
 
Additionally, this study demonstrated the importance of well-characterised cohorts and clear, 
standardised definitions of concepts such as remission, treatment-refractoriness, and early 
treatment response. The nonconcordance between genetic correlates and clinical 
classifications necessitates a re-evaluation of treatment outcome criteria. This is particularly 
important with regards to early response as a predictor of later positive outcomes. If accurate 
biomarkers can be uncovered, better first-line treatments can be applied and ADRs can be 
avoided. This, however, relies on extensive clinical characterisation.   
Lastly, the Eurocentric nature of GWAS means that other population groups have been 
understudied. It is important to note that although not all bioinformatic candidates were found 
to be statistically significant in this study cohort, the absence of significance may just be 
representative of insufficient power to detect associations in this study, or that these loci may 
only be relevant in alternative population groups. The analysis of the FES cohort has 
contributed to narrowing the research gap between LMIC and developed countries, although 
the road ahead is long. Improvement in treatment outcomes calls for population-specific 
studies that benefit the individuals carrying the largest burden of disease.  
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CHAPTER 5: Conclusion and future perspectives 
5.1. Conclusion 
This study aimed to improve upon the interpretations of existing research on antipsychotic 
pharmacogenomics in schizophrenia by combining novel bioinformatic tools with validation 
within a previously underrepresented population group. The all-encompassing nature of this 
study – i.e. analysis of LD regions rather than only tag SNPs, inclusion of coding and 
noncoding variants, and evaluation of diverse, well-characterised clinical outcomes – has led 
to the formation of new hypotheses regarding the biology of antipsychotic mechanisms and 
treatment response. Firstly, many previously implicated SNPs were predicted to have roles 
in proximal, distal, and post-transcriptional regulation. Several have evidence for acting as 
eQTLs in the expression of genes previously not associated with treatment response. 
Perhaps the most important finding is that over half of the characterised rSNPs were 
predicted to affect the expression of NFKB1, which is itself a master regulator. This gene, as 
well as several other implicated proteins and motifs, have roles in immune functioning. 
Abnormal immune responses have long been suggested to contribute to the development of 
schizophrenia, and these results suggest that this may extend to the treatment outcomes of 
the disorder too. NFKB1 is one of several examples of potential novel pharmacogenes. 
Interestingly, the region most significant for regulation was previously associated with 
treatment-refractoriness. The results of the bioinformatic analyses support the notion that 
treatment-refractoriness may be a unique endophenotype of schizophrenia, with distinct 
biological pathways leading to its development.  
Importantly, the association analyses supported the hypothesised roles of regulatory regions 
in treatment response, as the majority of SNPs were significantly associated with at least 
one treatment outcome in the FES cohort. The weight of significant associations was found 
to be with the PANSS Negative outcome, which is an exciting avenue to follow since 
negative symptoms are the most chronic and pervasive, yet least understood of the 
symptom domains. The involvement of the 4q24 region in this respect suggests that there is 
a biological link between negative symptoms and treatment-refractoriness.  
Interestingly, lending weight to the LD approach of the bioinformatic pipeline, there were 
instances in which the tag SNP and LD SNPs did not achieve the same or even similar 
patterns of associations within the cohort. This has important repercussions for the design 
and subsequent interpretation of GWAS studies. Furthermore, this study proved the 
importance of thorough clinical characterisation. Treatment response is complex and 
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heterogeneous, and a cohort must be well-characterised and homogenised as far as 
possible in order to arrive at robust conclusions regarding genetic correlates of drug 
response. The FES cohort is an example of such a cohort, particularly in comparison with 
previous GWAS cohorts. It is clear that GWAS patient recruitment and assessment must be 
improved so as not to dilute the phenotype. With this improvement, statistical power is 
increased and associations carry more weight.  
The novel findings of this study suggest new directions for treatment response research in 
schizophrenia. Importantly, results of the association analyses suggest a new approach 
regarding characterisation of response states in schizophrenia. With the help of genetic 
studies, coupled with clinical guidelines such as RDoC (Insel et al., 2010), classifying patient 
subgroups and response states based on biology can guide treatment strategies and 
improve long-term outcomes. Repeatedly following traditional hypotheses and candidate 
genes has been a popular approach, but has had limited success in underpinning the 
biology of drug response. The findings of this study, however, open new avenues for 
research by expanding focus to candidate gene pathways and networks, and have the 
potential to improve on a treatment approach that has been suboptimal for over 60 years. 
5.2. Future perspectives 
It is important to remember that GWAS is only one approach to uncovering the genetics of 
complex traits. GWAS are the hallmark for contributing knowledge to the CDCV hypothesis, 
but it is likely that a combination of rare, common, and de novo variation amalgamate to 
produce complex trait phenotypes such as antipsychotic response (van Dongen and 
Boomsma, 2013). In the future, a combination of studies, including large sample GWAS, 
whole genome sequencing, and subsequent functional validation should be employed. The 
key to uncovering variation of small effect size is a large study sample. Population-specific 
analyses of tens to hundreds of thousands of individuals, with replication, would advance 
pharmacogenomics as it has schizophrenia research (Ripke et al., 2014). 
 
Such large-scale studies generate massive amounts of data, often without including a post-
analysis step of functional validation. This step is problematic, given the lack of a suitable in 
vitro model for schizophrenia or treatment response. An exciting area of research designed 
to address this is the engineering of induced pluripotent stem cell (iPSC)-derived neurons.  
With this approach, in vitro study of brain structures in different states is possible. For 
example, Brennand and colleagues (2011) reprogrammed fibroblasts from schizophrenia 
patients into neurons and found reduced neuronal connectivity and glutamate receptor 
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expression. Although only beginning, this type of research could allow for discovery of 
implicated pathways in action. The structural effects on neurons of regulatory variation can 
be investigated with this functional method and used to confirm results from predictive 
computational tools. Furthermore, a case/ control study in which iPSC-derived neurons are 
incubated with different antipsychotics could provide insight on the mechanisms and 
biological outcomes of FGAs and SGAs. Functional studies are essential for the discovery 
and implementation of accurate, clinically actionable biomarkers of treatment response.   
 
Given the significance of thorough clinical characterisation for association studies, 18 
European institutes recently joined forces to form the Optimization of Treatment and 
Management of Schizophrenia in Europe (OPTiMiSE) programme 
(http://www.optimisetrial.eu/).  This initiative aims to recruit 500 drug-naïve schizophrenia 
patients and perform a closely-monitored six-year trial of SGA treatment. Combined with 
genomic studies, the goal of this project is to optimise current treatment and develop new 
treatment strategies. This could provide unparalleled insight into early treatment response 
and antipsychotic mechanisms, and sets an example for other consortia by emphasising the 
importance of clinical stringency for genomic studies.  
Closer to home, a promising new development in the study of previously underrepresented 
populations is the release of the African Genome Variation Project (Gurdasani et al., 2015). 
The African LD populations included on publically available databases – such as YRI – are 
not necessarily accurate proxies for sub-Saharan African populations such as South 
Africans. Progress in research in LMIC is particularly important since these individuals are 
disproportionately burdened by communicable diseases and psychiatric disorders. 
Understudied and overburdened, research in this field would be immensely beneficial to 
individuals, communities, as well as societies and the economy of LMIC. 
Pharmacogenomics has the power to achieve some of these goals. The results of Gurdasani 
and colleagues’ (2015) research add more variation to the growing pool of genetic 
information on understudied groups, and allow for improvement upon the novel bioinformatic 
pipeline. What is more, this pipeline needs not be restricted to antipsychotic treatment 
response; it is applicable to any complex genetic disorder, and is an agnostic approach with 
the potential to reveal novel dysregulated pathways and ultimately improve disease 
outcomes.  
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APPENDIX A: Bioinformatics supplementary data 
Script S1: Unix shell commands for TRAP workflow, including tRap (http://trap.molgen.mpg.de/cgi-
bin/download.cgi), written by Dr N. Ishaque of the German Cancer Research Center (Heidelberg, 
Germany)*.  
tr '\n' '|' < AllSNPs.txt > AllSNPs2.txt 
 
egrep -w 'rsID1|rsID2|rsID3|rsIDn-1|rsIDn' 00-All.SNV.bed > All_results.txt 
 
awk '{print $1"\t"$2"\t"($3+1)"\t"$4"\t"$5"\t"$6}' All_results.txt > All_results.bed 
 
bedtools getfasta -fi GRCh37_FINAL.fa -bed All_results.bed -fo Allfasta 
 
awk '{print $1"\t"($2-16)"\t"($3-1)"\t"$4}' All_results.bed > All_pre15.bed 
 
awk '{print $1"\t"($2)"\t"($3+15)"\t"$4}' All_results.bed > All_post15.bed 
 
bedtools getfasta -fi GRCh37_FINAL.fa -bed All_pre15.bed -fo All_pre15.fa 
 
bedtools getfasta -fi GRCh37_FINAL.fa -bed All_post15.bed -fo All_post15.fa 
 
perl weave_fasta_for_sTRAP.pl All_results.txt All_pre15.fa All_post15.fa > 
All_results_weaved_for_sTRAP.fa 
 
grep WT All_results_weaved_for_sTRAP.fa > AllpairsWT.txt 
 
grep MUT All_results_weaved_for_sTRAP.fa > AllpairsMUT.txt 
 
paste AllpairsWT.txt AllpairsMUT.txt > Allpairs.txt 
 







sequences = readFASTA("All_results_weaved_for_sTRAP.fa") 
names(sequences) = gsub(">", "", sapply(sequences, "[[", "desc")) 
pairs = read.csv("Allpairs.pairs", sep="\t", header=F, stringsAsFactors=F) 
strap = rank.factors.for.pairs(jaspar, sequences, pairs) 
filtered = strap[which(strap[,"min.p"] < 0.01 & abs(strap[,"log.ratio"]) > log(1.2)),] 
save.image(file="strap_try1.RData") 




cut -f 3 All_strap_results_for_pairs.txt | sed 's|, |\n|g' | sort | uniq -c | sort -rg > 
All_strap_results_for_pairs_u.txt 
 
- Manually search for motifs on Jaspar database ("All_strap_results_for_pairs_u_hs.txt") 
- Create .txt file with list of Jaspar IDs for motifs only in humans 
 
grep -f All_strap_results_for_pairs_u_hs.txt All_strap_results_for_pairs.txt > 
All_strap_results_for_pairs_onlyhs.txt 
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* Input SNPs were obtained from HuGE Navigator, the NHGRI Catalog, and subsequent LD analysis, 
and saved as “AllSNPs.txt” prior to analysis. The “control” traits were each analysed in the same way, 
with input files “Control1SNPs.txt” for response to antidepressants, “Control2SNPs.txt” for response to 
hepatitis C treatment, and “Control3SNPs.txt” for eye colour. Italicised text represents commands of 
tRap script. Editable fields are indicated in bold. Instructions are indicated in grey.   
Script S2: Perl script “weave_fasta_for_sTRAP.pl” written by Dr N. Ishaque (German Cancer 
Research Center, Heidelberg, Germany). 
# use strict; 
 
my $usage = "This program weaves fasta files for sTRAP\n\n\t$0 [dbSNP bed file, 4th col = ref, 5th 
col = alt] [PRE FASTA] [POST FASTA]\n\n"; 
my $nex  = shift or die "Please provide SNP CSV file\n\n$usage"; 
my $pre  = shift or die "Please provide PRE FASTA file\n\n$usage"; 
my $post = shift or die "Please provide POST FASTA file\n\n$usage"; 
open (NEX_F, "$nex") or die "Cannot open NEXUS FILE '$nex'\n\n$usage"; 
open (PRE_F, "$pre") or die "Cannot open PRE FASTA FILE '$nex'\n\n$usage"; 
open (POST_F, "$post") or die "Cannot open POST FASTA FILE '$nex'\n\n$usage"; 
 
my %iupac=("B" => ["C","G","T"], "D" => ["A","G","T"], "K" => ["G","T"], "M" => ["A","C"], "R" => 
["A","G"], "S" => ["C","G"], "V" => ["A","C","G"], "W" => ["A","T"], "Y" => ["C","T"]); 
 
while (<NEX_F>){ if (/^(.*?)\t(.*?)\t(.*?)\t(.*?)\t(.*?)\t(.*?)$/){my ($snp, $ref, $alt) = ($4,$5,$6); 
my $pre_f_line= <PRE_F>; 
$pre_f_line= <PRE_F>;    








    } 
    else { 
      #my @bases=$iupac{$alt}; 
      foreach my $base (@{$iupac{$alt}}){ 
# warn "$snp $alt $base\n"; 
print ">$snp"."_$alt$base"."_WT\n$pre_f_line$ref$post_f_line\n"; 
print ">$snp"."_$alt$base"."_MUT\n$pre_f_line$base$post_f_line\n"; 
      } 
    } 
  } 
  else { 
    die "invalid line in SNP NEXUS file: $_\n"; 
  } 
} 
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- amygdala - adult, donor10196.CNhs13793.10167-103B5 
- amygdala, adult, donor10252.CNhs12311.10151-102I7 
- Astrocyte - cerebellum, donor1.CNhs11321.11500-119F6 
- Astrocyte - cerebellum, donor3.CNhs12117.11661-122F5 
- Astrocyte - cerebellum, donor2.CNhs12081.11580-120F5 
- Astrocyte - cerebral cortex, donor1.CNhs10864.11235-116D2 
- Astrocyte - cerebral cortex, donor2.CNhs11960.11316-117D2 
- Astrocyte - cerebral cortex, donor3.CNhs12005.11392-118C6 
- brain, fetal, pool1.CNhs11797.10085-102B4 
- brain, adult, pool1.CNhs10617.10012-101C3 
- brain, adult, donor1.CNhs11796.10084-102B3 
- cerebellum - adult, donor10196.CNhs13799.10173-103C2 
- cerebellum, adult, donor10252.CNhs12323.10166-103B4 
- cerebellum, adult, pool1.CNhs11795.10083-102B2 
- cerebral meninges, adult.CNhs12840.10188-103D8 
- corpus callosum, adult, pool1.CNhs10649.10042-101F6 
- diencephalon, adult.CNhs12610.10193-103E4 
- dura mater, adult, donor1.CNhs10648.10041-101F5 
- frontal lobe, adult, pool1.CNhs10647.10040-101F4 
- globus pallidus - adult, donor10196.CNhs13801.10175-103C4 
- globus pallidus, adult, donor10252.CNhs12319.10161-103A8 
- hippocampus - adult, donor10196.CNhs13795.10169-103B7 
- hippocampus, adult, donor10252.CNhs12312.10153-102I9 
- locus coeruleus, adult, donor10252.CNhs12322.10165-103B3 
- locus coeruleus - adult, donor10196.CNhs13808.10182-103D2 
- medial frontal gyrus - adult, donor10196.CNhs13796.10170-103B8 
- medial temporal gyrus - adult, donor10196.CNhs13809.10183-103D3 
- medial temporal gyrus, adult, donor10252.CNhs12310.10150-102I6 
- medulla oblongata, adult, donor10252.CNhs12315.10155-103A2 
- medulla oblongata, adult, pool1.CNhs10645.10038-101F2 
- medulla oblongata - adult, donor10196.CNhs13800.10174-103C3 
- Meningeal Cells, donor1.CNhs11320.11493-119E8 
- Meningeal Cells, donor2.CNhs12080.11573-120E7 
- Meningeal Cells, donor3.CNhs12731.11654-122E7 
- middle temporal gyrus, donor10252.CNhs12316.10156-103A3 
- nucleus accumbens, adult, pool1.CNhs10644.10037-101F1 
- occipital cortex, adult, donor10252.CNhs12320.10163-103B1 
- occipital cortex - adult, donor10196.CNhs13798.10172-103C1 
- occipital lobe, adult, donor1.CNhs11787.10076-102A4 
- occipital lobe, fetal, donor1.CNhs11784.10073-102A1 
- paracentral gyrus, adult, pool1.CNhs10642.10035-101E8 
- parietal lobe, adult, pool1.CNhs10641.10034-101E7 
- parietal lobe, adult, donor10252.CNhs12317.10157-103A4 
- parietal lobe, fetal, donor1.CNhs11782.10072-101I9 
- parietal lobe - adult, donor10196.CNhs13797.10171-103B9 
- pineal gland - adult, donor10196.CNhs13804.10179-103C8 
- pineal gland, adult, donor10252.CNhs12228.10160-103A7 
- pituitary gland - adult, donor10196.CNhs13805.10180-103C9 
- pons, adult, pool1.CNhs10640.10033-101E6 
- postcentral gyrus, adult, pool1.CNhs10638.10032-101E5 
- putamen, adult, donor10196.CNhs12324.10176-103C5 
- Smooth Muscle Cells - Brain Vascular, donor1.CNhs10863.11234-116D1 
- Smooth Muscle Cells - Brain Vascular, donor2.CNhs11900.11315-117D1 
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Brain tissue (continued)  
- Smooth Muscle Cells - Brain Vascular, donor3.CNhs12004.11391-118C5 
- substantia nigra, adult, donor10252.CNhs12318.10158-103A5 
- temporal lobe, adult, pool1.CNhs10637.10031-101E4 
- temporal lobe, fetal, donor1, tech_rep2.CNhs12996.10063-101H9 
- temporal lobe, fetal, donor1, tech_rep1.CNhs11772.10063-101H9 
- thalamus, adult, donor10252.CNhs12314.10154-103A1 
- thalamus - adult, donor10196.CNhs13794.10168-103B6 
 
Liver tissue 
- Hepatic Sinusoidal Endothelial Cells, donor1.CNhs12075.11521-119H9 
- Hepatic Sinusoidal Endothelial Cells, donor2.CNhs12092.11601-120H8 
- Hepatic Stellate Cells (lipocyte), donor1.CNhs11335.11524-119I3 
- Hepatic Stellate Cells (lipocyte), donor2.CNhs12093.11604-120I2 
- Hepatocyte, donor1.CNhs12340.11523-119I2 
- Hepatocyte, donor2.CNhs12349.11603-120I1 
- Hepatocyte, donor3.CNhs12626.11684-122I1 
- liver, fetal, pool1.CNhs11798.10086-102B5 
- liver, adult, pool1.CNhs10624.10018-101C9 
- Mesenchymal stem cells - hepatic, donor0.CNhs10845.11218-116B3 
- Mesenchymal Stem Cells - hepatic, donor2.CNhs12730.11618-122A7 
Stellenbosch University  https://scholar.sun.ac.za
APPENDIX A                                                   BIOINFORMATICS SUPPLEMENTARY DATA 
114 
  
Table S1: Unique tRap motifs and number of associated SNPs for antipsychotic response and three 
control traits.  
Antipsychotic response 
Control 1:                    
Antidepressant 
response 
Control 2:                          
Hepatitis C 
response 
Control 3:                                  
Eye colour 
Jaspar ID SNPs Motif name Jaspar ID SNPs Jaspar ID SNPs Jaspar ID SNPs 
MA0156.1 2 FEV MA0197.1 6 MA0393.1 1 MA0268.1 2 
MA0107.1 2 RELA MA0151.1 6 MA0389.1 1 MA0446.1 1 
MA0101.1 2 REL MA0398.1 5 MA0321.1 1 MA0441.1 1 
MA0080.2 2 SPI1 MA0387.1 5 MA0302.1 1 MA0434.1 1 
MA0059.1 2 MYC::MAX MA0346.1 5 
  
MA0431.1 1 
MA0259.1 1 HIF1A::ARNT MA0231.1 5 
  
MA0429.1 1 
MA0160.1 1 NR4A2 MA0038.1 5 
  
MA0428.1 1 
MA0112.2 1 ESR1 MA0243.1 4 
  
MA0425.1 1 
MA0091.1 1 TAL1::TCF3 MA0200.1 4 
  
MA0424.1 1 
MA0076.1 1 ELK4 MA0125.1 4 
  
MA0381.1 1 
MA0037.1 1 GATA3 MA0102.2 4 
  
MA0380.1 1 
MA0031.1 1 FOXD1 MA0032.1 4 
  
MA0367.1 1 




































































   
MA0223.1 3 
    
   
MA0220.1 3 
    
   
MA0206.1 3 
    
   
MA0202.1 3 
    
   
MA0198.1 3 
    
   
MA0195.1 3 
    
   
MA0187.1 3 
    
   
MA0184.1 3 
    
   
MA0183.1 3 
    
   
MA0181.1 3 
    
   
MA0179.1 3 
    
   
MA0178.1 3 
    
   
MA0177.1 3 
    
   
MA0175.1 3 
    
   
MA0172.1 3 
    
   
MA0167.1 3 
    
   
MA0132.1 3 
    
   
83 more 
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Table S2: 118 affected genes uploaded to DAVID and GeneMANIA for further analyses.  
Gene symbol Gene name 
ACTG1 actin, gamma 1 
ADH7 alcohol dehydrogenase 7 (class IV), mu/sigma polypeptide 
AK7 adenylate kinase 7 
ALPK2 alpha-kinase 2 
ANKS1B ankyrin repeat and sterile alpha motif domain containing 1B 
APOA1BP apolipoprotein A-I binding protein 
ARFGEF2 ADP-ribosylation factor guanine nucleotide-exchange factor 2  
ARRDC3 arrestin domain containing 3 
ASTN2 astrotactin 2 
ATP1A2 ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide 
AVL9 AVL9 homolog (S. cerevisiase) 
BANK1 B-cell scaffold protein with ankyrin repeats 1 
BCL7B B-cell CLL/lymphoma 7B 
C18orf21 chromosome 18 open reading frame 21 
C19Orf12 chromosome 19 open reading frame 12 
C1orf194 chromosome 1 open reading frame 194 
C2orf34 chromosome 2 open reading frame 34 
C6orf25 chromosome 6 open reading frame 25 
C8orf56 chromosome 8 open reading frame 56 
C9orf37 chromosome 9 open reading frame 37 
CACNB1 calcium channel, voltage-dependent, beta 1 subunit 
CASQ1 calsequestrin 1 (fast-twitch, skeletal muscle) 
CCBE1 collagen and calcium binding EGF domains 1 
CCDC114 coiled-coil domain containing 114 
CCNG2 cyclin G2 
CCT5 chaperonin containing TCP1, subunit 5 (epsilon) 
CD74 CD74 molecule, major histocompatibility complex, class II invariant chain 
CISD2 CDGSH iron sulfur domain 2 
CKAP4 cytoskeleton-associated protein 4 
CKS2 CDC28 protein kinase regulatory subunit 2 
CLMN calmin (calponin-like, transmembrane) 
CNTNAP5 contactin associated protein-like 5 
COL9A2 collagen, type IX, alpha 2 
CRLS1 cardiolipin synthase 1 
CUL5 cullin 5 
DALRD3 DALR anticodon binding domain containing 3 
DCAF8 WD repeat domain 42A 
DDX11 DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 11 
DICER1 dicer 1, ribonuclease type III 
DRD2 dopamine receptor D2 
EFHB EF-hand domain family, member B 
EFNA4 ephrin-A4 
EFR3B EFR3 homolog B 
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Gene symbol Gene name 
EHF ets homologous factor 
EIF4E2 eukaryotic translation initiation factor 4E family member 2 
EMP3 epithelial membrane protein 3 
ENPP6 ectonucleotide pyrophosphatase/phosphodiesterase 6 
FAM173B family with sequence similarity 173, member B 
FAM55B family with sequence similarity 55, member B 
FHOD3 formin homology 2 domain containing 3 
GABRA5 gamma-aminobutyric acid (GABA) A receptor, alpha 5 
GLS2 glutaminase 2 (liver, mitochondrial) 
GPR137B G protein-coupled receptor 137B 
GPR98 G protein-coupled receptor 98 
HBD hemoglobin, delta 
HEATR4 HEAT repeat containing 4 
HSD11B1L hydroxysteroid (11-beta) dehydrogenase 1-like 
ING2 inhibitor of growth family, member 2 
KIAA1549 KIAA1549 
LAMP3 lysosomal-associated membrane protein 3 
LAYN layilin 
LRRN4CL LRRN4 C-terminal like 
LSM5 LSM5 homolog, U6 small nuclear RNA associated 
MANBA mannosidase, beta A, lysosomal 
MAPKSP1 MAPK scaffold protein 1 
MEIS2 Meis homeobox 2 
MIR582 microRNA 582 
MYOG myogenin (myogenic factor 4) 
NDUFS2 NADH dehydrogenase (ubiquinone) Fe-S protein 2 
NFKB1 nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 
NHEDC1 similar to Na+/H+ exchanger domain containing 1 
NHEDC2 Na+/H+ exchanger domain containing 2 
OSBPL10 oxysterol binding protein-like 10 
PANK3 pantothenate kinase 3 
PCP4L1 Purkinje cell protein 4 like 1 
PDE4D cAMP-specific phosphodiesterase 4D 
PEG10 paternally expressed 10 
PIGK phosphatidylinositol glycan anchor biosynthesis, class K 
PKIG protein kinase (cAMP-dependent, catalytic) inhibitor gamma 
PKN2 protein kinase N2 
PLEKHA4 pleckstrin homology domain containing, family A, member 4 
PPA2 pyrophosphatase (inorganic) 2 
PPARD peroxisome proliferator-activated receptor delta 
PPP1R9B protein phosphatase 1, regulatory (inhibitor) subunit 9B 
PSG6 pregnancy specific beta-1-glycoprotein 6 
PTS 6-pyruvoyltetrahydropterin synthase 
PXDN peroxidasin homolog 
RAB25 RAB25, member RAS oncogene family 
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Gene symbol Gene name 
RB1 retinoblastoma 1 
RBM7 RNA binding motif protein 7 
RNF144A ring finger protein 144A 
SFRS5 splicing factor, arginine/serine-rich 5 
SFTPC surfactant protein C 
SH2D3C SH2 domain containing 3C 
SHC1 SHC (Src homology 2 domain containing) transforming protein 1 
SLAMF1 signaling lymphocytic activation molecule family member 1 
SLC22A23 solute carrier family 22, member 23 
SLC26A9 solute carrier family 26, member 9 
SLC39A8 solute carrier family 39 (zinc transporter), member 8 
SMTNL2 smoothelin-like 2 
SNORD116-27 small nucleolar RNA, C/D box 116-27 
SOCS3 suppressor of cytokine signaling 3 
SPOPL speckle-type POZ protein-like 
TC2N tandem C2 domains, nuclear 
THRA thyroid hormone receptor, alpha 
TJP1 tight junction protein 1 (zona occludens 1) 
TMED2 transmembrane emp24 domain trafficking protein 2 
TOMM40L translocase of outer mitochondrial membrane 40 homolog 
VILL villin-like 
WDR27 WD repeat domain 27 
WDR74 WD repeat domain 74 
ZBTB7B zinc finger and BTB domain containing 7B 
ZFAND3 zinc finger, AN1-type domain 3 
ZFYVE26 zinc finger, FYVE domain containing 26 
ZNF202 zinc finger protein 202 
ZNF276 zinc finger protein 276 
ZNF74 zinc finger protein 74 
ZNF860 zinc finger protein 860 
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APPENDIX B: Association analyses supplementary data 





rs10458561 G A C___3184113_10 
rs6688363 C T C___9406882_10 
rs10218843 A G C___2823177_10 
rs11265461 T C C___2823180_10 
rs6427540 C T C__29332596_10 
rs7520258 T C C__27150348_10 
rs6741819 C T C__29310709_10 
rs17727261 C T C__25927585_20 
rs62161711 G A AHWSJXV 
rs10170310 A G C__30363993_10 
rs747559 G A C____804250_10 
rs3774933 T C C__27479814_10 
rs1599961 A G C___8935034_10 
rs230534 C T C___3066477_10 
rs230532 A T C___3066475_10 
rs230529 T C C____804246_10 
rs230526 A G C____804243_10 
rs118882 C T C_176056349_10 
rs230520 A G C___3066470_10 
rs230505 G T C___3066462_10 
rs230504 C T C____804227_10 
rs230492 G A C___3066459_10 
rs230493 T A C___3066458_10 
rs230495 G A C___3066455_10 
rs230539 A G C____804223_10 
rs3774959 G A C__26458339_10 
rs4648055 G A C___3066440_10 
rs17440909 C T C__34264764_10 
rs17742120 A G C__34264798_10 
rs1352318 G A C___8339393_10 
rs10492354 G A C__30433133_20 
a According to frequencies within the FES cohort. 
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Figure S1: Two haplotype blocks on chromosome four, designated by Haploview version 4.2 (D’ > 0.7 
- > 0.98) (Barrett et al., 2005). Dark squares indicate significant LD between SNPs; numbers within 
squares represent D’ values as percentages. 
 
 




S4d: Chromosome 4 block 2 
Tables S4a – e: Haplotypes in the FES cohort from Haploview with frequencies ≥ 0.01.  
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C A C G C A T C G T G A G G 0.46 
T T T A T G G T A A A G A A 0.20 
C T T A T A G T G A A A A G 0.10 
C A T A C A G C G T A A G G 0.09 
C A T A C A G C G T A A A G 0.04 
C A T A C A G T G A A A A G 0.03 
C T T A T A T C G T G A G G 0.02 






















C A 0.85 
T G 0.15 
S4a: Chromosome 1 S4b: Chromosome 2 S4c: Chromosome 4 block 1 
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Table S5: Significant associations (P < 0.05) with treatment outcomes in the FES cohort. Highlighted 
associations survived Bonferroni correction. 
Response measurement Variant/ haplotype Association P-value 
PANSS Positive rs230504 Allelic 0.0344 
PANSS Positive rs230493 Allelic 0.0249 
PANSS Positive rs230495 Allelic 0.0399 




PANSS Positive C.A.T.A.C.A.G.T.G.A.A.A.A.G Haplotypic 0.0002 
PANSS Positive C.T.T.A.T.A.T.C.G.T.G.A.G.G Haplotypic 0.0337 








PANSS Negative G.C.T Haplotypic 0.0380 
PANSS Negative G.C.C Haplotypic 0.0046 
PANSS Negative rs6741819 Allelic 0.0361 
PANSS Negative T.A Haplotypic 0.0469 
PANSS Negative rs230532 Genotypic 0.0130 




PANSS Negative rs118882 Genotypic 0.0192 








PANSS Negative rs230492 Genotypic 0.0246 








PANSS Negative rs3774959 Genotypic 0.0000 
PANSS Negative C.A.T.A.C.A.G.T.G.A.A.A.A.G Haplotypic 0.0479 
PANSS Negative C.T.T.A.T.A.G.C.G.T.A.A.G.G Haplotypic 0.0015 








PANSS Negative C.A Haplotypic 0.0246 
PANSS Negative T.G Haplotypic 0.0246 
PANSS General rs230532 Genotypic 0.0105 
PANSS General rs118882 Genotypic 0.0461 
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Response measurement Variant/ haplotype Association P-value 
PANSS General rs230495 Allelic 0.0312 








PANSS Total G.C.C Haplotypic 0.0416 
PANSS Total rs230532 Genotypic 0.0083 
PANSS Total rs118882 Genotypic 0.0288 
PANSS Total rs230505 Allelic 0.0168 
















PANSS Total C.A.T.A.C.A.G.T.G.A.A.A.A.G Haplotypic 0.0123 
PANSS Total rs10492354 Allelic 0.0361 
Treatment-refractoriness rs7520258 Genotypic 0.0380 
Treatment-refractoriness rs1352318 Allelic 0.0338 
Remission rs1352318 Genotypic 0.0083 
Early treatment response C.A.T.A.C.A.G.C.G.T.A.A.A.G Haplotypic 0.0243 
Weight rs230532 Genotypic 0.0425 
Weight rs118882 Genotypic 0.0210 
BMI rs118882 Genotypic 0.0304 
HDL rs17727261 Allelic 0.0445 
LDL rs230534 Genotypic 0.0123 
LDL rs230532 Genotypic 0.0222 
LDL rs118882 Genotypic 0.0082 
LDL rs230520 Genotypic 0.0150 








LDL rs230539 Genotypic 0.0148 
Total cholesterol rs230534 Genotypic 0.0128 
Total cholesterol rs230532 Genotypic 0.0413 
Total cholesterol rs118882 Genotypic 0.0255 
Total cholesterol rs230520 Genotypic 0.0124 
Total cholesterol rs230492 Genotypic 0.0203 
Total cholesterol rs230539 Genotypic 0.0096 
Total cholesterol rs4648055 Genotypic 0.0459 
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Response measurement Variant/ haplotype Association P-value 
Triglycerides A.T.C Haplotypic 0.0492 
Triglycerides rs230532 Allelic 0.0237 
Triglycerides rs118882 Allelic 0.0209 
Triglycerides rs230504 Allelic 0.0288 
Triglycerides rs230493 Allelic 0.0271 
Triglycerides rs230539 Allelic 0.0412 
Triglycerides rs4648055 Allelic 0.0442 
Triglycerides C.A.T.A.C.A.G.C.G.T.A.A.A.G Haplotypic 0.0237 
Triglycerides rs10492354 Allelic 0.0389 
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APPENDIX C: Conference outputs 
Poster presentations 
Ovenden, E.S., Drögemöller, B.I., Emsley, R.A., Warnich, L. 2015. Investigating the 
functional significance of genome-wide variants associated with treatment response in 
schizophrenia. The XXIIIrd World Congress of Psychiatric Genetics (WCPG). 16-20 October. 
Toronto, Canada. 
Awarded Early Career Investigator Program (ECIP) Travel Award. 
Ovenden, E.S., Drögemöller, B.I., Roetz, N.J., Emsley, R.A., Warnich, L. 2013. Investigating 
the functional significance of GWAS associations with antipsychotic treatment response in 
schizophrenia. The 15th Biennial Conference of the Southern African Society for Human 
Genetics (SASHG). 6-9 October. Johannesburg, South Africa. 
Oral presentations 
Ovenden, E.S., Drögemöller, B.I., Emsley, R.A., Warnich, L. 2015. Investigating the 
functional significance of genome-wide variants associated with treatment response in 
schizophrenia. Pharmacogenetics in Psychiatry (PIP). 15 October. Toronto, Canada.  
Awarded Young Investigator Travel Award. 
Ovenden, E.S., Drögemöller, B.I., Emsley, R.A., Warnich, L. 2015. Investigating the 
functional significance of genome-wide variants associated with treatment response in 
schizophrenia. The 16th Biennial Congress of the Southern African Society for Human 
Genetics (SASHG). 16-19 August. Pretoria, South Africa.  
Ovenden, E.S., Drögemöller, B.I., Emsley, R.A., Warnich, L. 2014. Investigating the 
functional significance of genome-wide variants associated with antipsychotic treatment 
response. Joint South African Society for Bioinformatics and South African Genetics Society 
(SASBi-SAGS) Congress 2014. 23-26 September. Pretoria, South Africa.  
Awarded best SASBi MSc oral presentation.  
Ovenden, E.S., Drögemöller, B.I., Ishaque, N., Emsley, R.A., Warnich, L. 2014. Investigating 
the functional significance of genome-wide variants associated with antipsychotic treatment 
response. The 17th World Congress of Basic and Clinical Pharmacology (WCP). 13-18 July. 
Cape Town, South Africa. 
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